var title_f23_47_24304="Partial septate uterus PI";
var content_f23_47_24304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Uterine birth defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Some women are born with a uterus that is divided by a band of tissue called a septum. This piece of abnormal tissue can contribute to infertility.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_47_24304=[""].join("\n");
var outline_f23_47_24304=null;
var title_f23_47_24305="Patient information: Tinea versicolor (The Basics)";
var content_f23_47_24305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17233\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/49/21270\">",
"         Tinea versicolor on the shoulder and arm",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/61/21459\">",
"          Tinea versicolor on the back",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/34/10785\">",
"           Tinea versicolor on the chest",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Tinea versicolor (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/tinea-versicolor-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29905689\">",
"      <span class=\"h1\">",
"       What tinea versicolor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Tinea versicolor is a skin infection that causes areas of the skin to change color. The skin might have lighter patches, darker patches, or both light and dark patches.",
"     </p>",
"     <p>",
"      Tinea versicolor is caused by a fungus. This fungus lives on people&rsquo;s skin and does not cause problems normally. But in some people, the fungus can cause tinea versicolor. This happens more often in people who live where the weather is hot and humid.",
"     </p>",
"     <p>",
"      Even though tinea versicolor is caused by fungus, it does NOT spread from one person to another. It is not &ldquo;contagious.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29905704\">",
"      <span class=\"h1\">",
"       What are the symptoms of tinea versicolor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Tinea versicolor often appears as lots of small spots of color that seem to run into each other and form large patches. The colors can vary from white to light brown, dark brown, gray-black or pinkish red. There can also be a mix of colors.",
"     </p>",
"     <p>",
"      Tinea versicolor usually shows up on the back, chest, or upper arms (",
"      <a class=\"graphic graphic_picture graphicRef58608 \" href=\"UTD.htm?20/49/21270\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef74426 \" href=\"UTD.htm?20/61/21459\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef82464 \" href=\"UTD.htm?10/34/10785\">",
"       picture 3",
"      </a>",
"      ). It can also happen on the face or in places where the skin rubs together, such as the armpit.",
"     </p>",
"     <p>",
"      People often notice this problem more in the summer when affected areas of the skin stand out because they don&rsquo;t get tan from the sun.",
"     </p>",
"     <p>",
"      Some people have mild itching with tinea versicolor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29905718\">",
"      <span class=\"h1\">",
"       Is there a test for tinea versicolor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. After learning about your symptoms and doing an exam, your doctor or nurse will probably scrape the surface of your skin and look at the scrapings under a microscope. This procedure is usually not painful. If you have tinea versicolor, the doctor or nurse will see the fungus that causes the condition in the scrapings from your skin. He or she might also use a special light called a Wood&rsquo;s lamp to look at your skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29905733\">",
"      <span class=\"h1\">",
"       How is tinea versicolor treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most mild cases of tinea versicolor only need a special &ldquo;shampoo&rdquo; or cream. The shampoo is used like a soap on the affected skin.",
"     </p>",
"     <p>",
"      If your tinea versicolor covers a large part of your body, or if it doesn&rsquo;t get better with the shampoo or cream, you might need medicine that comes in pills. Your doctor will decide if you need pills.",
"     </p>",
"     <p>",
"      Even after you get treated, your skin might not go back to its normal color for several months. This does not mean the treatment didn&rsquo;t work. It just takes time for the skin to heal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29905748\">",
"      <span class=\"h1\">",
"       Can tinea versicolor be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the tinea versicolor keeps coming back, there are shampoos or medicines that can help prevent it. Your doctor will work with you on the best treatment plan for your situation.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/47/24305?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17233 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_47_24305=[""].join("\n");
var outline_f23_47_24305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29905689\">",
"      What tinea versicolor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29905704\">",
"      What are the symptoms of tinea versicolor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29905718\">",
"      Is there a test for tinea versicolor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29905733\">",
"      How is tinea versicolor treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29905748\">",
"      Can tinea versicolor be prevented?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17233\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/49/21270\">",
"      Tinea versicolor on the shoulder and arm",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/61/21459\">",
"       Tinea versicolor on the back",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/34/10785\">",
"        Tinea versicolor on the chest",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_47_24306="Lipodermatosclerosis sclerotic changes";
var content_f23_47_24306=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lipodermatosclerosis (sclerosing panniculitis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFQAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5po7UlFIQvanRIZZFRfvMcCmVu+FbI3F75rA7V6GlKXKrlQjzSSR3HhmxEFvHGB0Fdxp8W0qDgetY+kW+1FwPpXR2cOGw2Cc14s58zuezTgkrGjaqIyAV46A1q2/IOOD6+lUItudvJz0rStuQqgHmsrmvKXoFYkDrx96r1uQEB5255yOapwgYIRz15q/ErBMsAE7H1ppiaLkLHfhVJGPyqaOPchZVBJPNQQx7EZ1ySenPWriKXCndgDsKoh6DURVYlcByMnNOKPI2NvyY5NTeWwQME5pwCqpYkgnsaLEEQPlrluccZp3O0Fhk+gp0nOGP3fSmAbgXUHd7mmPoIyoQQRjd1FCoIyEBwo6DNI6Nu3DGT1zTS4G1W5kPtRcLDtxDA4xnjmmvkMT19qZuYliTwOntQzBeT1NSyrEcgUZGSzHnaajXr82AccCpJGGcgfjUG/nLjGOh9aQrCMxC9M5/So3cEAE89cimPISoZeAD3qtNMzZYYC4/Gi4OIy4YMeOQKyruU5z0PTFWpJCVBPWsq8b5iQKfQEZOoy5H3sdziuO1ebY5O7rXTapIFRjkV5z4gvj5pVDuYnAA9a1pR5mTUlZEmn211qOpO9mAVU7ST2r0LwvbPYDa0m+QnLE96o+G7GHQtEHmgNfTDLd8E1pXN3FZac1wxwFGWyeleqlyx5TyJPmlzEfjbxFDpdkSAPtTcKqdzXiWva3JaQzKzbr+45duu0elM8X+JptQ1N5kbgHCL6Vy4iknlMk7Es3PNVGIrjbaIudz8/WvTPhNbXMN5d3sJMcDJ5JOOW9a4awtHurmK2gGXkYKK928PafHpunQ20QwqLjPqfWsMVV5I2W7OnC0ueV3sjXgUAAZA9qkOEyMrjH+RTCMDCgAj1ppJZWOCxx6dK8hs9iKElmKMF4GRmodrSAhuff+tSFBgEknB4I71KpOCJdqnqoB7e9Q2aJDFQoApQEdCx9aazspIwcHhB0P41OC6sCmGAOTnpUQKufNOSeeW/pU3LSJFGwsXIyRgYGamSEfMpXcDgdajgfecrLg9TuFWrZ0Q/MwcHkDtUtlWLCFY3VQOAMt6LViNgRyqLnkbTyaiUAKRwpb+Pb19qtRKgdcFAO2RgilcixNbj5WLK6k843DJNW4pI4ijs7o/TawyD+VVowdzvtUNjAPXNWIpGRdgwpYc4P+NVcmxdZvmU+YUAz94YDfjU2JGiDKqevPT8Ky7e4LOFfbNHyCWbGD6U8SbWyy+XtOVKnpVKQnA0vMLSfNGWUc9en4U0EkM2zBPUHvVWO5ZnZZMLn7p708TqUaMMd6DvyaLi5R6fJKSzZU9vSnOuU4I3g9cfpVVZo4wGU8OeTjpVjqxBPykdRTTJkinMAjoclQTjHrVUyM6MAoUg9WFX5gFt9jMSR0c1QkVw6liMY7dc0xIqTIrKAEyrHt2qtdQ4DHbnHTHWrzAAcfKp6iqc2Jdy72A6Hn0qkJoqGXadm4E7e/pWZbXbaVdkoWFrMQCucqpPfHvVq8YI+/AOO9ZWqEPFtQEgjA9u9a0pOMroxqQU42Z1VrL5ElypYzWE4wV7xue/0Na2nTEp5VyqGaNghZT1yOM/z+tc34HLz6asLlXL/K5Iznt+YrRsWaK9WC4YKxLID1Ln+Fh6HHFeqtrnkNW0NOZHlQFpuDlQewPcml01na28ppRk78Ajpj29Ky7qeaRkRht3KQ+DwuOOnvV7QmHnOhA4/iB5+b+lNqxNynrQ8zRZYZgVgGFOec5HJoqbWSq6TOkY/dq3QdXOcc0VpFO2hLaW58gUUUoplCohkYKoyxOBXpnhPThBBGuMnH61x/hbTzc3YlcfIp4+tet6LaFU4XGK4cXVt7qO7CUr+8zRsINp2g8962LQYftnGciorVdiEADNXolUrycMfSvNbPUjEtWy8gk5H86uwlgQq9+561QR0ThWGRxWja/MEO3OOpIqLltF22jMh3Idyjg46VrW0L8/Kdg6DqazIidu3AxnoOK04XXfkyAAD7qnrVozkjQtwgYhQN+PXOBTlVfLbHyDPUVGroEZgMA9T0pysI/lU/KO5HWtDJxLALZAHIx1700kkMGYD0NG4feycL3pkwJZdpA+vekJIcGyDk5wOaZ5mAC/y9gKVwwBwelBUH5nOaAVuoHBADtk1CpdZG3kbf4aeOQehJ6VHknAAHB5pMaQsjhByQV71Gz5xtAwaZM4Cthc5OCKaQRgAAj1NIdhHbLEDcajmLYxwSKCwUFsnNRPIFAz/F3oEyGX5uhK/1qpLtBPzZPT6VZmbC8EE1n3LZ6HHPagRXkcKpJznpWZfOFUnPNWZpsM3Py+lYes3QSE89aqwupz+vXaxxOA3OK88sQ+qeJIYo2wEbe7elafizVRHbyEmuQ8MeI10p7iVoDJLJ0b0r0MNT+0cWKqfZPZ5rqNYcBh5cf3nY815h498YPqEp0/TWIhHDsD96sbWPEt/qi+Up8mE9QOprKghEfTk+tdiicNyOKHb80nLVIetPepdPtXvbyK2hGXkbb9B61TdtWCV9Edp8M9I8yaXUpV+VPkj/AKmvU4PlCk4OTj6Vn6Bp8VhYQQIuI0XHTrWmoaME4Ug8jPavEr1faTbPcoUvZwUSZuQ2Acg/rUTS/u2XvznHeo5ZCzZQjJ7dqj553hSw4Fc9jqSHxEqM5AUDKqOp96lOHjC7ecc5NUXuVDMF3Z6E+vtSh3CyAKMk8Y5NS0Ui7C5WPDKu70XkZpJFV1BdznPTHX8KhgXhRnI/ug/1q3GNrhlGAvHA4qWaJD7e3ThwvC9z1zU8Q3AOyZbtnj8ahOd4EQJY8sCMgCp7a3kUu0n+pY7iwbPPsKgZoeWe3LDqD1P0og/fRjOdmeVk65p6biEEUgBHUdTipY5DjepDjHCYxQSSYTy8SEqDx1qOYsqIPMwucYXnNSKyrtwoTd1BOSDSrEj+Zlmb39KYiqjSBikgC5OQNvP40RhtjbgVXdyW71OhYRqfMDMvGSMU2VD5g3FMDoaBiFtyoyyFFHr1NOimffgEe7nrVdgMsrsJCvYdqHKoI2COe4Y9KLhYui4/iDKQpw4xUyzbhuBww7HpWWLhVjZwGAB5Hf8A+vViKRh86LuB9+atMhxNGXy/JZWBKv17iqVyAEYOSuAEDdxUrSMqNtYEkbgp7U1cOAx5LDBB7VRlaxQdHCRAyMWjPzH+99arTv8AdwNyNn5vT61dugoYScqxGOazpgJI+TjGQV9feqRJn3w3oFDYUd6xLhweQ2QeDWnczblzj5MfdrEustk9DngitYoykzd8F6h5TSQrIFKPwD6Hvmuq8QbJ3srhBsIk2HHdD0b868x0S426uFk/1brhvb3rtNbvUS0soGdgfMBUdeK9WnrFHk1VaTL8zR+fgEs2MdepUcfnUmkToupkAAFl2kj+EZz/APWrGWZWuQg8wvj5M/3f8a1dJjliu2mAGFQYyMArmtGZJF2Yz3MccUKqCZcs3qBzRUIu44tPn1IgMdjxxLuwck8tRVw22Mp6s+RKlt4WnmjiQEsxxUddd4K0wyN9pdMk8Ln0qKk1CPMdFODnLlOs8K6QsMCJjoOtdvbxBIwAfaqGlWwhhG7Azz9K1YwuCWPA714s5OTuz3KUFFWRJEFC9x/Wke5YsAvH8zUEkxAIGQPU1DJOsKhjkZGKytc64xNK3lOF+XABzg1uwykBfmLB+gA6VyNpqCGQAMD2x61vW84dVBcKe4ocWgcbm9FKS5AGWXnk1r2k78ZjQKBzgdawrVUKhkfIHXb1Na9rKkZ2F3DN1px0MpJGkxzGGlIAzxsB/WpkILYYluPwqvE3JwzEdgaer5lJBxnpV3MrF5Rkd2Hp2p7N8q8AY/Sq0bFSAW6c4qQAKRwdvWnczcR5zvOcEelRNyuCOfSl3Eksq/N0qPkllAIBHX0pMEhrk7QAdvtUc0m05Bxt68U2Rg2UD4A4z3okBAHTH86Qxm8E78/KagkZgeDke9Slsgjj2FQT/cYluvGKQxrPlQcYXvVe5mypAHQcGot7YC85x0NQXLkhRuAI60CY53B4XrjrVOdhyG4PanM52552+tUZp8ZJH/1qpIiTKF5NgNjhq4/xBfYQjcNoFbOsXaruG7pXnfivUlht3OcVtCHMyJSsjiPFuoG6uxAh4HWsqNdqgCmITPO8rdSamAFevCPKrHkzlzO45e1Tr61GgyRU2OPaqJInPpXefDHSdzvqDrkn5I8+nc1xNvbvd3UNvF9+Rgor3TQrOOwsIYYgFVAAcVx4ypyw5V1OzB0uafM+hprt8puT06Cmyy/KOfm9O1RyzKHYkY5+martKoJLnaQDj6V5Vj1kS+ZjkH5uuPWqc9yfKByd2ec9aimnB/iPsKgYhuCM5PU9adirk4ZZBkEYPX61Yj2hBhnDfXiqcAzISw4J4C8BavKm11WVWbHJKjOfaokaxRYBAKAp8w6A9zVyHqvmgoVPB7Z9qS1gILMysxcfLk8rV1UaFVVVG0cZbk896xbNSaHKqsfzbzySBnNWRL5eJS2OMKrcAGoIt3mNH8/TqRgVKeI1Uouc5Ytzn/CkFieAs7eZsjDYySTVlVAZVmYDdzxxk+1VU4x5ablz82elTxSOSA4U/N2PSkSwZTNIxYttBIxjFMgcLCQC6jPTqTU8pMjgkbQvcdxSBWaQIBgH+L0pgNmcnaRgAdyOtRTAcOIyc8A+1SmKcyj5gbfHzFutD4B74xyppiKr5AwpDEHGQOVpH2K5idsOwyAT0+lIpZkDwsCzcqG9PSnzcqshChQpy3U5oQ2VEb9/IpBULxz/ABCrVs+GDHbHIeOuazyRyZGBDfdcdcU6F2+UDJwcEmmKSNnfjIcc46+tIGLRsH+71BHUVTgeSRAT8jBuVP8AEPWld/nUkndyPrVoxZJdSZDYIxtyOf1rKlyY22nLYyD9asXGyNFTHKcY74NU2kYglcADoDWiM2ZVwHGBkBwvzjsax7liC4PIY/lWzqRbJwwwec1zV5JtzjI/oK2grmMynFcfZ9VhYjhjtI+tdldTrcG3fO7y0JVyfvY9PfNcJHbG/wBTgtw2GY5U+4GRW/by3V5p8FpbMUvFlIJZc4PcfSvTor3Ty67946vTrgSrtb5pD8vI6epHvW4TK0EdrDIiyup82Vj8qpjrn+VY+kWc0McUdxItxeckOBjk9sVW8V6nBpFmYhmW8CYby+in0+lbRjzM55SsjG+IWoxSSQW1leeXZIAgA4Jorzm+murq7mvrzDxou4leFVfT60V0LRWMbXOQ061a7u44lGcnn6V6/wCHLAQQoqrgAdK5LwTpDLF9okUb5Omewr0S3228WGwAOprxsXV5nyroe3g6VlzPqaSFNpVMEgflRI+CRnC9aqRzxP8AMsu0HsRU7xsxZVbP9a4Wj0oWWhFcTsirheMVliZ72baowi9STitC6imMZH8PsKda2tlNZFLi6WKccmMDHmei5q4uyulqVNu6u9BbKO2gl3RSpdKAPNCc4GegrX1C6tmZJIE8p3ODznH4Vi3FxGuy3t7VLUcZCj5m+rVfsNCup3YyLsVfvZPIPp7Gqs1vqZpK6aOu0jyTGiecSf4sJW7hQ67shgOrpiuc021e1J+dmK4xtwcfjWwkztkySMzN6nP4Vk2aSjcuh/LYnbgHuD1qSGXfgkg9qrh/kjzgD0qUbQ3ycfhSI2L6NvYMhG0DGakDAsSWJXGMVVQdAq4Hc1MQxUgADmqRmybhtgQHb1oIAPLflUbOFGQrEjjimhlQnB4PP40yLDW3CVsgBexHU1Fu+Q8k55FLLwcZy46e1RMfl+9yOtAWDOFzgLnrUMpXaBJyeuaZIw2lSTg81C7jBySSRwKQitcOc/L8v1qnK+5uAOnWrMznIyOo/KqTYYknPNFh30GSyFYiM8Dt61iXl1sQkk5q5eXJAOGGB6VymuXwVGIbr+laRRm2Y+tXoyx3c15R4q1Fry8MKHKg84ro/FOreTC5DZY8CuGt1Ls0kn3mOa9HD0/tM4cRU+yiaNNqgU8DNIKeBzXWcZJGox1qXkU2NfenNxmgDqPh3pxudWa5ZcrFwPqe9esNE8UKsVKgnj3rmfANiNP0VJXTG/5nJ7ZroXu3Yl253cKTzjFePiJc82z2MPDkppENwCqneMuQOvQVUZjnA4z09Sf8KnnXcCXOcepqnMFZtyqNvQc9awOlDXYZLNyR2Hc0kTH7pAdmPb+GmsMOfmLkjLGp4IQ7xyBSoXgD+uKTZaVyzGgJBYnavOBwK0rGPYpcMGBGMHt7k1Rt4pdzkgyRhsbSME1s2kSOuYyqpjDgnp+FYyZ0xWhLFlIyHZSxGQR/jUynfFiYbpD0IzjPbNORVkG0gSdsdAoFTSQMjoYwn3cMBWZQ63VxDmUh5c84PFSbY12AhmyMFc9frULCRtsgUokZyc96mjcyygt0PKkDoKQEvl+WBEAcn5kUH9Kcp3W4MiBSchivBqTIUklvpmlRlUENIrZ52tTIBSUVQM+XxyeuPWmxbm8zbKxG77xHNOZswMsuGHPCdxTdgkjRogQi8jHXPpQMfDJ5gLfM2SQAR6UbSBvm2s5OFI/lRh9zBZArkZUEciiMohKoQrAZ9cU0JlSaPfE7ImHzkKeMH1qPyyXVpTjK/d7GrVzIi7C7kOx27l7moCGkljG87Yz8wI4b3piuVpEXJj2YUdP/AK1V8pMWUnOzBGOMGrU3DOrKQu3O4d6qSxYiBDkOADu7kfSmDJY5gHjY/KSTtUmrR+ZeBg9cZ7etU0+/vUb1PSrkQzljxngVSM5Iz7iQhQqncyjlj1xn+dZ6H92TvZtpBHvV+4+QluCMgdenrWWzYLo4wpbj+laIykVdQkBUqeCQRXM6jJtJwc45xW3qD7VZwfl71zGqzkDnG7HOK6KS1Oaq9CbQbZrzVFdHKCH58jv7V6RpyIrS/ZIS0rty2Op9c+tcr8PYI0tJbyZSWd8KB3ArtZrubT7X7TshSTBLLI23b7/WvUgtLHk1Jatkep340O0lkuZIkndcuf4h7CvMJ/ETatdon2YmIEhN3BP1qXxVq2nXlw7meV3xvkw+R+FcTrPiYWMEtrp8SB5VwWYZKD1HvXSkoq5z6yZF421vzXbTbQgLu3TFOhPpRXL2URZy7c9+e9FQ9TRK2h7XpcRhiXao2gYA9a0sNIFVjj1pltH+7CjtWjBbq5Xk+pPavAm7s+kpxshYrYG2MgHzZwq+o9a2GRIoh8wLBcZIwAarwqjnazMBnAA4wPWrzw+bEfkBROM9eKh7aFre7KLQOypIGJLf3f6VUmtoriQmSJ1BHJFbPlNlA+VY/dUcYxU4ZBkbsMDxkZGe9StDZWZkWdpbedsjWZlI/ibofet+JYEzBbSyCM8sruSM+vvSrYh442VUQE7i309anht/3jELuU/e7flVNvYWnQtwD5QEVQB/EO5q9GCqJvYbvp1qoIlg/wBS7mInGCuMfWrccyCPGCNvelbuQ3fYn4IBUAd8+pqxbssjAHp65qBCCAysNhqZEJIxt45GKZBYIBBUAgDvmpo3Gzc3RenFRKSwJJxjggU2RmyuDhenPei9ibXJXYqm/Jwx446Uwth8sBj1olc5AX7oHINVWZlYDIKA9aCbEs8oIIBAY8bqrmQAn5eD1NRylS5TOARmojKuPlzheKZNiRpAwI6r0GO1VppFIbIxgcH1pGcDO0gAckVUnkICkjdznPpVCaGzvvHUj0rOu7j5SwbtjFLcztvJBrG1C4A5yPUU0iWVb+7EaH17ivPfEuqhC4yAOta/iHUhGjkuM/zryTXtTe8uGRD8ua7KFLmZzVqvKitqN02oXZOfkB4pygAYqOGMRp05PWpR0r0ErKyPNbu7sVRUiCkUdqkVcnimIkQcVYtYTcXlvAnLSSBf1qJRWz4SiD6xGxTPlnfu3Y2/h3qZOybHFXaR6XETbWyIpzFHhTjjccdMVKZN6jaMj+VZiysqBJGAO7eOOTn1rQMu/wCdRliOSfWvGkrHtU3dCysSgY5PoP8ACq0se3DEZ9cdBVtlDYJbCLyTnBNQl95C/wAI6D+tZt2OiKuRJvaVFQLzwc961IBvkK+V84OCQei1BaxLJ04I6nHUVpRRkKo3bUc5IC/MR/hWTZvFFqEICn7vJ6ZJ7fStG3iSMoYoxkn5to7/AI1TtFkec8iPAPXtWlDEqW3712fnklu/tismzWxIFwXVEDMBk4NJKwhOVQIXIAIOctVtI2MSttVRjnFN8rjMRVj1VTUgiQ7o1QO25HHJwBg04IwQoEAA7juPpRHH58RSVAZBhiM5H4VZdM7JfM8srwR1H40EkHysqKiggDnNMMavPwwUEcD1qc7j5gdBnPG09qhQbQqREFuqk0wGSRiPy3wcA4UqOfxqeTais3OPvDb/ACqZUZjvVhuXG9cdRUboqziQLn0YH9KYiAMo8tmUsG5B7igbVRmdRuHqOcU8rIYSQcMeVJ9KrTbVuUd1YsFIyO3saEG5FI+4gRL+7Zch+1Vz5pZcyKo/j47e1WpJAFXySpHUjtiqQRWZ2G7DDJBpgOVjEkkeWdhyAeuKWFV87JQjevUnp7UxGd4FJQJIp7nJxTFbqwkJflR6A0ySWSJ0CsSATxtHSmudr7dpwvzBs9TTjIFKMcs4G7joaYVVwoweMyZPb2q0Q2VrvBB3LtRl5HfOax7xyAxBxg8/StW553tISy4C4x0rn72TLyA5J549a0ijGRSvZN8Rbt6GuM1actcCNeWJ4x3Jrpr2UqjcjOOSa57w9El74qg80kQREyuevTp+tduHhdnDiJ8sT1vwwkGi6LbNPGoaKPOO7MfWvO/Gd7PqlxJJO7jr8oPb0AqbxBqt7ql01tpSPhDh3zwB2PtWHrd9ZeH7NJDM1xqoGJVkOdre3tXsU4curPGlJt2Rh6xs0W2/0mPE7cpGTndnua4wB7mYvIc5qxdXFxqt209y7OSe56D0FShQgAA4qJO+xrFWWo5MIAB0FFIRRSGfQVugIwV71oQRknoMHoKltrfzPukbQOPrV5I2yoyvTkgV84z6dFJoSCB/F1P0qa3MiSSsgzxjrV5I9zHavJ6k1MtuAXiAAxyQveov1NFbZk0EZcQomNzfO5PZfTNSRWO6QsF3bedoHFNghdiQu3aeMelaELMEWPA2Djd3NaJp7kNOOzGxRgRETbi3JUqMge1LHGrc42nuKu7gse1eTnBA60eUAoCruyfWh6kp2K4R1JQODDjIHvT41JGDtLdPrVloQIiNoVx0+lM8sgg4GAODSsO4qptZRjAx29akjPzswG09MnvTAxChWO1jyD60plyByMDkjFAtSykm1Mrjc3c055N54YYXrVG5Znh/dSbXHQkULJvACck/eIpk26k7PiNj8z57VVkk+YRrlcDOamZ2ySCOmMVUmkwozjcKCRkjbySWyOwqOSQoFzgE9QKbI4XG48kdPQ1TllzkFiStMRI02DjHzHvVS6nCDrzmo55gF+8VAGc1kXt5wSGzVpGciS8ugu45GR15rlta1IIjNu47U/U9QVIySwwB0NeZ+K9fIVo42yx6VvTpuTMKk1FXM7xbrjTSNDEfqRXO20X8bdaZEjTSGR+ec1cHoK9SEFFWR5k5ubuHQ+1PAzSDpT1GAPWqIFAIAzUqCmYJqVFJwc8CgCRa634c6at9fXs0siJHaRGRgTgjPH5VyWMc12ngmN4bK7dEy9wQhPcKvPH41lWdoM0oxvNHQxxu1wylACBjB/nWmnyRxooUD1A/T6VFbxhFVUbd796sR9+ACPlz2ryJSue1CNhXC7SsnOBnC9z7+1Qxo0isOAwGQT3PpirUcIfaFOR1POMmrS24kYJGNgU4wOMn1rCTOqCIbOB/vuHVB6fxewrStAzncSwdjkKPbuTTI495bzHCN049B6Vo2uzaCucn1P8AKspM2SJ44t2RuQTZ5K9/arUSB1ZYwu5ThiOaSNUR1JTaSQEOOatqgE5jEbLnksO/vUXKERFSRPncBR0P3fxqWXJkQxkLgZzjr+NKiMV2ROSF+9uGc/SkHyIDCASrYK47UCEURh/N34YcZU1M7MpUoEaNhzjrSQgx+YvG4nI44NPVXkQkxhXT7vuKaE0QzxBWYPIecAHpikXEabi+QR8ue/41Z8jcd8alW2gHd/KonUMwTYpi9R2PamIYo+bzGyG7r7U5hh0WNR5TDJOentSpKvmNlcSKMZPQ1WeWXY6uAuGzlfSmBIXj3jDkyrkMp6Adqq5wZtqkEHJJH3j6ipJXCxlyuVwCGB5OKq+cso3RH7642elBJE4kCkptWQjOwc1TyfPjaXcrEEtg8CpZTGrqu5leIbuT2qjKVEjOCXDYHXoKY7FiOSUFQu0qBhj/AFpUd0iJKZO77q85yetVuCFhQYjIKsQec9qngZiyIhBhVSC3fNNEsmkZw5CABM9PQUSFlm4+6yk59DQER4whLEsvXPaobobgrAkKv3Md+1WjORUvWdLclWBfbjA6Zrmr+QJuOcknFdDeEm3JZxuKlfbIrj9TfZIBnLAc1tBHPNmVrFxsib5uAMVmeForqQ3N0T5NjK/lPOOWAHXFUvE96I45ADyTgVUl8QrpmjJpto3nORuOOgJr18JBL3meRjJt+6jpfEuu2nhpWi0pg07rtJzkSD1NeZSmfULhri5YszHJJqVY3nlM10xaQ881YGBwBgV0yk5HNCCiRqoQYQYFL3xTscg0jdagoYQOlFOxjk96KAPqhLY/LtG3H61ajgXJxnPckcVLGuCfmJz0z2q1FE5Rd2Pw6V84z6dMZDaKT8uQRye2alSFnzlMEdgasrF9zccmp1iKFl3ZOMk+lKw7kCQDgqQrDvUvksoXgbepOamhiHDbRub0NTov7soFOxT371SE3YrQxtvZh9zHTFTRBlfHHPOCKeVBBIDYHYU9owWBB+Ydc1RDZDKylPMJ3MvUColdQgkO7Dcc1M/yHgYB6+9M+UsgwSaAI2A43jJU5HsKjk3FlYgjntUj8qxYDk7RULH5jHn7vIqShksm07m6bsDHpSRSN/AVBzzjuKQMvl4UHBzVOECFht3AKxHPekG6LzMu7rjB496qXEhySw49aa0mF3Dklvyqlcz4VlPODgn0qiLEct1tON3Cnv3qvPc4Zue3FUJ3Ly5O4KvFZdzeNuIH3B1JPWriiJF+7vvkzwCegrmNV1NY1fB5NQ6vqgiQkMOnGa871/XsZwcnsK6aVNyOapUUUWvEuviOMqGyx7CuEZpLucs5JJokeS7mLOck1dijEagDrXo06agjzalRzYiKEUKKeB6UpzilAzWhkIgqQAmgL1NPHQZFACqDkVNGueM8UxRx7VNGBxkfLSAntojLKECksTtAx39a9C0PT47S1jQSZ2jO4Hr9feud8H2Jknad1JQcKfU967uOFRheNy+neuDF1NeVHoYSlpzMfEu4EHC+mO1WIo1myqDIHXnBqrOQi4TJLMFAHQfWtOwiCI2cZAyQO1edNnqQiTxpHAhdguRzwckGpoEG0scjf81QW0BeAEl1hDZVOgLd/rV21DTSOJkRUGCvzZLfWsWzqirD0Hmhs4ULyV/rVi0wGYtLvBHUVLFGd5RsnHU7eMY7U6CLHyqnIOKhsstM7+UpVTIwHAz2+tWYxLhShDAj5gWwQaGST90PlXjoKkjWN5MRoN/XnvSEyNizuqRDcpPzEnkVK5Jn8ryyVHO4Hp9aSRQAUgKq3WnwKsOZZHYvLhSByBjvRYQ2NHIbMhVT/C64/WnMSgEKsCFGCQec9qbO6RKwbdKAfu9SKYYorctNgFm4BHH500BaR/MQNFIVMZwwYdaileMEKwI3k5Uev9KiLY3R8gSDODz9aSS4jVEMce9OFyOce9MViCUkBt7bB1B9KYsjxxKrNvfuT1Ip/kODIWbeD0BqjKzhiZEw0bALg54oQyYy7cPJhNpwBn7wNVZXeMeYEU/PjrnAPeknJBkM20pnIPoKgcyOdpCqhU89yaZNh9yWjjVtu/JAyOSM1Smt0jdyMtv4PtUkkmA0Rc5UAsx6MMVE6OYXCSklmJTPYVSAit3CnymUnA69sVoQqrjKHDoM7KoRt5rqW4xwR61dgkK4V1AZsnjpxTREiVG3eWc7SB8w/pUM5yqMPkI7H0zQr7pEJC+ZjBI6YqpcSMIWEoAXLD/gParSMpMp6jO21yoUAfdP864bVLkNcSODxjH1rotcvFiQrnIUcfyrzrXdQFvayN0JyBXZRhdnFWmkjmPEN0bu/wDLU/Kp5x61DDAsYzjn1qCzUu7Sv1Jq575r1YqyseTKXM7gO3rTweKjzT1I4/WmSL2NIevFOHelA4oAi4zg9KKkYdx+NFAH2EkQ3AkAqe+KtJFsDFcsT61IqDnP3R129fwq1HCGG5ImJUZz1wPevnrH0dyskWDtG3cenPAq0qhF2/LuI5x3pHt1ZlPlsxB5I7CpyuxSQvGfTrTsNsREUgZABHOaSRVZcgsMtyBT2I4YsVA/I0ko3DAztI5IoADjDKQcEZzUTH5dwJ9MU8vtgZOWA6H1psbHOBgcd6BWK8oAIUH7x4zVZQ0bsAxJJ5zVyTDswQjeozj0qsy5YsWPXkUikxsbLsXupPfrUQcFjkevzUTSbADgNg5AHpUEmP3nJbPakAqnMYUMfUNVSeQqMPyd3GPSnNLtwMZQ8cHpVWdgu3HUfypiBnRF+Xsc1l3lw7EgADJzn2p15cLsx0A6n1rF1K8KplOoGKpImTIb69AUheATwfWuW1XVVgQgHke9R61quxSxbkdAO1eb69rTyyMkbE57110aLkcdasoos6/rxdiqNuNcuTJcy5bJJojRpn7+5rRiiWJQB19a9GEFFaHmzm5u7EghEae/rT8DFOJzQBVmYgpwX0xQRx70Ed6AFHX1qRc01QMZpw56UAOXk47Vds4pJ5lgiyWYj5R/Oq0cZJAA5Ndv4N0cxILyZCZHwYwR1Hp9ayq1FTjdmtKm6krHR6Rp6WsCpGCAAPwrTEfylF4kfjNCIETfJxzwBViCLzZww+UAZJzyB0rxZzu7s9ynTsrIS2teFdiCRwnoPr71oJAF8pQAzk8k8UwYXA5z2A/lVqOFwSxQkHtjpWDkdcYWJRbFwftErMFHyHoB7Adqnt4DHECFQnqW7D6Vb5MIL4OT0I4FMmhWXh5PlAxgDHHes2zVRLNqyiJtj7mA6HjFOkg3rknBY9qcpihgG5CQBjCjtVmzdVdExuYn5cjp7Ug8whjAnRTneRweuKnEUoRm3RqUbG48Z/GrKDaDu3blJJ2/56UjkTsHQ/umG3bjigncpSHfGxlCk9FMZqK1uNscrwxkMv8ACRzmrFxFiFGjiDBT0BwaqzQMkhWNmQNyD70x6DmlklTfEg3/AMWeOKkRWdi05VlI4X0NQht5RVb5iSrjoDSOU4gZH55znoRQDQStwduVJH3T0/OooS2FCoInJO4etPlkfy5GZCEA4XHI9aoyPvT5S6pjcH70wSuWGZFgkXzXYjnjkgelVZgcIS4Ee35gfX1p6OxQFEwrHBZT2Peq1xJCglbc8gA2FR60ICqZSVVIBuTp179hUKF/O3O/3l+6exB61WklVZVjUFVHzg+tQqwWFTNIWdG4/wDr1SQMsyyby0c5CpjGO59qcTtXKEhQm3b6e9U5JI2uGMrh5mOQMcD6VJul2sXA2qPlx1OKqxA+BkLxsVIcDIz1xVgTyMER48FgenQD61VgZi0eQBkZPqBUxm/cqmNjEkD196pIykxssjFFydrnG7FUL+dih+YEcn8adLOEUM0m5cY+pzXO6veACQowC9P8cVrCNznqSsZOv3xMZ5zkdfWvM9cuzdXQiU5RP51u+JNSKo+GyTwBXLWaFpN7c16tCnyq55OIqXdkW4V2oB6U8CnHgcCkAOfauk5QA45NLjHpRx70oNAC5GOetP57cimD1Ipy5LHigAIFFL0AooA+20jChztzn7vBqVTJ5Q3qwX+70qVACg8stuPrxipdv3hkMPXPFeDY98qKdhAZmy3KjNTRqWiGTgDqaXJLNvVcDp60hP8AEjAqRjmkUBBIIKApjjFNYAISFbJ4x6UsbFRukXBHQA5zSSFWJcNtZxgZNIdyuf3URWI8DqDzimMxIyuBxwadID5bY2tKowSO9QEFgCf9YFwVB4pDGtKQzE7duMEjrmoZCQ244OOmKc2CAVj5Iy1QyhpVzkqpUgj0oGMlyzAoNuOM+oqmspEYVGztbBJ708l1jLA5GMAGqrSDB5G3+IjsaBiPIMDbgJz+BrPvJVBbkhsdfanTXI3ERnPGaxdUu9sLFiPMx+GapIluxW1G8IBwwwSDgelcprmqhVY7xx29KTVdS2o25ue5Fea+ItZMkjRwn6n0rqo0XJnJWqqCGeIdaaeRoom47msCKNpm/maIo2lf+ZrRjQRrtAr04xUVZHlTm5O7CONY0AA4p9KentQBVEAOBQDSqR3o5ye9ACAccU4Hj1pKcB7UAKB2/KpY0ywHc00AZrV0fSJtTuRCny4+ZieoH0qW0ldlRi5OyNDwlob6ncNM6nyIMNnOMmvUbK2KxoHOQOeRjn1qPRtNjsbSNIxsiUYAHer0hV0YAlc8da8fEV/aS02Pbw2G9nHXcrzqZpI0iCsCefYep9q11tCuEMijufl/Sq9tbsOcgZ9T19hWjDCyY8zIGPv47e1ccmd8IdR0MHO7YnmY+Ud8Vdt4JBlhxnORnkf4U1IfKTdHy7fdZh0q4kI8ry3Z5MjLMBwazubJDRCXwoA2YzuZs4oBCjAYMgPYZINWjDs2JHCSTgfQVPGirIUjjHm/Tj8qQ7kMSssYlCsQ38BwMCpIFkL8hQCeAO1WZ41YKHOH4GV6UjrElyIgGLHox70EXFVyPmhALgEHJpPMMEhllDgBeVHQ+9JFGqlwM7WPQdhSouJDDHvVYzkludynqPzp2ARgFjlZUzGQCuO9UryNXtsu0iqjBlq9PLvG8IwEZIwB0FVJpC8Q2MMN8yhuo9c0MaK8uAp84hQMfODSyStHNEUAdD1+nSmfelYPFwRggio2BXzASok52jtQgY11YtPiXbKRjBPC1RkQ+cGE2UA27c8E067mMZMoQ7ljGW7HjpVZWEzIzqBF98AHkGmCLAfDLHzG+zOQPlyKrXcqyO6rlNuG3Do1IZlLyrCWdyN6o3Tnt9KqXxcQIuFSN0wcHkGmkJmdO/LhpB97C44NNMiuZVVcAMM5HU9qryeWr+WCNy425OSR60iudjPMCvzcAcng9a0SJbLsRdgHKKGx83oKfHI0gQNjew6Z469apxs4eUsSxx8qelWIX+TJwsgUZ9BTsQ2WJOEdlLIQRkqOoHaob2YgNIpUqq9T29abcz7cPhizDG3+tYuo3xwyoMgEDHf61cY3MJyGajeBCShJyMj2rjte1AKpUHBHb09a0L+92RsSecnINee67fmWRkU8n9BXfh6V2efiKvKihfTm7ueDlRwKtQx7UAqCygwu9hVvkdK9FI8xu4MDxSdgKXryO3aimIOpHWl6nH60Y4yOnpSnnGKQB6n0pQTnPpSY4z2pSvH0oAUHPXrRTR0PrRQB92y+UyFWJK56HvSskeE+QkfypEz5eFyN3Q1JFheEIJHWvCPoNiFkYOWU5QCmsCQEwSrDqOgqSSRA5B3Kq8knpTXJRP3QGOwpDTIWjZCCJCSO9RIN5yw+ZTkVJNjgAEhvvHPSoGIDgxuCg4PNKwxZMbQw+Vs1XunjTe2drZA/GpDcojvk5QnHPaq8shk3FkUrng+ooaEQuCjEqxy/UelVhKCu/JKjj6mpnI3mTGQ3AOeoqndEKwC8Z6DtSsUnfQhvH3Jhmwh5645qnO5Ck/LzSzlTGxk5AHI7Vg3t6hZlVvlJz+VCQ2x+o3YjjbBC54464rjtf1Ly4uWOcd6n1jUkctjpnOTXmvirXCSURsseBXTSpOTOatUUEU/EGtOdyK2Xb9K5dFaV/Uk8mj5ppMnljWhDEI0xjmvUhBRVkeRUm5u7FijEa4HWpOMc0lKKszDoc07HPWkA5NL0oATgHgUoBApQPWlI5z2oATOTjFOQHdzSAVNGm5ljUFmYgADqT6UAWNOtJb66S3gGZHPp0+teweGvD6abaoPvyn77Ec1m+CtFW1iE8o3XDgAsR90Doo9hXYMQkRKgsx4AFeTisRzvljsezg8NyLmluyO4IYCEEgdTj+tLFCvn4T06nv8AT3qSztGLNyxZjnI6L+NbFvbbUIZFGDgE9TXnuR6cUUXxGAcjkcnNXrWFii7DxnJLHPFWBZgOGbb06AZH0qaKIKnlhWKD8AKzbNUPcJjGzc5461KofG0t5S47d6IxCU3SHHl8E5xirCW+4eYMH1pDJoWSNFbzAZG4HPAqZVYxkFRnuw61DMUUx7goG3G3uPel4K7WfB9vSgVizBiNZYs7iuPvDvSiGIqzOxkYHBI7VH5zeQzRoHcDaF6bqdscQDyzhi2SuOvqKpEsrSoECm3YGNm5HoP8atB2Ko3yjHy/N3pJAHYxpHghcVCsAjgHnEgsfuselXYV+4l2252UqyInOR/F/jVKWUlm8yMKgXKkdqvTBzM/zAxMgKn/AGqzpgfIYMxMxGMD271DKWxTfc8flCRllKkhz6VFeskQhlLhZhjkng1IHzjJUs6Y981n3YjLRQud7xHf8xoQxrl2UtxtI2hcdPeqVvLC7oZMl42xgdMntSXzMCHlYLhvkxxkVTEzNJI0YCosnVhzj1q0g6Fu5vQIlkiRimSmMcnPeqV2FaBkkZtuSTz+lI8ryMViARVxgnqRmofPWJJCreaWb1461SREmQShY2LBdxbjPeiIsC6yEZyMc05nVm45XGRz1NVYC5ZRJgHPJ/XNUkZtlvBLt8xDDnd6+wpWmGTu5CkEgjio2fYUA+bk8kjiqtxcOi4fAVvT+tOxDY6/umVCVbK9F3cVzN7c5Zir9TnAqS+vPlUklgvQnvmue1C8SC3kmkbHpzXVSpnJVqJGd4j1EQxsqnLN/nFcpaxGeUs3Pc06eWS/uyxzyeB6CtKCJYl2jt+tepCHKrHj1Z87uSbAqBccCoWznjpVgfMaiYcVZmRdTzThk80jDil5XA7mgBwGSecGnYx0FN6jFKcLkfpQADvmlPzE0Ejj9KQ5xxQAd6KG/wDr0UAfdRyTjIHfjrTw3zlR97qabjjJPIpgYcjBB9a8E99ain77ZHHrmk2qAeuH4yKj8xlyTt25p0coYFehNIqzK9xEcLiQrt9O/wBaz4ZG86VHj2onII6GtF1ADFi2W6g9qqTOVdCADH3oLi9LDAge32nDKSc5qAgum1coqEgjHWpH+aLIYrhsgDvVeWbdgfMrfexQSMBUIVjOApxzVC8kGyQOeMdqlmmPLdsEYrCuJpWKlgvAO7FArdSrqtzstiGJChcj/A1w+o3oWEKsnBzkDtWt4i1Iorpnlhgr6V53quobdxY4HU1rThzMmc+VEfiDVlhhZudxGBzXn80r3ExdjljVjVL1r24LE/IOFFOs4MDc3U9K9WlT5EePWq+0Y62hCICfvVYBFAGcelLgdq1MAPFL7UYBBpR096AExRjDU48HmlC8c0ANA9etOA/KlAx1pSTn0oAQYxz2rsvBWjvPKl1JHlWHyggHA/vfjXP6Hpst9doAjBVOTx19q9o0HS1tIxuUR5GSo7VxYuvyR5Vud+Cw/PLneyLtnAkMIXACgck9Kv21qZMMDnPAbH3RRFE0rL8qxoOVzz/+utO2iKy+oAxknivFlK57sYjYrbK7VVgF4JBxmr42wpjyx04OcmmxRysW84BUHQ56/hU6WpMgnbPljgKD1rM0QkBDqDsZWPAzUhGwb2GzPAFSvDMz71IWM8/MOahAwcs5kwfur2/GgYyFWlkDSFBt52CtFIwVDYZAvO31qCNTLKBG23bzjHrVtC7cx/vFBwc8ZpgMKqUYiLJznBouNqbREoYEjPPSp3jPmbtu4Hn1/Oh4kwA64dvbiiwXK+XbIxgEfe9KSSRlQg7w0ZHPrRtkY/vGOAcDBwD7VE0haKTY33iMBuoxTQibMjzO3DJwRg4/CmXEqS20pk/1a5ClhgjHOf51DK5OfJO1yMnHTioHkDgK8e9W5Zl6DHrTuJonUlntpFYkEcDpn3qnM6ZkMC5fdtYH9TUsdwPOdwpCqNqE9Me31qrdOwjWRxtkyPu0DRnyR+SDgFirEcd81QupERvky8mTkHsKvzq0bMwYI7NkKeQRWXNIysw+RiznnHtRYspXZLSycNKhUEA9B9KrM5d1yCOmAp7ep9qsRnI8suWkX5z2A+tZ0rsrPIiqN4AIbr+NaJGcmOecIZJdvzZIVTVN5gUIPyRBfuj35zUbyfMz5Yh+MDv9KqeZt3qzDbg4OeSfStVEwlItySpgnkAAY47UGQpzIwEbYHPb/wCvVYuPNyM+XxjPWpFfdltuUxxuPJ571ViLkkrgqJN5QFjkD+L0rKubhgrbyzADjPSrV5MViYIVCg8Y/Wuf1G7ODlhtI6elaQhcyqTsirqNwCSWbgdvauJ1vUmvp9iH90pwAO5qfXdUMztDC3y9GYd/aqmm229vMccDoK9OlT5VdnkV63M7Is6bbiNNzfeNW2UZ5796fkcYGBSPyuP51scwxR15xUb9cdhU2Bn8OajkPUEcCgCA8YzRnPXmlOc9OKQDI470AKOnIp2TnJpg7Zpc8kigB5JGPSnA7ck9ajOMA+tOPpmgAyKKQ9eM0UAfcbuwbdxj0z1NI8u1c56nGOwqFx84LD/A0Fg5I2n6HvXgH0KQXKKYSHY4JowSVw20rjn1pisQDkfN0wTQScgkbWHakWEr77oFWKlRyppkjKWYZyduTSvhjk8SEYOKi9Np5B5BpiIMhwG5BAxj2qCY7Mk4+bpU8r43Hqw/lWddXG2FvmyV5ye1MllG5d8K0nyjJ6Vh6vdIsfygcHI9TVy+uzgjOeO9cP4g1RVZsMCRwMVUY3JlLuc34n1LEjjK5Yckda821e+adzGrEjPJ9a0fE2pmSdo4zz3Nc/DGZG9u9enQpcquzy8RW5nZElpFvbcfuitMEYGBUS4QBR2p4rpOQcT6Cjv70UDpQA79KMd+tAHFKM4GKADvz0NKRRjnIpcjOKAARllLDoOpPAFXdIsJ9RvEhgVmII3sBnaP8afo2lXOsXiW9qrMoOXYdF/+vXtHhfw7baNaIqJl+eepJNcuIxKoqy3OvC4V1nd7Ffwz4ci07YREBJjcQeQG9Mnkn+ddRDA5Y+h6nsasW1sxxsXBPYmr0cIQMJBubHIrxJ1HN3Z78KagrIjtrYBSxC8dCT1FSB/Mdtu0uB+A+lK0QcrjAkH8JPSpEUbW+Yq69gOKyN0hIclcOC20c7TV6ECTa21gAOBnGKighWI+YqgseSuanZmaVBtxH1OeMUWGyRTI0Z3jaF7ZzmoFi2gtCNuTz7mpJAkjAozKQenvSqgwd7cg0xDo/OUZ+VZeBgelXURmkwp2DH51ShIacybizYxnPA/CtCFo2AkkkB4PfAFCQNjYw8VyAGUREdqZcOsTeWrks3K56H8aldIohGgUsHOciq1zI6lkITZnh++aZO43yXBDtIPMbgqen4VFchvOMSxZAHBI6mn+aoKbh5rp1I61BI8r3DFnIaQ4Qf3RQNIgKNiSJlKHBIYHnNVkLCHEW44GeafOzLsRpsMpww9aimcqbjbMdpwB7UDCYmOEGRcqADsXrmobhjGpMSu5Zh16AY5pBKA4aSXcpwBkd6r3FzsSYfPJltu1TzRYZHMkmAyoMgkZc87T3rHufKdm8ss2WJ+XkZHpV26mG4tu4C48st0+tZnnqrYjdUTZkBew/wA96tITZDJIdsbbQAyfMD1+tZd0QC20ZbPc/wA60pSMKVbCjg8YzWXO+55DIvJOQemKuKMpMoXEpyy7xnOBj0quGXCrxt6/4VHeTF5Dk56g4HU1WEmAyBcDG0jvXRGOhzSkaUbGQglxz0wKZLMAnzksB83+FN3JDAwfAUADOeT7AVh6hqAY7yOBwOcVUYOTInNJEmoXg2vv7nPHFcTrmrNIzRQN7EjtRrmrtIxihP1I7VjW8DTN/s9zXoUaPLqzy69fmdkPsrczPk/dHJrYTCrtUdKhiURqAvAqQHaxNdBxkuecd6eDzjt1qANjp1p2SR0y1MCVhwcYqCQ547etP3Hk9+mKgkORSAaTwaF6jPWk7il9R0NACnrijgD1pCfpg0nbg9KAHkjIFIe31pucHjrS+tACjOeOKKT60UAfbzeg6dRimg4G7kH0qMMM8cYpS+FO7pXz59Ghd645yuTjmo5HZcA4D9hSO42ZHXHGagkcPtLEYA+93pDJHIEm85G0ZHPWmM6yRseVZuTiofMYkZO7tUcrgqwHGODVEsZczFNuBkk4yO1Yl9MR+7Djjls9xVy8uOTnAHrmuZ1a8U723YwcY9aaV2Juxna1fCOJzuwMnmvJfFeteWXWJslj8o9K3vGWtpFFJhvmHGBXltxNJd3Bdsknt6V34ejfVnn4mtb3UNUNPLknJJ5NaEcYRQoFRwxiJeOtSg5rvPPF605T+lM6d6cD69KBDwQTQAcUijkU4cHrQA4cAe1L1HFJnjnpS5AHJ4oAUHjFbfhnw5d6/cgQgx2yn55iOB7D1NafhHwdLqu261JZILHqq9Gl/wABXsGlWiW8KW9vEsMMYAVUHSuHE4tU/dhuehhcE6nvT2M/QtGttHtUtrKJQ3Uk9SfU+tdBDAS4GenpUsUUY5bgD8zViK3XzVJDKM54PWvHnNyd2e5CCirImtlZclsAnp9KtQKkmcHHqafFAqlt/Le3pUkKnZukjAGSQF5zWZdiAwlHDKqhu+e4qVI1aMOF3euOKuQCOReVA9ARyKR8qGXaIscZ6/jQVcgKxoAzArjpz3qPlpCQw5GTjt/9arClWURyk/Nn5iKg3R27yO65B+UHrkU0BDyi742Xb1OD1pk1xl1jxgHjIpZlBQSxYAHGAOKhmYDadpwerd81QIu2kaxO/wAxI69MgVLDKs8JDxjYGw2eMiq8BdYPLicOz9yP51JvVSY2fLgc7RxUjLc1ysSoiBjuxyBnFRyzKElZzvGQORwKpCUjYsY5LYAPaobuUoxdpMpjBA/vUxJF6dlhJYAhiNoAHr0rPjaZiRLJznII6j60kDFYw21i0gwNx/rVYu+5Ymk/fN8zYHUCgaLdzMq8tHuccLu7mq0jNtkEqqsZIJ4+9StIrokkm45OFGO9RXG0SBgXOePYUxERCbwmwnk7eOgqs4YQMdyxsGwTj/PNXB5qP8hDuDlsdhWbqE6MGXCkg5x2FNILlC8lbdKSF3n/AMerMEjk5VEJVcMe30pbiYSOFJJJG0tUSmMRIrsVzk1okRJklwdoZXb0II7+tY9/NgkoC3oCelT3dwGiYrwrHPzd6y7iRSjlznp171rGJzzkVXkIzLkBxjBqCJtpZ2b5zzzTLmfozDnt6D8Kybq/EPJbk+prpjBvQ5ZzUdS5q1+AMFenAbvXFatqrSM0cLZPRm/wqHVdUe5kZEJC9Cc1BZWRlIeThP5120qSjuebWrueiIrW2adgTkJ3NaojWJNqjg1KqbFwo+UccUmfm55rc5RpAI6UmPXrTm55Y8Uhx9aAEzg9KM9+9HUjbQeuOlACZ6YppAJ4PFPA5ppAXODwKAEAO3H6Ud+KDx0zSdCKAAAd/wBKOhHWlXrnvScZ4oAMAn+lJ1HApf50nfmgAxjPTFFB+lFAH2owKtncfrTstnGc+1N3YHQ59KgEjZIZTjsRXz9j6JMmdsDGB0qpcFcAAlQDyB0qRssSS2V7A9aqzzAMO4z3osO4hfYAVxVSefGSG4HWiWTaSwbr2rGvbvaHyeO1NakvQr6nfbeW4zXE+KNWSK3ZgRuxxzU2vXu6Usz/ACrzgHg15X4v1trudoIm+UdTXVRpczOatWUFcyNa1B7+7Y5JQHj3qK2j2DJ+9TLWLPzsOO1WjXqRVlZHkyk5O7F4pfbFNAIpwH1yaZIe1O4xx2pO+KMenSgByjnrThzg00cEZHNT2tvNd3MdvaxNNPIcKidT/n1ouNK+g0AsyqFLMxwAvJJ9AK9H8G+CwhS91mMvJkGODGQp9W9T+lbngvwVBpapc3YWfUcZLjlY/ZR6+9d7a2qRoAxO9uhA4ry8TjL+5T+89bC4Ll9+pv2Kltb4UEqD6A9Kv28Bw+4ke46mrccaIq4XOO47+1TlQBlACAeR0x9a8xs9ZIghQqigcAVajGQPMPzE4HvSIzSnZ8qqBnd/9arUCD92WccnBIHNQy1oOhQB927gdu1XbUo28gHfkZ4qEq5cbMCP8iauxLi1Plr8zZ68YoSBsbG0ZugrIeFzuHSopAZkcBgTzx6VOyMigEgSMOR6CmLEqK2PvkdKdgRTaTYqs+DxycVFInO9AXRuSM5xVobmCq6DPQjp+NNfhJPIIwvagq5UmSONSQPdVHrVdg4XcwCsDkA+lXAdyG5kX5l42Cq7M7OxY71P8IHNNMCK3xvZUYb34+vrUpbeWjBCuBnOO9VwiIGjj+XA4YmlijZ0KsDtTBVieWpDFbAnRmlBKcEDqTTLpBIyJtA2ndjP6mnRMP3gQDzF701pzCoZVDydGPbHemII22xLGjF9xPPp9PSq0jRpHJHC5L7ic5yfeoLi/kjIjgiLZyzyE+/AHpxVSVofnQH5mHzY5IqrEosCURzKuS8Z43dhRDMJIlETAKSQXPp6VUc+VbJE+3J5RFPVccGq32rZA6sCoxtG33700gbLVxLtR13MVOSSD/WsWQmUgHdgfMcH9TUxYLGE2ARDgZOST70rjeNm4AKMkAdapITZmEbGbcwwRux+lZ88+D8uW2/K2OrH09quXsypvjwJCGBJxwKx5J8l2zgMSQMVrFGE5DLmbBCqSyKDnP6VlXVx8jAnknv/AEpL26QEkhsjpnvXL6nqqxANIckHIHc11UqTZxVqqjuWtT1FIVd2ICgcA85NcfeahNcsVUlUbggfxUy6uJr64Jbkk8KO1X7OyWEBnG6T+VehTpqKPKq1nNkFjZDKvMM+grRGCP0+lC5GccUuMe30rQxEGeg4FOBXHI6UAgI2AMk5BP8AKk4LEAHgY5oATAP19aY2ONp5FPPUD1oIAGKAIjzxjmk5Gc8+9OIJUc//AFqQYHWgAwQAMUnHSlxgE5+tG3Pp70AMB+Wj0p3TnA+tAXCk9qAGnrSDtxT8F+MflTsYOOrfyoAiyQOnPSl5P49KkAzjJ6d6NmADQBGeKKeAP/rUUAfYwYEAlwQR3NI7YGOpHOMU3K7CMY544phLdQM4rwGfQRFaUMvU+lZ8jYBUHOCdoNSyyNHwDkE+lZ13OXJGCNvJ9qErjZFd3O1SCec4rjNb1PaXXPC1f1rUAiPIDwCQK8r8Va8Ig4Vssx4Ga3pU3JmNWairsq+LdfwrRQn52/T3ri7eJppCTkjPJ9aQmS6nLMcsx5PpWjCixoFXqOpr1acFBWPJqVHN3ArtwAOBSdeKfgZOOhppx0BqzMbyB3pwHr17UY6Z4pfegQYIpee/Srem6fd6lLssbeSVifvAfKPqeld1ofgmyhKyaw7XUg5MSArGPr3NZVK0KfxM2pUJ1PhRxmh6Lfa3MEsYiyA4aVuET8e59hXrXhPw5aaDEWQGW6cYlnI5PsB2HtWxYx20MSxwIkUS8BEGAPoBWinlEEqVHHfpXl18VKpotEeth8JCn7z1Y+ORFA+Ybj0z0+laMVykaZZSB3bNZcRIl+YALnhs4yal8vJJbOQcgjkH/GuI9BGvHPG6jnG77q9/wqRpACADw3oKxlkI+Zduecj0q7bS5Ubsjdxz0z9aVizRilTJDZIHJ9vwq3CdxHZvT0FZCOwcr8oc8HP8VX4JTCnlcem70/8ArUrDNqERFt4OcDGT3q7uKEMSDkflWbbOpXEgDt6DtVuOVI0AwSxGTnotMmxJETIrSOMYPyk1WYEb5EO992fpSzXAZVaNtyng8+lVcqVaRXIU8sc4o3LRLjzZt24bB29/epJEEQcRqvTI9zVDKCIKGPlE5JJ6mpLll3hhkTBeBntUjsVLoh3ADEDPzD1NV55UTzFgbL4GT7U28m8nezOCM/d9/WsyErl/NBCs3GOppodi+SjuplfkcBc9acZFVRJuKnG1V/rWbLJ5RCypgbsIOpFSRShW6s7MSORmiwFwXIYIIANzevcVXuZjH5gk2iNeAE6n1qEK7plW2Fchdx7+uKp3krRqAWy+3Jb1NUkSwcRvM6fMRtDbQeMelVCW83MS5bbyq8Z/GpJxIYCwfYTgE96rMwxgNg52gg96tITYr488fJlzj7pwPpUXDygEYOcjHPNKwKFcbfQkn9KfbtHb5dNrKc5cnv6UybkrRLGoLHAxwepzWfc3Aw68ZH4Uy9vAzltxCYPQ8YrIuLhUTdF03ZY55z6fSqjG5lKdiG+uWDlyAgJOQetYGoXItgGDfOfmzn9cU3UtQVC5LdW6CuK1nWWYtFGcuOCewrto0Wzz6+IUSxrWsBCwU7nPQelc2xmvbgsfmdvyFLBDJdyk5JzyzGteC3S3VQvGe5716MYKKsjyqlRzd2R2tssCfLy56n+lTl+MEHj0oc57fgKQYCncSKozHK2cDFKDz1600AAcdTSL09c0AOzk8Dmn4wuOfWowCOQcD2p24k8c+1AC7MgYxnHem7fmHHFPVwM49MdKDk59PbtQAzBCnNNKhcMOnepCuckH8qRgOQo49aAI+cdM/Wk2jp609iNoz/k0bflzxj2oAYQvYnilGMEgClC4/AUnbHTNACDJ57dMUbtpHHHUUDaAecnFHAz1zjtQAqnhjj3o9DuPtSZJxxgA4I9KMj5gKAAAYBJ59hRTdxJzxnPaigD6ya4YH90SSTnaT1/Gni6VhuOVPcN61SZ0VWUnLe/UVWt7tZI5GXkg42+vvXgPyPoFuaEzqylw2Pp0rB1C6IDBmGfarF3dJHCSMqc8jNcfreopCCS5I/z0qoq5MnY57xpq3kxsS4AGeleSXdxJeXLSNkkngegrY8X6mby9MSH5F6/Ws6zh2rvYcmvVoU+WNzysRV55WJLeERKO7HrUuOOKkhjeeQRQxvLIegUZJrcsvCOr3WPMhS1Q95mwfyFbSnGHxOxjGEp/CrnPtx1FIc98Beua7y38Bx8G61NunIjjx/Ot7SfCmk2jK8Vt9okH8U534P06VzyxdNbanRHB1Zb6Hnui+HNS1hw0EPl2/eaX5V/Dufwr0LQ/AmmWgV7sNez8ZMn3AfZf8a6NLZ1wDnHYLU0AaNjhjk9dwrhq4uc9FojupYSENXqyeCyiiiVVVUA4CgYH5CnmAD/lmGzxxxUiXPAWQcHv2xVhUDruVgB271yNnaomXJbRhhs4fOeOlPWyYnA3c9zWzDAjcMAoq2LbY3AJXHfqKXMUoI55NPulbIlIjU8bRz9atwq8YYOpYDqcc/jW+saqu48+nvTvKj2/KPrxyKlyNIqxhqvQjkY4Y1PGJOMAkdyp4/KrMls0THC/un5IHTPqPQ1BtMUwXdlPUdSP8aa1KYqTeZPHAc7+qnGQwH8jWlCrEFXJDA8MT1psCqvLH930EuORn1/xq1tTv8wXBbA6+9DQ0yZJRbhpFb95gAn0FWpJVNum1sO3NUkVfMJboeuOcimFwCzkAn17YpMaLDyKrhMEIOp96jusiMqBhG7A/wA6q3ErTkeV91cc+tRtOFjaJDljnOT0+lCKLwKKEVhlR0FOupSqEIq+Z0yewqjZv5gRX4Crz70kxJLu0gUZy2fSpY2Vr5lfcc7sfe+tRxwMyptbAzk561JNslkjSIja/p296bdExxNAPkJwA/r600DdiO7AlkIlYGQjjHYVRW8dNiAbcDLeppuWV0LttVcjAPpVaY+XGC+5gxGD3Of6VSRJeLqUDK5VwMKp7Z7mqVzcb5Qpbdx/COaaoXaWTBAbqfX+tMjVi7HA5Py47/WqSES3JRbYkZ5wSvXn3qIKsnlnPJyQzcYHsKRzhuWX5TgEDgf4mq11cJAzMM5Hylu9UQ3YSeURsFK5wf4up/Cs66uzuEeFUKeB6HtVa6uj88hYbuo9ST/SsafUo4i0rAEAHt3/AMa0hTbMalRI15LtI0DOwJwcK3Un1rk9X1pI8kPhQDkt2rI17xGN/Ubscqp5Ncbd3Ut0+6ViR2XsK76OG6s8yvi+kS9qesSXRKRkrHn73c1Us7OS4OeQnc1YstOL4eYYXqFrVVcKByMcYHeu1RS0R5spOTuxscSxoFXCqPSkIGcHJI7U8naxBB4ppGV5+lUQN27c8ml2547d8dqUodp9O3alA79Ogx60DGnJGM9OOKMcDt2p7L6YFAJztx15NIBm0nHrT9vYdPpTgQ3Tr2HalbnBzkDgZPSgBFIAO4AA0gbkg59zSjOTjjtzSEDB5zj7wFADSFXp06ZpAv3gAc1Jj5evbABFMdc/dBAyM0AMI5B7CkIGwjt60/8AiwTSNnGKAGFieRn60hHOB2PNOOMNkcHmlBXnIOfagCPb9MUHhfTtSjG5QO55z2peuCOPagCM9Oc57ClAyOvOKXpx6DrQRgD19KAGKMk/riinDAIOcZ/zzRQB9Hx3qTqY5gUkHqeR9DVCeV7eQSIMkfxLxkVTM73rAgxxuP7vUVY+xzupEkzFTzxivDtY95y7EGpX6vAssbgqwyRivMPFurzSMILUO8z5CogJ/GvVP7ERsq5YoecHpn1p0Hh+0hkLLGgc8blHJrSnOMXexnOLkrI8P0vwZq164kuFS1QnJMzfMfwHNdtpPgexTDXTS3ZAxjOxQfw5rvv7JiQE+WAw7ipYrPy0zuLY/hFXPFTls7GcMLBbq5kabp1vZqI7S1SFOn7tf61pC0iYcA5HrWvaIhwCDn6YwKsLbp1wMk+nFckpN7nXGK6HNvpznOxcED606GJ4uGhJYfxDg11a2+UG04z39akaAMFwA3HNS5FpHNxg4yF3e/etWGzW4jXcBuH4fnUstsFckL9aliVUYD5wO5A6VDNEQNpgDcNwOuKabN43G1d6+tdDBADGpQqQB9c0jxBR0+U96llIy7SP5iNp555q4VwNrDochhTnh8tsp8w7Ed6dHjB3cnpRcY1WXaSy4z1qSNAepz3B9RRtAUOVLEdM9P8A9dM3AZQsMHkE96CkDxvtK4+Vv4vSs+4UI7eYcp0btitjJVNm7cffqfwqnqECshYL7MB3FLYta7laENErBDgDqTxj2+hq9CcICg2lTwvoT29we1ZfzqyqxyhGA5/T/CrKTFCqAMOwzzhe6/1FaRd9CZKxPK+1mCjY38X1/wADUckynGOI8YUe/ei73+eAG3RjpJn16fhVSV/3xZwQuMhRQ1ZlRdyaQ8eXkJgcepqqqlpEMbcL196r3Nzub90hyeCTUKSDYMMBhsYz1o2Gbe8L+8kOFx1WoJTFNFsAPJ3cn+dQKu5fLJyvUZNMlU4MKZBb77joB6ZqbDuTvLHAqqrKH9cdBVO5BMirvLsik5z92kkU5dVYMQMKT0P1qF2kKhF2hT1b1ppCuQXAUbBGWIGcKO/1qNt4jUSn5VAAc9TUl3viYYyXK881Ut5DLuVsMyHcT2BqkhNl6RUO05HToOgNRSOLeFSPmweg6c96SMAxsrDdH7ng+9Ur24wCJMFeOAfvf/qppEN2HSylS5BUKBwx/n9a5rVL7IYAkOxwc9cUzU9SMEblztIP3c1wmua8sbMS+52zhV6iuqlRcmcdfEKC3NfU9XWGNjvUBT8xPU1xer67JdORASE6ZNZd5dS3cm6QnHZR0FWLLTZJvmlyqenc16VOioHj1sRKfoU4opJ3IQFj3NbVpYJAu9sPKPXtVyKGOOMJGgQkfnSkfN1wPfqPrWxzXGHAwTkkUY44OT09KU/NgjBx7UHIB6nBpgIo5bjim4BGcj2qXHOOKacDnjoenakIaGZmzjk9u1AGMZGPY84pflxhT9KVVzyeCD60DECgnjvk5FKSBjIzn+VHYAdenAxmnKCT8vbg+maAGADK5/E04ZORu9wMelKQ3OOARnOaQ8sGHQ4AxQAFT/Fz3PNNIJ6ZAxjPrT2yVGDzmmsQe/OBk0ADHAx37+5pCAMHjHYim5+Y80mQceuOtAAQQTjHPHHrSDGckYHpTycEkcLnrTADt6c9OvWgBDjB9etIcck/iRTiTnnn19KZuG3oBnjOKAFH38nrntSEqduAM88mjGVI6g8k0ADJPXB9KAGZwOvbmg8YAwfxpSMcfr60mcE7sfhQAKDk7eM9vWijkZB5GeKKAPoJ9PjLcDDCkWOeJ8I5IPFXkBLc8mplUgZBH0rwEz6FxK0TSDO8kVajR8qUOT71LDh8Ky5JpyDY4ycHtQ2CQ7yMruJOaRY2AyFyParMPQrkHmpVXkADANQ2aJFYqI3UZ49hx9KmTDEYAwePpSyxFW/2e4p0LBpBhSF6fSlcaQ/y2VgFAwepz0pzx4JCnOO471PEFXIbrnmpimAcDOOlJlIrxxhxyAKbLbYOQcj2q5Cu4BgPYGrPlgIRwSaQzHsLj7NNsuGIhY9R2PrWx5aspAyR94VlXFuqOyL1PQn+VT6VO6EwSnBHKk0LXQb01JvKPIzyORgVHjc2WGDnNW5MLIwHUckVVkmKgk4wR37VNrFIOqt8wDDse9QsFYZIJH9aYTyMt855B9al+TYGP3Tww9PekVYlQM8YEeMr/EeuKSYFFO4NkDL8dKdbsYiSeVAxg1a+/knoR0PcUDWhiXSYYnbw4xjpg9jVR5JMfvANyLk56Y7itW7jBBwchehNVJgsiFiBgrtP1oTKGxSieAZPzE7HU9B2yPY8Gqk0rB3ikXD5+Yen+TTF3iF4m+QsNgyffg/0/Gq8zqrhiWyyjJY55/yK1bvqQtCG5YmYbDhug+tPsGiQMz4c7uQPX0FUZJy8qqpAI70QyrEFywCjJz70WKcjYW5hCHzGIDHrUQlMqhgzMScjBwMds1m/bEy4RQfTNQR3pVdu7DvxgCjlE5Ghc8BpXbLZwqr0qpNJJG21eSADnoBmiS5VFwMKxPrwBVc5dd4JZgc7TT5RXL8jB0xncwHIPb8aht1ESYGMk849PeoGkeNGcH75xgfxGqlzdeVtJO51G5vQU1EiUrE13e7GY54xtHYD/wDVXMa5rKIuS4AAwT3xVPX9cWEO7yDdt4zwPpXmGs6xNqEzYZlizwO5+tdtDDuWrODE4tQ0W5f1rX2mkZYW3c9R0FYEcclzNtUF3buansbCW7bIG2MdW/wrfgto7eLZEFxjk+vvXpRioqyPGnUc3dlSy02OABpMSS/oKug8sRjBOMGgksqtkse1DYyf4gRnniqIEYFchucUjdlGM9yDTlGVHbjmkx059eopiEAAAP8ACf1FJnJPQ9KcWyMjI4z9aMb2KxjnGOaQxgG0g/xenvRgYJyVxz9acpOevSnY+fIwSedvegBikEHGfYYoKdADnjmpBhfmUjI4PoBTV5DDcVOOtAAOn8I46UYUds/XpSEguB6jIPrTvl4BHA4+goAHbkKM4zijyx3IAHAz60wtyN7HI7UjdDk/N1oAcdoBxnrkgdKjJzz1A4IxSKAPvKQPX60o3AD1PpQAoGAFYjJXg0wjaM4zkcAdxUhGAR7biPwppPXByuKAEIBGeuemOgoyVAPJz1HtSghccjONxI7CmYGducj+XpQMXAGeuM/lTc9AScGnbTkgN0OKbkduexoEIck5BUAfpSdGIBK9DR8wJ6cUgwfr0oAOR0+n0oG4gD/9dAOBnnr+VD9cen50AIR755xRSMM52j0/CigD6SdTFIQT16GnxsxBIGKtzxB1GaqlGjAJHy186mfTtDlcZGO5qwxJxuwTioVUZUg8VajUMox1FMmwiMdnAwRyKlgm8yMqeG7ZqWJUI5GCO/aoJo9qZz0akMuYIwrCq75Q8Dr/ADqaF/MUK/3wMg0yZSDhgc5oasNMtwvuiDt34PFWtwAwuMVn2wIfaD1PP+NTsDG3A/dk/lQwRaiBDNweORTlkzt45HJqGJiG+YnB71IwKvuA4H61JYThJEqhdk7wy43IePer8qMAecowz9KrmEOhYHDDjHrSsCZPbz/akBYASqOCOjD/ABqGaPBB5O7nFV1HkkKSUO7crAdD/hV6UKwEiH5ujD0Pt7VTV9QTtoZqIBIwPB6r7e1ThgHPXb0NIeTuYfNnB46e9MmJSPcBlj1HtWdjQtxyMzBB1HA9KtI/yAYJx0FY9nOQwVuQOP8AA1f8w7VOOejZ6CgAnxv3EYwecjsazZjui2k85IC/Sr8jbgd53KeM+orMkIyUcZycgemKEUUb5gwVgMsD+RrMuz5g4bkMDz2H/wCup9Qlwso3kHPBFZ0WAzqxO0nuelaxIk7Ec8i7eRgHg1UWQXD4c98gdgtPvJhsJA55696o2z4yZOXIxgelaRRlKRb3SHaqbRjIJ/pQoAIZOZOg9KimuAIwvTjH4elVYpXmmDAlQDgAHtVcouY0FUync5LEfwjpV5bgW9uI1QGRvvyHt9KpGUQRlThWY8D29az767Ox2VgXPy/hU8tynKyLV7eOigRYOTjPoK5LxNr0dqkoMowOmP4vaqXibxDHa5CspYjG3uf8+tec3VzPfXG58s54VR2ruoYa+sjzcTi+X3Y7kup6jNqEuZCdmeFzVnTNKaXEs4wnUL6irGlaWqFZbkZbsvp9a1W5QruBG7IH9PavQStoeTKTbuxqx+XgDCLj+HtTWGdvI4GAQMcVJuAGMBeOvXimMxI5wx9MUyQ2DnIz25pv8JGMH0PelBJUnDevJ7USF+nLN0b+lAyMYZlHRgPTFJt5xn8cU8HJ3OOemO9BVsYCjA5JPp70CGDO3uWHOM9PWnAK+cHHTmjHUEHJGODjNAYALu6gYxjqKBgTkAbQT19c0innnnIyAe9LgcckBumKb82BtK496QC5AjHXPI//AF03GFzntgEUgyB685NPYbQCCdrde596AEUY+9ubH5Y70jHk4HzYpzZXCqSAO5Pam5wdwJA9u9AC8bTjcO4yOaYzZ5zkg0g6/eIGemM8UqZOMqORgA0AC55B5x2FOk9m6enbNJgFiOfb/CgbcnPfjAHQUAIcFRyc4OM9jTclQSwJ9PSj1PAyPQfpTTncTyRnqOaAFDckDGTnn2ozzn5QeuKGDHPy9OenNAweFztz37UDELY4AwKaffBGOPWnHOCScr3Pb0ppAy2BnsKBDivHHcAHNNGfYHqcmlzzk87h39qTHAwKAEIOB3LZGKaQD09e1OwAx4o2/L7cdaAECqQcHkDGPWiggBjznJ6Y70UAfVZjEigdx2qu8RJIP3c1bXAJYdaQlZOnB7183Y+pKJh2sTnvU8K8DDAZ6VLNGAAw/GnJGOOOPWqRIsPO5SaXZvTnkgdadFEA27JpwGMgHGKBFFMhtwJDocj6VflHmrGTz3qncuFkWRfXBq3Agxt3cHkexprVA9AVOVZMZ9Pb0q6gMqndggfex+hqLYAFcDAJ6e9Tx/unz1jIwfpTsBBIpRypPXgGpt27CjIwMVJNDzuTk+9J5YVjkHn0qWikx9uVKlX7Go5I2Vw+MewoLbNpIyM0+Rg8QK5JHQe1IfUrTx+Y5OAc9s1WmLx4J7HDY7ireOc+nam3qIQxGQPb0pDTIZ2IZWOM9OO4qnOzByF4A4yatFQyKGbPb/Cq11hTuBwRwc1JaG2ZzMwVQpAyKu28occd+TuqrbKoXAPyn5ifQmrEmIiAMeh9hRYGxk7EEbQMZxx2rMu5F88byRk1cedA4YchWwRWLeSjziQcD+96e1CWo0ynqkibgWH3Mt9TWN9pYRkqfmJqxrc4ZggLDIHA6nPasa8lKRrtKjCk8Hofet4RMZyH3MoVQD3aq5myWAPzEfe9BVVn3oCAS3TilZGVcqD747muhRsczldjjNvZV+baPvf/AFqvQgR7A2NueQOpqjAwRfNbqOOap32oLC7Etlhwe/Peizloik1FXZoy38e6R5OTj14ArjPEnifyRJFCwMhHC9MfX0rK8Q+IG3mG2xuB5IOQP/r1z1raT30pb5tpOWkPSuyjh0tZHn4jF392Az9/fXOSWklY8k1vafp6WpBbJkPO/wBPpU9tbRWsWyJGOfvEdSKsgIVI5yOdwI9K60jzm7iPyVCfM3U8c0xwoYgClIJZiBn0JPftzSjJJyo+XrnkYpiIjjcGIGOvJ60HH3gD9T/OnNhv4htznilIUbQuMZ+8DQA3jg5JGO/Wk3kbuTgcFjTh8vUcjn60hQlsYGF4wpz9KAAgAHcecbsH/Cm/wZGcr79RSADOCCCT1Pp3pwBCZ/XocUDEYMyZbORx9KQgKu4fd7emPSgjIXJ68cHn3pVHpksDz9KQDUAzgdRx9aVgMsBjgA8Dt3pcKc7m5BpgPVl/4FjPegA+50zz0NJv3r82c9Tn09aFX5OOvrnpTs4+793tgdaAGMNoI+bP+cUrE78g5PseKNm0HIAGc9aCDggjnPUdKAE+YEKQGBHOKDwck5XGfT60NkEYz2x7nvQD821slM7cdxQAAkcAKBjr7UIFMgDSeWvALEFto9eOTSEHHJ68+mcd6VsYAAJAOc/0oAZkCTOenGcfqaduwG3DD9MUAFAGHBBwKQ8KOePfmgBCRn1x3pMlQcNkkcHHWk75zuPJ+tAbJAJ/HtQMUY5LDBBoJyWzjkdPU0xlxk4J45I6U7sBz7Y70AJkNz+hoJJXIB46+tC4BPBBwCfakXJYnPTnk8UAJj64HQUh55zxyD7U5+DxnAPX0zSLkDnoP1FACAjgjk4/zmilLZ5wOOmaKAPqyViDlRwKrO4DZB+9U7jK9yPWsu4kYMePl7V84fUGrHKHRec9uKtRICoUfjWNZOVHB5znBragfIBx1q7EMe6daqbh5jKe3JrQuGCrux061kyEtMGU5GcYosJO4+5hVyVB681NZ/8AHuvTI+U/hSqMv2DLwc1Kq+XcEKOH5x704oG9CRlIRhj7xyPY1NATJGnGRyp+tQ+YZPMU4+U5FXNJ2yCUcZHIWnbUL2RNbR8MJOuOlSFccMee1SPt9MNUUpyc0mgTuUrlcHKfr0qK3kDA+3rU8zEdOewFVYBhmwMeoqSuhJNjaApxk1BPJklCBlf1p8u4FeB7+1VroESMwPBGKllRGqQDn04x61Snm3SfNg55+lWLqXaoOAOOx5rJuHB3kcll49qk0Rfs5SUkPAYnH0pWmIOSODxz/Oq8RIQINpyNwqreztG6gkEY5I702IbeXEYDEMVJPQ1kzXAMrfPwwB9s1He3XmDA25OePQVRlcsGGMMQOPTFXGJLkQ6lOPM2sSQATn1rCu7hSdytnGOO1Tapc4DZ7gjI7VjjcyINvJPPP5ZrqpQ6nHVqGksh2Njk5x/9anpKyn5wFBzVcbdyqQeMnJ4yfWq9/dKsRJZQ2CRzWlr7GadtyW8vgoCnaFXkjFcHr+sly0Vu/wAxJDMO30PrUmv61GTLb2MrSknaZdu0EcdB1BzkVS0zTdo865UErgrGT/OuylR5dWcOIxHN7sdiDTdMM5Ek+Vj7L3P+AroI4xFEEQbVAwVA6U4jO0ZB9MDGfpUicLsbAYnBOM/5NdBxDAc89OeSOgP1pDwSN2MHGRz+VKQeAASM8dMilY4JIzjbwM8470ANOCoDDCqM9OKaRkckbc5GQaUZ6Y6HJ5z2oyVwd5HZfSgBrf6zGFz0yPWmqp44yvQj+VOPzYyDz8pBGPp9aRiF4x1HQDtQAqrxnBLdRzSfe2qjAdh2zSqDwADgHqPWkzkkuQAeD64oGIeGXJAxzwOaQDnOQcEgE96X7zqTknr759KQhudxyBzg9SDSEKEIUbDjIxS4+YqByCOPT2poyWOQqnpQQFIIJAPQN0xTGNc5JBUlvun60044x1BPXoBTtzEgE9s/lQy4XJU7RyefX+VACDbyCflJyOPzoIUE8c9gaVQFYsMBeoGaCM5zjIGOv5fWkAhIOD1I7njI/pTScNtPPP69qXAbjpznpQzHcCRh/UelAAQMkY6dfb2pvPGB0HX6UuChHPHIz3x9aTccAk8kDb6D2NAAWAyx69cYzmmgZOCSyDjGeBT1YgfMDt6fgaIxhckkcZoAa+AN2Md/wpjjO7sSKkK9RuXccjJ6fWo8fUDGRn0oAB1wM+n14pWAVANwyF5x/EaQ7hgr97nJzQOuOMdPx/woGIB8vQgZxx6H/wCvSKOeDgj7vankggM3pn8BTcE8dumTxQABcHIzzwSO9GBwB0zkcUFuu7ODihXbGT16emPagAK4AyMg8g55xSDGMeoPy0MQAQOh79j7UgHZmzz2HWgA2hGBx75HFFGSDuB4znJooEf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sclerotic changes involving the lower leg in a patient with lipodermatosclerosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_47_24306=[""].join("\n");
var outline_f23_47_24306=null;
var title_f23_47_24307="Type II endoleak after endovascular aortic repair";
var content_f23_47_24307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Type II endoleak after endovascular aortic repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 456px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Super-selective angiogram demonstrating a type II endoleak originating from the inferior mesenteric artery in a patient with an enlarging aneurysm sac after EVAR.",
"    <div class=\"footnotes\">",
"     EVAR: endovascular aneurysm repair.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_47_24307=[""].join("\n");
var outline_f23_47_24307=null;
var title_f23_47_24308="Degarelix: Patient drug information";
var content_f23_47_24308=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Degarelix: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/42/15013?source=see_link\">",
"     see \"Degarelix: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8018442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Firmagon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9746641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Firmagon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat prostate cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to degarelix or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697295",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low or high levels of calcium, magnesium, potassium, or sodium in your blood, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones with long-term use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use pressure (waist band or belt) on the part where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695745",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take calcium and vitamin D as you were told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12151 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_47_24308=[""].join("\n");
var outline_f23_47_24308=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018442\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9746641\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019095\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019097\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019096\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019101\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019102\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019104\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019099\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019100\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019106\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/42/15013?source=related_link\">",
"      Degarelix: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_47_24309="Evaluation and repair of tongue lacerations";
var content_f23_47_24309=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and repair of tongue lacerations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/47/24309/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24309/contributors\">",
"     Jill Jasper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24309/contributors\">",
"     Garrett Losh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24309/contributors\">",
"     Erin E Endom, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/47/24309/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24309/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24309/contributors\">",
"     Ann Griffen, DDS, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/47/24309/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24309/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/47/24309/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Falls, contact injuries, and child abuse are common causes of injury to the mouth. In children, tongue lacerations may occur through any of these mechanisms, but are most common after a fall or a collision with an object or person in the home [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24309/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision whether or not to repair a tongue laceration is controversial. The literature offers vague and conflicting recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24309/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. On the one hand, because of the rich vascular supply, most tongue lacerations heal rapidly without intervention. On the other hand, the tongue plays a crucial role in speech and swallowing, and poor outcomes may compromise these functions. Tongue lacerations in which poor healing may compromise tongue function require more aggressive treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in all trauma patients, the initial clinical assessment should provide rapid identification of potentially fatal conditions. Evaluation for airway compromise, impaired respiratory mechanics, hemorrhagic shock, and altered level of consciousness should be made on arrival at the emergency department. Such systematic evaluation helps ensure detection of potentially serious injuries. The approach to the injured child is discussed in detail separately (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H9#H9\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Primary survey'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Large lacerations may lead to hemorrhage that can potentially threaten the airway",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cause hypovolemia. The airway should be evaluated and secured if compromised. Cervical spine immobilization must be maintained in patients in whom cervical spine injury has not been excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link&amp;anchor=H13#H13\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\", section on 'Fluid resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determination of the mechanism of injury is crucial in the evaluation of children with tongue lacerations and potentially serious occult injury (eg, cervical spine injury). This is particularly important in children with high-impact trauma (eg, motor vehicle accidents, falls from height, direct blows to the face). Because the tongue is highly vascularized, bleeding caused by laceration may distract attention from the more serious injury.",
"   </p>",
"   <p>",
"    In addition, information regarding the child's past medical history, including tetanus immunization status, medications, and allergies, should be sought. The time of the patient's last oral intake also should be determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=see_link\">",
"     \"Classification of trauma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29432?source=see_link&amp;anchor=H11047750#H11047750\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\", section on 'Fasting and aspiration risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with tongue lacerations should undergo a thorough physical examination. As mentioned above, the initial clinical assessment should provide rapid identification of respiratory, circulatory, or neurologic compromise.",
"   </p>",
"   <p>",
"    After the primary survey, described above, the entire head and neck should be examined for signs of other injury. Because many tongue lacerations result from dental trauma sustained in falls or motor vehicle accidents, the oral cavity, maxilla, and mandible should be carefully examined:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The oral cavity should be evaluated for foreign bodies.",
"     </li>",
"     <li>",
"      The dentition should be carefully evaluated to assess for dental fracture or avulsion of teeth. Avulsed teeth or fragments of teeth may become an aspiration hazard. The outcome for reimplanted avulsed permanent teeth depends in large measure upon how quickly they are reimplanted, so intervention should be accomplished as early as possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32489?source=see_link\">",
"       \"Evaluation and management of dental injuries in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient should be assessed for malocclusion of the teeth or trismus, either of which may indicate mandibular fracture.",
"     </li>",
"     <li>",
"      The temporomandibular joint should be palpated bilaterally to assess for condylar fracture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evaluation and management of dental trauma and jaw fractures are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32489?source=see_link\">",
"     \"Evaluation and management of dental injuries in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6615?source=see_link\">",
"     \"Jaw fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the physician is confident there are no other injuries, he or she can proceed by examining the tongue laceration to determine whether it warrants repair. If the laceration is severe enough to warrant repair (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Wound assessment'",
"    </a>",
"    below), the wound should be prepared for closure. All tongue lacerations, whether or not they are closed primarily, should be irrigated and debrided if necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     WOUND ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision whether or not to repair the laceration depends upon the extent of the laceration and the risk of compromised function after healing, but evidence suggests that outcomes for most tongue lacerations in young children are not improved by suturing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24309/abstract/1\">",
"     1",
"    </a>",
"    ]. Lacerations that",
"    <strong>",
"     should",
"    </strong>",
"    be considered for repair include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large lacerations (&gt;1 cm in length) that extend into the muscular layers or pass completely through the tongue",
"     </li>",
"     <li>",
"      Deep lacerations on the lateral border of the tongue",
"     </li>",
"     <li>",
"      Large flaps or gaps in the tongue",
"     </li>",
"     <li>",
"      Lacerations with significant hemorrhage",
"     </li>",
"     <li>",
"      Lacerations that may cause dysfunction if healed improperly (anterior split tongue).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lacerations that do",
"    <strong>",
"     not",
"    </strong>",
"    need repair include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lacerations &lt;1 cm in length",
"     </li>",
"     <li>",
"      Non-gaping lacerations",
"     </li>",
"     <li>",
"      Lacerations assessed to be minor in the clinical judgment of the examiner.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     WOUND PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necessary equipment for repair of tongue lacerations includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suction (frequent suctioning of the mouth decreases the possibility of aspiration of saliva and blood)",
"     </li>",
"     <li>",
"      Anesthetic agent of choice (eg, 2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      5-mL syringe for anesthetic",
"     </li>",
"     <li>",
"      27-gauge needle for injection of anesthetic",
"     </li>",
"     <li>",
"      Tongue depressors",
"     </li>",
"     <li>",
"      Gauze",
"     </li>",
"     <li>",
"      Normal saline",
"     </li>",
"     <li>",
"      30-mL syringe for irrigation",
"     </li>",
"     <li>",
"      18-gauge angiocatheter for irrigation",
"     </li>",
"     <li>",
"      Absorbable suture material (3-0 or 4-0 chromic gut or Vicryl).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wound should be anesthetized",
"    <strong>",
"     before",
"    </strong>",
"    irrigation, debridement, and closure of the laceration. The ability of the patient to cooperate with the laceration repair plays an essential role in the choice of anesthesia. The options include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24309/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Direct local infiltration",
"     </li>",
"     <li>",
"      Intravenous sedation (may be necessary for young or uncooperative patients)",
"     </li>",
"     <li>",
"      Inferior alveolar nerve block.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infiltrative anesthetics and intravenous sedation are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .) Older children may tolerate an inferior alveolar nerve block if it is explained to them. This block anesthetizes the pulp of all mandibular teeth to the midline, the anterior two-thirds of the tongue, and regions innervated by the mental nerve. In experienced hands, it provides excellent anesthesia for anterior tongue lacerations.",
"   </p>",
"   <p>",
"    The inferior alveolar block is a deep injection, with local anesthetic deposited adjacent to the mandibular foramen. The mandibular ramus is grasped between the thumb (intraoral, on the coronoid notch) and index finger (extraoral) (",
"    <a class=\"graphic graphic_figure graphicRef78142 \" href=\"UTD.htm?14/14/14561\">",
"     figure 2",
"    </a>",
"    ). The target area for tissue entry is the mucosa lateral to the pterygomandibular raphe, medial to the anterior border of the mandibular ramus and approximately 6 to 10 mm above the occlusal plane of the mandibular teeth. The needle is inserted parallel to the mandibular occlusal plane and is rotated during the injection to approximately 30 degrees in a horizontal plane so that the syringe barrel rests on the anterior teeth. The depth of injection is approximately one-half the anteroposterior dimension of the ramus. Aspiration to rule out intravascular injection should be accomplished before injecting anesthetic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Site preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bite block may be necessary to help prop open the mouth during irrigation and laceration repair. A bite block can be made by securing gauze around a tongue depressor and placing it between the upper and lower teeth. A nurse or suture assistant can also use a 2\" x 2\" gauze pad to grip the protruding tongue and hold in place for suturing. Alternatively, a traction suture can be placed through the anterior portion of the anesthetized tongue to provide better positioning (",
"    <a class=\"graphic graphic_figure graphicRef66740 \" href=\"UTD.htm?17/2/17440\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Irrigation and debridement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wound should be examined for fractured teeth or other foreign bodies, which should be removed if present. To decrease the risk of contamination, the wound should be irrigated with at least 250 mL of normal saline per centimeter of laceration. A 30-mL syringe and 18-gauge angiocatheter can be used for irrigation to remove debris and necrotic material. Tissue that is clearly necrotic should be debrided. However, tissue with unknown viability should be debrided cautiously, since overzealous debridement may cause additional bleeding. Lacerations that are more than 24 hours old should be left open to heal by secondary intention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     WOUND REPAIR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tongue lacerations should be repaired with absorbable 3-0 or 4-0-suture material (chromic gut or Vicryl). Lacerations that are particularly deep may require a two- or three-layered closure to prevent formation of a hematoma. The deep muscle should be sutured first, followed by the submucosa and mucosa. Full-thickness bites of the mucosal surface and the lingual muscle should be taken to prevent dehiscence. Large tongue lacerations or lacerations involving the lateral border of the tongue should be well approximated and care should be taken not to overlap tissues.",
"   </p>",
"   <p>",
"    Sutures should be placed loosely to allow for swelling. Sutures that are placed too tightly are liable to pull through or cause necrosis of the wound edges. Each suture should be tied with at least four square knots to prevent the constant motion of the tongue from untying sutures. Alternatively, hidden sutures can help prevent chewing and loss of sutures. Absorbable sutures placed in the mucosa do not require removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Tetanus prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus prophylaxis may be indicated for dirty wounds, and should be considered in children who have avulsed teeth, deep lacerations, or intrusion injuries (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within the first 48 hours, complications of tongue laceration can include edema, hemorrhage, and aspiration of saliva and blood. Mild lingual edema may be controlled by application of cold (ie, ice chips, Popsicles). A single dose of intravenous steroids (eg, Decadron 0.6",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    may be considered in more severe cases if no contraindications are present; hospitalization may be warranted until airway patency is ensured.",
"   </p>",
"   <p>",
"    Other complications of tongue laceration include dehiscence and infection. Prevention of dehiscence, discussed above, entails placing sutures loose enough to permit swelling. The use of prophylactic antibiotic therapy to prevent infection in the management of tongue lacerations is controversial. Although it is reasonable to assume that all tongue lacerations are contaminated by microorganisms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    foreign bodies, there is little evidence that prophylactic antibiotics affect the rate of infection in mucosal wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24309/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylactic antibiotic coverage is indicated for patients who have [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24309/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heavily contaminated wounds in which debridement is suboptimal",
"     </li>",
"     <li>",
"      Delay in debridement for more than 24 hours",
"     </li>",
"     <li>",
"      Wounds associated with jaw fractures requiring open reduction",
"     </li>",
"     <li>",
"      Immune-compromised patients",
"     </li>",
"     <li>",
"      Wounds sustained in human or animal bites (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"       \"Initial management of animal and human bites\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The antibiotic should be chosen to provide Gram-positive and anaerobic coverage. Penicillin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    are two alternatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DISCHARGE INSTRUCTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The post-emergency department care of tongue lacerations, whether or not they are closed primarily, involves maintenance of good oral hygiene, ingestion of a soft diet, prevention of swelling, and monitoring the wound for signs of infection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient should avoid eating or drinking until the local anesthetic has worn off and oral sensation has returned.",
"     </li>",
"     <li>",
"      A soft diet is recommended for several days following repair to ensure rapid healing.",
"     </li>",
"     <li>",
"      The child should drink or rinse their mouth with water after eating.",
"     </li>",
"     <li>",
"      Frequent application of cold (by sucking on ice chips) may help prevent tongue swelling.",
"     </li>",
"     <li>",
"      The patient should be advised to watch for signs of wound infections (eg, fever, increased pain, swelling).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before the patient leaves the emergency department, follow-up within 48 hours should be arranged. This follow-up may occur with the patient's primary care provider, or in the emergency department (if primary-care follow-up cannot be arranged). In addition, patients with dental injuries should be seen by a dentist within 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tongue lacerations in children most often occur as a result of a fall or a collision with an object or person in the home [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24309/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with all injured patients, the initial clinical assessment should provide rapid identification of respiratory, circulatory, or neurologic compromise. The patient should be carefully examined for additional injuries to the head, neck, and oral cavity (eg, dental fractures, dental avulsions, jaw fractures).",
"   </p>",
"   <p>",
"    The majority of tongue lacerations heal without intervention. Repair is indicated in selected situations in which tongue function may be compromised after healing. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large lacerations (&gt;1 cm in length) that extend into the muscular layers or pass completely through the tongue",
"     </li>",
"     <li>",
"      Deep lacerations at the labial edge of the tongue",
"     </li>",
"     <li>",
"      Large flaps or gaps in the tongue",
"     </li>",
"     <li>",
"      Lacerations with significant hemorrhage",
"     </li>",
"     <li>",
"      Lacerations that may cause dysfunction if healed improperly (anterior split tongue).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Before discharge from the emergency department, tetanus prophylaxis should be provided for patients in whom it is indicated (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 1",
"    </a>",
"    ), and follow-up arranged within 48 hours. Patients should be instructed to eat a soft diet and monitor the oral cavity for signs of infection.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24309/abstract/1\">",
"      Lamell CW, Fraone G, Casamassimo PS, Wilson S. Presenting characteristics and treatment outcomes for tongue lacerations in children. Pediatr Dent 1999; 21:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24309/abstract/2\">",
"      Banks K, Merlino PG. Minor oral injuries in children. Mt Sinai J Med 1998; 65:333.",
"     </a>",
"    </li>",
"    <li>",
"     Bailey BJ. Management of soft tissue injuries. In: Oral and Maxillofacial Trauma, Fonesca RJ, Walker RV.  (Eds), WB Saunders, Philadelphia 1991. p.639.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24309/abstract/4\">",
"      Bringhurst C, Herr RD, Aldous JA. Oral trauma in the emergency department. Am J Emerg Med 1993; 11:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24309/abstract/5\">",
"      Powell SL, Robertson L, Doty BJ. Dental nerve blocks. Toothache remedies for the acute-care setting. Postgrad Med 2000; 107:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24309/abstract/6\">",
"      Steele MT, Sainsbury CR, Robinson WA, et al. Prophylactic penicillin for intraoral wounds. Ann Emerg Med 1989; 18:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24309/abstract/7\">",
"      Armstrong BD. Lacerations of the mouth. Emerg Med Clin North Am 2000; 18:471.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6317 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_47_24309=[""].join("\n");
var outline_f23_47_24309=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      WOUND ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      WOUND PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Site preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Irrigation and debridement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      WOUND REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DISCHARGE INSTRUCTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6317\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6317|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43834\" title=\"figure 1\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/14/14561\" title=\"figure 2\">",
"      Inferior alveolar block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/2/17440\" title=\"figure 3\">",
"      Traction suture tongue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6317|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 1\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=related_link\">",
"      Classification of trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32489?source=related_link\">",
"      Evaluation and management of dental injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=related_link\">",
"      Initial management of animal and human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6615?source=related_link\">",
"      Jaw fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29432?source=related_link\">",
"      Preparation for pediatric procedural sedation outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_47_24310="Traumatic diaphragmatic hernia on computed tomography";
var content_f23_47_24310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Traumatic diaphragmatic hernia on computed tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 406px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT scan shows a traumatic diaphragmatic hernia. Image A shows an intact left hemidiaphragm (thick white arrow).&nbsp; More inferiorly, image B shows a disrupted hemidiaphragm with a fragment of mesentry protruding (thick black arrow) and a grade I liver laceration (white arrow). Image C shows a portion of the splenic flexure herniating (arrowhead) and a subcapsular hematoma (black arrow).",
"    <div class=\"footnotes\">",
"     CT: computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_47_24310=[""].join("\n");
var outline_f23_47_24310=null;
var title_f23_47_24311="Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway";
var content_f23_47_24311=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/47/24311/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24311/contributors\">",
"     Luigi Di Biase, MD, PhD, FHRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24311/contributors\">",
"     Edward P Walsh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/47/24311/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24311/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24311/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/47/24311/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24311/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/47/24311/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1930, Louis Wolff, Sir John Parkinson, and Paul Dudley White published a seminal article describing 11 patients who suffered from attacks of tachycardia associated with a sinus rhythm electrocardiographic (ECG) pattern of bundle branch block with a short PR interval [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/1\">",
"     1",
"    </a>",
"    ]. This was subsequently termed the Wolff-Parkinson-White (WPW) syndrome, although earlier isolated case reports describing similar patients had been published. In 1943, the ECG features of preexcitation were correlated with anatomic evidence for the existence of anomalous bundles of conducting tissue that bypassed all or part of the normal atrioventricular (AV) conduction system (",
"    <a class=\"graphic graphic_figure graphicRef69078 \" href=\"UTD.htm?23/5/23634\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Atrioventricular reentrant (or reciprocating) tachycardia (AVRT) is a reentrant tachycardia with an anatomically defined circuit that consists of two distinct pathways, the normal AV conduction system and an AV accessory pathway, linked by common proximal (the atria) and distal (the ventricles) tissues. While other arrhythmias can utilize the accessory pathway for conduction from the anatomic site of tachycardia origin to other regions of the heart (eg, atrial fibrillation and atrial flutter) (",
"    <a class=\"graphic graphic_figure graphicRef82249 \" href=\"UTD.htm?38/33/39441\">",
"     figure 2",
"    </a>",
"    ), AVRT is a specific reentrant tachycardia in which the accessory pathway is necessary for initiation and maintenance of the tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The different types of AVRT, along with their ECG findings, will be discussed here. The approach to treatment of arrhythmias associated with an accessory pathway is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2718860\">",
"    <span class=\"h1\">",
"     NORMAL AV CONDUCTION VERSUS ACCESSORY AV PATHWAY CONDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal atrioventricular (AV) conduction occurs through the AV node. However, in the presence of an accessory pathway, conduction from the atria to the ventricles may occur in a variety of ways (exclusively via the AV node, exclusively via the accessory pathway, or a combination of both). Normal and accessory AV conduction are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=see_link&amp;anchor=H8470587#H8470587\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\", section on 'Normal AV conduction versus accessory AV pathway conduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TACHYCARDIAS REQUIRING AN AV ACCESSORY PATHWAY FOR INITIATION AND MAINTENANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular reentrant (or reciprocating) tachycardia (AVRT) is a reentrant tachycardia with an anatomically defined circuit that consists of two distinct pathways, the normal AV conduction system and an AV accessory pathway, linked by common proximal (the atria) and distal (the ventricles) tissues. If sufficient differences in conduction time and refractoriness exist between the normal conduction system and the accessory pathway, a properly timed premature impulse of atrial, junctional, or ventricular origin can initiate reentry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two major types of this arrhythmia in persons with an AV accessory pathway are orthodromic and antidromic AVRT. The width of the QRS complex can usually distinguish between these paroxysmal arrhythmias:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Orthodromic AVRT &ndash; If the tachycardia has a narrow QRS complex, the antegrade limb (ie, the pathway that conducts the supraventricular impulse to the ventricle) is the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system. In this setting, any preexcitation (manifest as a delta wave on the surface ECG) seen during sinus rhythm is lost since antegrade conduction is not occurring via the accessory pathway (ie, the ventricle is not preexcited) (",
"      <a class=\"graphic graphic_figure graphicRef71302 \" href=\"UTD.htm?15/35/15926\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef54720 \" href=\"UTD.htm?28/50/29478\">",
"       waveform 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef68804 \" href=\"UTD.htm?6/4/6217\">",
"       waveform 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Orthodromic AVRT'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Antidromic AVRT &ndash; If the tachycardia has a wide QRS complex, the possibilities include AVRT with antegrade conduction over the accessory pathway (antidromic AVRT) or orthodromic AVRT with aberrant QRS conduction resulting in a wide QRS complex (",
"      <a class=\"graphic graphic_figure graphicRef50433 \" href=\"UTD.htm?34/52/35655\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef54484 \" href=\"UTD.htm?24/55/25464\">",
"       waveform 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef71410 \" href=\"UTD.htm?43/2/44072\">",
"       waveform 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Antidromic AVRT'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=see_link&amp;anchor=H176001#H176001\">",
"       \"Left bundle branch block\", section on 'Functional LBBB'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"       \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A third type of arrhythmia, permanent junctional reciprocating tachycardia, is a type of orthodromic AVRT that is typically seen in childhood. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Permanent junctional reciprocating tachycardia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Orthodromic AVRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthodromic AVRT comprises 90 to 95 percent of the reentrant tachycardias associated with the Wolff-Parkinson-White syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Orthodromic AVRT can be initiated by atrial or ventricular premature beats (APBs or VPBs) (",
"    <a class=\"graphic graphic_figure graphicRef71302 \" href=\"UTD.htm?15/35/15926\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      APBs initiating orthodromic AVRT are blocked in the accessory pathway but conduct antegrade to the ventricles over the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system. After conduction through the ventricles, the impulse then travels back to the atria in a retrograde fashion via the AV accessory pathway to complete the first reentrant loop.",
"     </li>",
"     <li>",
"      VPBs initiating orthodromic AVRT are blocked in the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system but conduct retrograde to the atria over the accessory pathway. After conduction through the atria, the impulse then travels back to the ventricles in an antegrade fashion via the normal AV conduction system to complete the reentrant circuit [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/2,4\">",
"       2,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3785676\">",
"    <span class=\"h3\">",
"     ECG findings in orthodromic AVRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG during orthodromic AVRT (",
"    <a class=\"graphic graphic_waveform graphicRef54720 \" href=\"UTD.htm?28/50/29478\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef68804 \" href=\"UTD.htm?6/4/6217\">",
"     waveform 2",
"    </a>",
"    ) typically shows the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ventricular rate ranging from 150 to 250 (or greater) beats per minute and usually regular",
"     </li>",
"     <li>",
"      <strong>",
"       Narrow",
"      </strong>",
"      QRS complexes (in the absence of underlying conduction system disease or in the absence of aberrancy)",
"     </li>",
"     <li>",
"      Inverted P waves with an RP interval that is usually",
"      <strong>",
"       less than one-half",
"      </strong>",
"      the tachycardia RR interval (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H20#H20\">",
"       \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'RP relationship'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Constant RP interval regardless of the tachycardia cycle length [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Beat-to-beat oscillation in QRS amplitude (QRS alternans) sometimes occurs during orthodromic AVRT and is most commonly seen when the rate is very rapid [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The mechanism for QRS alternans is not clear but may in part result from oscillations in the relative refractory period of the His-Purkinje system [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ischemic-appearing ST segment depression also can occur during orthodromic AVRT, even in young individuals who are unlikely to have coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/10\">",
"     10",
"    </a>",
"    ]. Several factors may contribute to the ST segment depression in these arrhythmias, including changes in autonomic nervous system tone, intraventricular conduction disturbances, a longer ventriculoatrial interval, and a retrograde P wave of longer duration that overlaps into the ST segment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/11\">",
"     11",
"    </a>",
"    ]. The location of the ST segment changes may vary with the location of the accessory pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antidromic AVRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidromic AVRT is the least common arrhythmia associated with Wolff-Parkinson-White syndrome, occurring in only 5 to 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/2\">",
"     2",
"    </a>",
"    ]. As with orthodromic AVRT, antidromic AVRT can be initiated by atrial or ventricular premature beats (APBs or VPBs) (",
"    <a class=\"graphic graphic_figure graphicRef50433 \" href=\"UTD.htm?34/52/35655\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      APBs initiating antidromic AVRT are blocked in the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system but conduct antegrade to the ventricles over the accessory pathway. After conduction through the ventricles, the impulse then travels back to the atria in a retrograde fashion via the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system to complete the first reentrant loop.",
"     </li>",
"     <li>",
"      VPBs initiating antidromic AVRT are blocked in the accessory pathway but conduct retrograde to the atria over the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system. After conduction through the atria, the impulse then travels back to the ventricles in an antegrade fashion via the accessory pathway to complete the reentrant circuit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3785970\">",
"    <span class=\"h3\">",
"     ECG findings in antidromic AVRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG during antidromic AVRT (",
"    <a class=\"graphic graphic_figure graphicRef50433 \" href=\"UTD.htm?34/52/35655\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef54484 \" href=\"UTD.htm?24/55/25464\">",
"     waveform 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef71410 \" href=\"UTD.htm?43/2/44072\">",
"     waveform 4",
"    </a>",
"    ) typically shows the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ventricular rate ranging from 150 to 250 (or greater) beats per minute and usually regular",
"     </li>",
"     <li>",
"      <strong>",
"       Wide",
"      </strong>",
"      QRS complexes which are fully preexcited",
"     </li>",
"     <li>",
"      Inverted P waves with an RP interval that is usually",
"      <strong>",
"       more than one-half",
"      </strong>",
"      the tachycardia RR interval and a short PR interval (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H20#H20\">",
"       \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'RP relationship'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Constant RP interval regardless of the tachycardia cycle length [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Susceptibility to antidromic AVRT also appears to be dependent upon a transverse distance of at least 4 cm between the bypass tract and the normal AV conduction system. Consequently, most antidromic AVRTs use a left-sided accessory pathway as the antegrade route for conduction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients with antidromic AVRT and a left-sided accessory pathway, preexcitation may not be apparent in sinus rhythm because the time for the atrial impulse to reach the atrial insertion of the accessory pathway is longer than the time to reach the AV node (",
"    <a class=\"graphic graphic_waveform graphicRef80663 \" href=\"UTD.htm?24/45/25296\">",
"     waveform 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Permanent junctional reciprocating tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent or incessant junctional reciprocating (or reentrant) tachycardia (PJRT) is a type of orthodromic AVRT that most often occurs in early childhood, although clinically asymptomatic patients presenting later in life are not uncommon. In the older patient, PJRT tends to be less incessant, perhaps due to variable autonomic tone, and has a somewhat slower ventricular rate, felt to be the result of a prolongation of retrograde conduction through the accessory pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/14\">",
"     14",
"    </a>",
"    ]. The heart rate is usually between 120 and 200",
"    <span class=\"nowrap\">",
"     beats/minute,",
"    </span>",
"    and the QRS duration is generally normal (",
"    <a class=\"graphic graphic_waveform graphicRef67767 \" href=\"UTD.htm?25/13/25814\">",
"     waveform 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Chronic suppression of PJRT is usually not possible with drugs, and ablation of the accessory pathway is often necessary to achieve arrhythmia control [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/3,15-17\">",
"     3,15-17",
"    </a>",
"    ]. The incessant nature of PJRT may result in dilated cardiomyopathy and heart failure; these changes are potentially reversible if the accessory pathway can be successfully ablated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/3,14,15,18\">",
"     3,14,15,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link&amp;anchor=H8#H8\">",
"     \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\", section on 'Permanent junctional reciprocating tachycardia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3052121\">",
"    <span class=\"h3\">",
"     ECG findings in PJRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;PJRT is an orthodromic AVRT mediated by a concealed, retrogradely conducting AV accessory pathway that has slow and decremental conduction properties [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/16,19,20\">",
"     16,19,20",
"    </a>",
"    ]. Because of this, PJRT has similar ECG findings as seen in typical orthodromic AVRT. (See",
"    <a class=\"local\" href=\"#H3785676\">",
"     'ECG findings in orthodromic AVRT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, one major ECG difference is seen between PJRT and typical orthodromic AVRT. The retrograde conduction properties of the accessory pathway in PJRT are slower compared with both the anterograde conduction properties of the AV node and the usual \"fast\" accessory pathways found in patients with AVRT [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/14\">",
"     14",
"    </a>",
"    ]. Therefore, slow retrograde conduction over the accessory pathway causes the RP interval during PJRT to be long, usually",
"    <strong>",
"     more than one-half",
"    </strong>",
"    the tachycardia RR interval.",
"   </p>",
"   <p>",
"    The accessory pathway in patients with PJRT is most often located within the posteroseptal region, although other portions of the AV groove may also harbor this unique pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24311/abstract/16,17,20,21\">",
"     16,17,20,21",
"    </a>",
"    ]. P waves resulting from retrograde conduction are easily seen on the ECG and are inverted in leads 2, 3, aVF, and V3 to V6.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3051623\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS OF AVRT AND PJRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to a rapid heart rate can be quite variable depending on how fast the heart is beating, resultant blood pressure and tissue perfusion, underlying comorbidities, and the sensitivity of the individual patient to the symptoms. Patients with atrioventricular reentrant (or reciprocating) tachycardia (AVRT) or permanent junctional reciprocating (or reentrant) tachycardia (PJRT) can present with a variety of symptoms, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Syncope or presyncope",
"     </li>",
"     <li>",
"      Lightheadedness or dizziness",
"     </li>",
"     <li>",
"      Diaphoresis",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Shortness of breath",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most commonly, patients with AVRT present with palpitations, the sensation of a rapid or irregular heart beat felt in the anterior chest or neck. Because of the persistent nature and the rapid ventricular heart rate associated with PJRT, some patients with PJRT may present with findings of impaired left ventricular function compatible with a tachycardia-mediated cardiomyopathy. The presenting symptoms of tachycardias and tachycardia-mediated cardiomyopathy are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20665?source=see_link\">",
"     \"Overview of palpitations in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H436578#H436578\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3051738\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF AVRT AND PJRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of atrioventricular reentrant (or reciprocating) tachycardia (AVRT) or permanent junctional reciprocating (or reentrant) tachycardia (PJRT) typically requires only a surface electrocardiogram (ECG) which shows a heart rate greater than 100 beats per minute along with regularly occurring QRS complexes. An old ECG performed when the patient is not having a tachycardia can be helpful for identifying the presence of a delta wave suggesting preexcitation and an accessory pathway. Once a narrow QRS complex tachycardia has been identified, further scrutiny of the ECG is required to identify the specific arrhythmia in a particular patient, as diagnostic evaluation and therapy will differ depending on the underlying arrhythmia. (See",
"    <a class=\"local\" href=\"#H3785676\">",
"     'ECG findings in orthodromic AVRT'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3785970\">",
"     'ECG findings in antidromic AVRT'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3052121\">",
"     'ECG findings in PJRT'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H684866#H684866\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Invasive electrophysiology testing is usually not required to broadly make the diagnosis of AVRT or PJRT, but on rare occasions it is needed to diagnose (and potentially treat with catheter ablation) the specific arrhythmia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Electrophysiologic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3051869\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for patients with orthodromic atrioventricular reentrant (or reciprocating) tachycardia (AVRT) or permanent junctional reciprocating (or reentrant) tachycardia (PJRT) and a narrow QRS complex (&lt;120 msec duration) included other supraventricular tachyarrhythmias with regularly occurring, narrow QRS complexes. This differential diagnosis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Types of narrow QRS complex tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with a wide QRS complex tachycardia (ie, those with antidromic AVRT; or those with orthodromic AVRT or PJRT and underlying conduction system disease), ventricular tachycardia should be a part of the differential diagnosis along with aberrantly conducted supraventricular tachyarrhythmias. This differential diagnosis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\", section on 'Causes of WCT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3051921\">",
"    <span class=\"h1\">",
"     TREATMENT OF AVRT AND PJRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approaches to both acute and chronic treatment of atrioventricular reentrant (or reciprocating) tachycardia or permanent junctional reciprocating (or reentrant) tachycardia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the acute management of tachyarrhythmias\", section on 'Regular narrow complex tachycardias'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2718881\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrioventricular reentrant (or reciprocating) tachycardia (AVRT) is a reentrant tachycardia with an anatomically defined circuit that consists of two distinct pathways, the normal AV conduction system and an AV accessory pathway, linked by common proximal (the atria) and distal (the ventricles) tissues. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two major types of this arrhythmia in persons with an AV accessory pathway are orthodromic AVRT (including permanent junctional reciprocating tachycardia [PJRT]) and antidromic AVRT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Orthodromic AVRT comprises 90 to 95 percent of the reentrant tachycardias associated with the Wolff-Parkinson-White (WPW) syndrome. The ECG during orthodromic AVRT (",
"      <a class=\"graphic graphic_waveform graphicRef54720 \" href=\"UTD.htm?28/50/29478\">",
"       waveform 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef68804 \" href=\"UTD.htm?6/4/6217\">",
"       waveform 2",
"      </a>",
"      ) typically shows a regular ventricular rate ranging from 150 to 250 (or greater) beats per minute,",
"      <strong>",
"       narrow",
"      </strong>",
"      QRS complexes, inverted P waves with an RP interval that is usually",
"      <strong>",
"       less than one-half",
"      </strong>",
"      the tachycardia RR interval, and a constant RP interval. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Orthodromic AVRT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3785676\">",
"       'ECG findings in orthodromic AVRT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antidromic AVRT is the least common arrhythmia associated with WPW syndrome, occurring in only 5 to 10 percent of patients. The ECG during antidromic AVRT (",
"      <a class=\"graphic graphic_figure graphicRef50433 \" href=\"UTD.htm?34/52/35655\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef54484 \" href=\"UTD.htm?24/55/25464\">",
"       waveform 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef71410 \" href=\"UTD.htm?43/2/44072\">",
"       waveform 4",
"      </a>",
"      ) typically shows a regular ventricular rate ranging from 150 to 250 (or greater) beats per minute,",
"      <strong>",
"       wide",
"      </strong>",
"      QRS complexes, inverted P waves with an RP interval that is usually",
"      <strong>",
"       more than one-half",
"      </strong>",
"      the tachycardia RR interval, and a constant RP interval. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Antidromic AVRT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3785970\">",
"       'ECG findings in antidromic AVRT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PJRT is an orthodromic AVRT most often occurring in early childhood. PJRT has similar ECG findings as seen in typical orthodromic AVRT with one major difference; slow retrograde conduction over the accessory pathway causes the RP interval during PJRT to be long, usually",
"      <strong>",
"       more than one-half",
"      </strong>",
"      the tachycardia RR interval. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Permanent junctional reciprocating tachycardia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3052121\">",
"       'ECG findings in PJRT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most commonly, patients with AVRT present with palpitations, the sensation of a rapid or irregular heart beat felt in the anterior chest or neck. Because of the persistent nature and the rapid ventricular heart rate associated with PJRT, some patients with PJRT may present with findings of impaired left ventricular function compatible with a tachycardia-mediated cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H3051623\">",
"       'Clinical manifestations of AVRT and PJRT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of AVRT or PJRT typically requires only a surface electrocardiogram (ECG) which shows a heart rate greater than 100 beats per minute along with regularly occurring QRS complexes. An old ECG performed when the patient is not having a tachycardia can be helpful for identifying the presence of a delta wave suggesting preexcitation and an accessory pathway. Once a narrow QRS complex tachycardia has been identified, further scrutiny of the ECG is required to identify the specific arrhythmia in a particular patient. (See",
"      <a class=\"local\" href=\"#H3051738\">",
"       'Diagnosis of AVRT and PJRT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis and approach to treatment for AVRT and PJRT are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Types of narrow QRS complex tachycardia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"       \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272903275\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and UpToDate would like to thank Dr. Philip Podrid, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/1\">",
"      Wolff L, Parkinson J, White PD. Bundle-branch block with short P-R interval in healthy young people prone to paroxysmal tachycardia. 1930. Ann Noninvasive Electrocardiol 2006; 11:340.",
"     </a>",
"    </li>",
"    <li>",
"     Josephson ME. Preexcitation syndromes. In: Clinical Cardiac Electrophysiology, 4th, Lippincot Williams &amp; Wilkins, Philadelphia 2008. p.339.",
"    </li>",
"    <li>",
"     Chugh A, Morady F. Atrioventricular reentry and variants. In: Cardiac electrophysiology from cell to bedside, 5th edition, Zipes DP, Jalife J.  (Eds), Saunders/Elsevier, Philadelphia 2009. p.605-614.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/4\">",
"      Akhtar M, Lehmann MH, Denker ST, et al. Electrophysiologic mechanisms of orthodromic tachycardia initiation during ventricular pacing in the Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1987; 9:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/5\">",
"      Cain ME, Luke RA, Lindsay BD. Diagnosis and localization of accessory pathways. Pacing Clin Electrophysiol 1992; 15:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/6\">",
"      Green M, Heddle B, Dassen W, et al. Value of QRS alteration in determining the site of origin of narrow QRS supraventricular tachycardia. Circulation 1983; 68:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/7\">",
"      Kay GN, Pressley JC, Packer DL, et al. Value of the 12-lead electrocardiogram in discriminating atrioventricular nodal reciprocating tachycardia from circus movement atrioventricular tachycardia utilizing a retrograde accessory pathway. Am J Cardiol 1987; 59:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/8\">",
"      Tchou PJ, Lehmann MH, Dongas J, et al. Effect of sudden rate acceleration on the human His-Purkinje system: adaptation of refractoriness in a dampened oscillatory pattern. Circulation 1986; 73:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/9\">",
"      Gallagher JJ, Sealy WC, Kasell J, Wallace AG. Multiple accessory pathways in patients with the pre-excitation syndrome. Circulation 1976; 54:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/10\">",
"      Man KC, Brinkman K, Bogun F, et al. 2:1 atrioventricular block during atrioventricular node reentrant tachycardia. J Am Coll Cardiol 1996; 28:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/11\">",
"      Nelson SD, Kou WH, Annesley T, et al. Significance of ST segment depression during paroxysmal supraventricular tachycardia. J Am Coll Cardiol 1988; 12:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/12\">",
"      Riva SI, Della Bella P, Fassini G, et al. Value of analysis of ST segment changes during tachycardia in determining type of narrow QRS complex tachycardia. J Am Coll Cardiol 1996; 27:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/13\">",
"      Scheinman MM, Wang YS, Van Hare GF, Lesh MD. Electrocardiographic and electrophysiologic characteristics of anterior, midseptal and right anterior free wall accessory pathways. J Am Coll Cardiol 1992; 20:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/14\">",
"      Dorostkar PC, Silka MJ, Morady F, Dick M 2nd. Clinical course of persistent junctional reciprocating tachycardia. J Am Coll Cardiol 1999; 33:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/15\">",
"      Aguinaga L, Primo J, Anguera I, et al. Long-term follow-up in patients with the permanent form of junctional reciprocating tachycardia treated with radiofrequency ablation. Pacing Clin Electrophysiol 1998; 21:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/16\">",
"      Guarnieri T, Sealy WC, Kasell JH, et al. The nonpharmacologic management of the permanent form of junctional reciprocating tachycardia. Circulation 1984; 69:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/17\">",
"      Ticho BS, Saul JP, Hulse JE, et al. Variable location of accessory pathways associated with the permanent form of junctional reciprocating tachycardia and confirmation with radiofrequency ablation. Am J Cardiol 1992; 70:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/18\">",
"      Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/19\">",
"      Brugada P, Vanagt EJ, Bar FW, Wellens HJ. Incessant reciprocating atrioventricular tachycardia. Factors playing a role in the mechanism of the arrhythmia. Pacing Clin Electrophysiol 1980; 3:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/20\">",
"      Critelli G, Gallagher JJ, Monda V, et al. Anatomic and electrophysiologic substrate of the permanent form of junctional reciprocating tachycardia. J Am Coll Cardiol 1984; 4:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24311/abstract/21\">",
"      Okumura K, Henthorn RW, Epstein AE, et al. \"Incessant\" atrioventricular (AV) reciprocating tachycardia utilizing left lateral AV bypass pathway with a long retrograde conduction time. Pacing Clin Electrophysiol 1986; 9:332.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 976 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_47_24311=[""].join("\n");
var outline_f23_47_24311=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2718881\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2718860\">",
"      NORMAL AV CONDUCTION VERSUS ACCESSORY AV PATHWAY CONDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TACHYCARDIAS REQUIRING AN AV ACCESSORY PATHWAY FOR INITIATION AND MAINTENANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Orthodromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3785676\">",
"      - ECG findings in orthodromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3785970\">",
"      - ECG findings in antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Permanent junctional reciprocating tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3052121\">",
"      - ECG findings in PJRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3051623\">",
"      CLINICAL MANIFESTATIONS OF AVRT AND PJRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3051738\">",
"      DIAGNOSIS OF AVRT AND PJRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3051869\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3051921\">",
"      TREATMENT OF AVRT AND PJRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2718881\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272903275\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/976\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/976|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/5/23634\" title=\"figure 1\">",
"      Anatomy AV accessory pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/33/39441\" title=\"figure 2\">",
"      Sites of reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/35/15926\" title=\"figure 3\">",
"      Orthodromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/52/35655\" title=\"figure 4\">",
"      Antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/976|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/50/29478\" title=\"waveform 1\">",
"      Orthodromic AVRT tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?6/4/6217\" title=\"waveform 2\">",
"      12 lead ECG orthodromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?24/55/25464\" title=\"waveform 3\">",
"      12 lead ECG antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?43/2/44072\" title=\"waveform 4\">",
"      ECG Antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?24/45/25296\" title=\"waveform 5\">",
"      ECG WPW left posterior path",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?25/13/25814\" title=\"waveform 6\">",
"      Permanent junctional tachy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=related_link\">",
"      Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20665?source=related_link\">",
"      Overview of palpitations in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=related_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=related_link\">",
"      Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_47_24312="Diagnosis of polyuria and diabetes insipidus";
var content_f23_47_24312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of polyuria and diabetes insipidus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/47/24312/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24312/contributors\">",
"     Daniel G Bichet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/47/24312/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24312/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24312/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/47/24312/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24312/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/47/24312/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyuria has generally been defined as a urine output exceeding 3",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    in adults and 2",
"    <span class=\"nowrap\">",
"     L/m2",
"    </span>",
"    in children. It must be differentiated from the more common complaints of frequency or nocturia, which are not associated with an increase in the total urine output.",
"   </p>",
"   <p>",
"    The following is an overview of the diagnosis of polyuria and diabetes insipidus (DI). The causes and treatment of polyuria due to central or nephrogenic DI are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"     \"Treatment of central diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=see_link\">",
"     \"Treatment of nephrogenic diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of a glucose-induced osmotic diuresis in uncontrolled diabetes mellitus, there are three major causes of polyuria in the outpatient setting, each of which is due to a defect in water balance leading to the excretion of large volumes of dilute urine (urine osmolality usually below 250",
"    <span class=\"nowrap\">",
"     mosmol/kg):",
"    </span>",
"    primary polydipsia, which is primarily seen in adults and adolescents; central DI; and nephrogenic DI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Primary polydipsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary polydipsia (sometimes called psychogenic polydipsia) is characterized by a primary increase in water intake. This disorder is most often seen middle-aged women and in patients with psychiatric illnesses, including those taking a phenothiazine which can lead to the sensation of a dry mouth. Primary polydipsia can also be induced by hypothalamic lesions that directly affect the thirst center, as may occur with an infiltrative disease such as sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Central DI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central DI (also called neurohypophyseal or neurogenic DI) is associated with deficient secretion of antidiuretic hormone (ADH). This condition is most often idiopathic (possibly due to autoimmune injury to the ADH-producing cells), or can be induced by trauma, pituitary surgery, or hypoxic or ischemic encephalopathy. Rare familial cases have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nephrogenic DI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrogenic DI is characterized by normal ADH secretion but varying degrees of renal resistance to its water-retaining effect. This problem, in its mild form, is relatively common, since most patients who are elderly or who have underlying renal disease have a reduction in maximum concentrating ability. This defect, however, is not severe enough to produce a symptomatic increase in urine output.",
"   </p>",
"   <p>",
"    Symptomatic polyuria due to ADH-resistance is seen primarily in four settings, all of which are discussed in detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nephrogenic DI presenting in childhood is almost always due to inherited defects. The most common are X-linked hereditary nephrogenic DI due to mutations in the AVPR2 gene encoding the ADH receptor V2, and autosomal recessive and dominant nephrogenic DI due to mutations in the aquaporin-2 (water channel) gene.",
"     </li>",
"     <li>",
"      Nephrogenic DI presenting in adults is almost always acquired with chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      use and hypercalcemia being the most common causes of a defect severe enough to produce polyuria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to nephrogenic and central DI, a variety of conditions may result in the complaint of polyuria, including psychogenic polydipsia, prostatic hypertrophy, or osmotic diuresis (including postobstructive diuresis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12050?source=see_link\">",
"     \"Urine output in urinary tract obstruction and postobstructive diuresis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cause of polyuria is often suggested from the history (eg, age of onset and eliciting the possible presence of the different causes of DI), and rarely by the plasma sodium concentration. Specific testing is then performed to establish the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Onset of polyuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient (or their parent) should be questioned about the rate of onset of the polyuria. In the majority of cases of hereditary nephrogenic DI, severe polyuria (with risk of dehydration and hypernatremia) manifests during the first week of life. In familial central DI (usually an autosomal dominant disease), polyuria may present after the first year of life, sometimes in young adulthood, due to preservation of function of the normal allele [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adults, the onset is usually abrupt in central DI (\"I suddenly began urinating too much a few days ago\"), and almost always gradual in acquired nephrogenic DI or primary polydipsia.",
"   </p>",
"   <p>",
"    The new onset of nocturia in the absence of other causes of nocturia (eg, prostatic enlargement in men over 50 years of age or urinary tract infection in children) is often a first clue to DI. The urine is normally most concentrated in the morning due to lack of fluid ingestion overnight; as a result, the first manifestation of a loss of concentrating ability is often nocturia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are familial forms of both central and nephrogenic DI. The defects in these disorders are due to mutations that impair ADH synthesis or the renal response to ADH; the latter defect is most often due to mutations in the AVPR2 gene encoding the V2 receptor but can also result from mutations in the aquaporin-2 (water channel gene) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/3\">",
"     3",
"    </a>",
"    ]. A family history of polyuria is helpful both for diagnosis and to identify asymptomatic members of affected families who harbor the suspect allele. Thus, all families with hereditary DI should have their molecular defect identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Plasma sodium and urine osmolality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the three causes of polyuria &mdash; primary polydipsia, central DI, and nephrogenic DI &mdash; is associated with an increase in water output and the excretion of a relatively dilute urine. With primary polydipsia, the polyuria is an appropriate response to enhanced water intake; in comparison, the water loss is inappropriate with either form of DI. Measurement of the plasma sodium concentration and the urine osmolality may be helpful in distinguishing between these disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A low plasma sodium concentration (less than 137",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      with a low urine osmolality (eg, less than one-half the plasma osmolality) is usually indicative of water overload due to primary polydipsia.",
"     </li>",
"     <li>",
"      A high-normal plasma sodium concentration (greater than 142",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      due to water loss) points toward DI, particularly if the urine osmolality is less than the plasma osmolality [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A normal plasma sodium concentration is not helpful in diagnosis but, if associated with a urine osmolality more than 600",
"      <span class=\"nowrap\">",
"       mosmol/kg,",
"      </span>",
"      excludes a diagnosis of DI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In adults with DI and no cognitive impairment, true hypernatremia (plasma sodium concentration greater than 150",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    should not occur because the initial loss of water stimulates thirst, resulting in an increase in intake to match the urinary losses (",
"    <a class=\"graphic graphic_figure graphicRef65195 \" href=\"UTD.htm?14/61/15325\">",
"     figure 1",
"    </a>",
"    ). An exception to this general rule occurs when DI is due to a central lesion that also impairs thirst, thereby causing hypodipsia or adipsia; in this setting, the plasma sodium concentration can exceed 160",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/4\">",
"     4",
"    </a>",
"    ]. Adipsic DI is associated with significant morbidity including obesity, sleep apnea, venous thrombosis during episodes of hypernatremia, thermoregulatory dysfunction, seizures, and significant mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, withholding water (eg, for diagnostic or surgical procedures) in adults with DI can result in severe dehydration. Thus, if oral intake has to be withheld, the patient should be hospitalized and hydrated intravenously, and the plasma sodium concentration closely monitored while intake is restricted.",
"   </p>",
"   <p>",
"    Hypernatremia during the first year of life is a common feature in children with hereditary nephrogenic DI. The intense and constant thirst of these young children is often not understood by adults, particularly if this is the first affected family member due to a de novo mutation or if an X-linked mutation has passed unrecognized through asymptomatic females [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1100220\">",
"    <span class=\"h2\">",
"     Measurement of urine output",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of obtaining a timed urine collection to confirm the presence of polyuria is uncertain. Potential problems include an incomplete collection and the necessity for multiple containers if the patient has severe polyuria, which can be minimized by obtaining an eight hour rather than a 24 hour collection. Measurement of urinary creatinine excretion can help determine if the collection is complete. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20663247#H20663247\">",
"     \"Assessment of kidney function\", section on 'Limitations of using creatinine clearance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Water restriction test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even if the history",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plasma sodium concentration and urine osmolality appear to be helpful, the diagnosis should be confirmed by raising the plasma osmolality either by water restriction or, less commonly in adults, by the administration of hypertonic saline (0.05",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min for no more than two hours). The administration of hypertonic saline is typically reserved for use if the water restriction test is inconclusive or cannot be performed. A water restriction test to exclude primary polydipsia is not necessary if the plasma sodium concentration is greater than 145",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and the urine osmolality is less than the plasma osmolality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Water restriction is important to differentiate central DI from primary polydipsia; simply giving exogenous ADH (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    [DDAVP] is generally preferred to aqueous vasopressin) without water restriction will not distinguish between these two conditions since both have submaximal plasma ADH levels and both will respond to desmopressin therapy. However, a water restriction test may not be necessary prior to desmopressin administration",
"   </p>",
"   <p>",
"    Exceptions to this general rule are patients with a dilute urine (ie, urine osmolality well below that of the plasma) who are strongly suspected of having nephrogenic DI (eg, long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    use), and newborns and young infants who are thought to have hereditary nephrogenic DI. In these patients who are resistant to ADH, the response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    can be evaluated without prior water restriction. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Infants and children'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The diagnostic approach is also different in patients with DI and a defect in thirst who present with overt hypernatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link\">",
"     \"Etiology and evaluation of hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The normal physiologic response to the water restriction test (or the administration of hypertonic saline) is based upon the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Raising the plasma osmolality leads to a progressive elevation in ADH release and an increase in urine osmolality in normal individuals (",
"      <a class=\"graphic graphic_figure graphicRef65195 \" href=\"UTD.htm?14/61/15325\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Once the plasma osmolality reaches 295 to 300",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      (normal 275 to 290",
"      <span class=\"nowrap\">",
"       mosmol/kg)",
"      </span>",
"      or the plasma sodium is 145",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or higher, the effect of endogenous ADH on the kidney is maximal. At this point, administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      will not further elevate the urine osmolality unless endogenous ADH release is impaired (ie, unless the patient has central DI).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;The water restriction test for the evaluation of polyuria involves measurement of the urine volume and osmolality every hour and the plasma sodium concentration and osmolality every two hours. We generally recommend that the patient stop drinking two to three hours before coming to the office or clinic; overnight fluid restriction should be",
"    <strong>",
"     avoided",
"    </strong>",
"    , since potentially severe volume depletion and hypernatremia can be induced in patients with marked polyuria. As an example, we saw a patient with undiagnosed DI who was scheduled for surgery in the morning and was told to stop drinking and eating after going to sleep the night before. Surgery was cancelled when routine preoperative laboratory testing revealed a plasma sodium of 162",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    water restriction test in adults is continued until one of the following end points is reached:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The urine osmolality reaches a clearly normal value (above 600",
"      <span class=\"nowrap\">",
"       mosmol/kg),",
"      </span>",
"      indicating that both ADH release and effect are intact. Patients with partial DI may have a substantial rise in urine osmolality, but not to this extent.",
"     </li>",
"     <li>",
"      The urine osmolality is stable on two or three successive hourly measurements despite a rising plasma osmolality",
"     </li>",
"     <li>",
"      The plasma osmolality exceeds 295 to 300",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      or the plasma sodium is 145",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or higher.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the last two settings,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    is administered (10 microg by nasal insufflation or 4 microg subcutaneously or intravenously), and the urine osmolality and volume monitored. The urine osmolality and volume should be measured every 30 minutes over the next two hours. The two hour monitoring period is particularly important if there is dilatation of the urinary bladder by previous high urine volumes. In this setting, any concentrated new urine might be diluted with post-micturitional residual urine (which could be as much as 200 to 400 mL).",
"   </p>",
"   <p>",
"    Plasma and urine ADH levels should be measured if the response to the water restriction test is equivocal (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Plasma and urine ADH measurement'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water restriction is not performed in newborns or very young infants suspected to have hereditary nephrogenic DI (eg, documented plasma sodium 145",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or higher with a concomitant urine osmolality &le;200",
"    <span class=\"nowrap\">",
"     mosmol/kg).",
"    </span>",
"    The preferred diagnostic test in this setting is the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (1 &micro;g subcutaneously or intravenously infused over 20 minutes, maximum dose 0.4",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    of body weight) with measurement of the urine osmolality at baseline and at 30 minutes intervals over the next two hours. If the urine osmolality does not increase by more than 100",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    over baseline, the diagnosis of nephrogenic DI is made and DNA should be obtained for mutation analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Water deprivation tests for older infants and children should be performed in the hospital under close medical supervision. The patient should not be allowed to lose more than 5 percent of their body weight. Monitoring of vital signs (temperature, pulse and blood pressure), body weight, and laboratory tests and urine and plasma osmolalities and the plasma sodium concentration are essential.",
"   </p>",
"   <p>",
"    A recommended protocol includes the following steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The test is performed after breakfast. It is started after the child voids or, in infants, after the first spontaneous void after the morning feed. Body weight and plasma sodium and osmolality are measured after the patient voids. No further fluid is given until the test is terminated.",
"     </li>",
"     <li>",
"      Record each urine void and measure the urine volume, specific gravity, and osmolality.",
"     </li>",
"     <li>",
"      Weight and vital signs are obtained every two hours for the first four hours and then hourly. The plasma sodium and osmolality are measured at four hours and then every two hours until the conclusion of the test.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The test is terminated when one of the following end points are attained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urine specific gravity &ge;1.020",
"     </li>",
"     <li>",
"      Urine osmolality is &ge;600",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"     </li>",
"     <li>",
"      Plasma osmolality exceeds 295 or 300",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      or plasma sodium is 145",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or higher",
"     </li>",
"     <li>",
"      The patient has lost 5 percent of body weight or exhibits signs of volume depletion",
"     </li>",
"     <li>",
"      If the period of water restriction reaches six hours in infants less than six months of age, eight hours in children from six months to two years of age, or 12 hours in children older than two years of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At the end of the test, weight, vital signs, plasma sodium, plasma and urine osmolality, and urine specific gravity should be measured. A specimen should also be obtained for measurement of plasma ADH, which is always elevated during short dehydration tests in patients with hereditary nephrogenic DI.",
"   </p>",
"   <p>",
"    Children who continue to have impaired urinary concentration despite reaching a plasma osmolality of 295",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    or a plasma sodium of 150",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    can be given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (5 to 10 microg by nasal insufflation or 2 to 4 &micro;g intravenously or subcutaneously). The urine volume and osmolality are measured to detect any antidiuretic response. We no longer use aqueous vasopressin which, due to its vasoconstrictive effect mediated by the V1a receptor, produces sudden and noticeable pallor that raises concerns with the mother.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate interpretation of the water restriction test usually requires that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    <strong>",
"     not be given",
"    </strong>",
"    before the urine osmolality has stabilized or the plasma osmolality has reached 295",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    Below this level, maximum endogenous ADH effect may not be present and an antidiuretic response to desmopressin is of no diagnostic benefit, since it will raise the urine osmolality even in normal subjects.",
"   </p>",
"   <p>",
"    Each of the causes of polyuria produces a distinctive pattern to water restriction and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/1,7-9\">",
"     1,7-9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central DI is usually partial, and therefore both ADH release and the urine osmolality may increase as the plasma osmolality rises, but submaximally.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       Desmopressin",
"      </a>",
"      will lead to a rise in urine osmolality (and an equivalent fall in urine output) of more than 100 percent in complete central DI and 15 to 50 percent in partial central DI [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nephrogenic DI is also associated with a submaximal rise in urine osmolality in response to water restriction. The elevation in plasma osmolality stimulates ADH release which, since most patients with acquired nephrogenic DI are partially (not completely) resistant to ADH, may induce a modest increase in urine osmolality. The administration of exogenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      (which increases plasma levels five- to ten-fold) produces [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No elevation in urine osmolality in complete nephrogenic DI",
"     </li>",
"     <li>",
"      A small (up to 45 percent) elevation in urine osmolality in partial nephrogenic DI.",
"      <br/>",
"      <br/>",
"      Although the directional change in partial nephrogenic DI is similar to that seen with partial central DI, the absolute numbers are quite different. Patients with the central DI usually achieve a urine osmolality of 300",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      or higher after water restriction, while patients with symptomatic acquired nephrogenic DI typically have a persistently dilute urine that rises, but remains well below isosmotic, after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. The history may also be helpful in distinguishing between these disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary polydipsia will be associated with a rise in urine osmolality, usually to above 500",
"      <span class=\"nowrap\">",
"       mosmol/kg,",
"      </span>",
"      and no response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      since endogenous release is intact. Maximum concentrating ability is frequently impaired in this disorder, resulting in a maximum urine osmolality that may reach 500 to 600",
"      <span class=\"nowrap\">",
"       mosmol/kg,",
"      </span>",
"      as compared to 800",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      or more in normal subjects. This acquired defect appears to be due to two effects of chronic polydipsia and polyuria: partial wash out the medullary interstitial gradient; and downregulation of ADH release [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A properly performed test in which ADH is not given until the plasma osmolality exceeds 295",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    will usually establish the correct diagnosis. If the diagnosis remains uncertain, it is reasonable to try",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    therapy. The polyuria and polydipsia will rapidly reverse with central DI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"     \"Treatment of central diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, careful monitoring is essential; the urine output will also fall in primary polydipsia, but the combination of persistent polydipsia and a concentrated urine can lead to potentially severe symptomatic hyponatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Sources of error",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major potential errors with the water restriction test. First, patients with partial central DI may be hyperresponsive to the submaximal rise in ADH induced by water restriction, perhaps due to receptor upregulation. As a result, they may be polyuric at the normal plasma osmolality of 285 to 290",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    when ADH levels are very low, but have a maximally concentrated urine at a plasma osmolality above 295",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    when ADH levels are somewhat higher. In this setting,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    will be without effect, resulting in a pattern suggestive of primary polydipsia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/9\">",
"     9",
"    </a>",
"    ]. As noted above, the history may provide important clues in this setting, with abrupt onset favoring central DI, and gradual onset, particularly with a history of psychiatric illness, favoring primary polydipsia.",
"   </p>",
"   <p>",
"    Second, polyuria developing during pregnancy may result from the release of vasopressinases from the placenta (a disorder that has been called gestational diabetes insipidus). In this setting, the patient will be resistant to aqueous vasopressin (mistakenly suggesting nephrogenic DI) but will respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    which is resistant to vasopressinase [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link\">",
"     \"Renal and urinary tract physiology in normal pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Plasma and urine ADH measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless the history and water restriction test provide unequivocal results, plasma or urine samples collected at baseline and following water deprivation (prior to the administration of ADH) should be sent for measurement of ADH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If there is an increase in plasma or urine ADH in response to the rising plasma osmolality, central DI is excluded.",
"     </li>",
"     <li>",
"      If there is an appropriate elevation in urine osmolality as ADH secretion is increased, nephrogenic DI is excluded.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However,&nbsp;measurement of ADH concentrations may be misleading for&nbsp;several reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The commercially available assays for both plasma and urine ADH are not very sensitive, especially in the range below 3",
"      <span class=\"nowrap\">",
"       pg/ml.",
"      </span>",
"     </li>",
"     <li>",
"      ADH in the circulation is largely bound to platelets, and without special handling of the specimen, falsely high and falsely low levels can be seen.",
"     </li>",
"     <li>",
"      ADH is unstable in isolated plasma, even when stored at -20&ordm; C so that send out assays may be unreliable. Even highly sensitive assays may be misleading in patients with primary polydipsia, since chronic overhydration can cause partial suppression of ADH release, mimicking the pattern in central DI [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Urinary assays have been suggested since the ADH concentration is higher in urine and the plasma separation issues may not apply. However, there are few data to support this approach.&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SOLUTE DIURESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above discussion has emphasized the diagnostic approach to a water diuresis. However, in some patients with polyuria, particularly of acute onset, the increase in urine output is due to a solute or osmotic diuresis in which the primary abnormality is an inability to reabsorb a substantial proportion of the filtered solute.",
"   </p>",
"   <p>",
"    Glucosuria is the major cause of an osmotic diuresis in outpatients, but other conditions are often responsible when polyuria develops in the hospital. These include high-protein feedings (in which urea acts as the osmotic agent) and volume expansion due to saline loading or the release of bilateral urinary tract obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/1,14-16\">",
"     1,14-16",
"    </a>",
"    ]; in addition, patients with severe central DI who are treated with large volumes of intravenous dextrose and water can develop hyperglycemia and polyuria that is ADH-resistant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"     \"Treatment of central diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A solute diuresis can be differentiated from diabetes insipidus based upon the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The urine osmolality in a solute diuresis is usually above 300",
"      <span class=\"nowrap\">",
"       mosmol/kg,",
"      </span>",
"      in contrast to the dilute urine typically found with a water diuresis.",
"     </li>",
"     <li>",
"      Total solute excretion (calculated on a 24-hour urine collection from the product of the urine osmolality and the urine volume [in liters]) is normal with a water diuresis (600 to 900 mosmol per day on a typical western diet) but markedly increased with an osmotic diuresis. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"       \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Salt-wasting nephropathy: not a cause of polyuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, underlying renal disease can impair sodium conservation in the presence of volume depletion but does",
"    <strong>",
"     not",
"    </strong>",
"    cause sufficient sodium wasting to induce true polyuria. This is in part due to the phenomenon of tubuloglomerular feedback in which increased sodium chloride delivery to the macula densa (due to decreased reabsorption in the more proximal segments) results in afferent arteriolar constriction and a fall in glomerular filtration rate, thereby limiting the degree of sodium chloride loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10985?source=see_link\">",
"     \"Chapter 2D: Regulation of GFR and renal plasma flow\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, polyuria in which there is a marked increase in sodium excretion (ie, sodium salts make up most of the increased solute excretion) is almost always",
"    <strong>",
"     appropriate",
"    </strong>",
"    , resulting from volume expansion induced either by saline loading or, following relief of urinary obstruction, by fluid retained during the period of obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In addition to the excretion of retained sodium, increased urea excretion can contribute to a postobstructive diuresis when urea has also been retained as evidenced by a substantial increase in blood urea nitrogen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12050?source=see_link\">",
"     \"Urine output in urinary tract obstruction and postobstructive diuresis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many clinicians faced with a urine output that may initially exceed 1000 mL per hour in adults feel compelled to replace the urine output with intravenous fluids. This will only prolong the polyuria driven by increased sodium excretion, since volume expansion will persist. Optimal therapy of a postobstructive diuresis consists of fluid infusion at a maintenance level, such as 75 mL of one-half isotonic saline per hour. The development of volume depletion, as evidenced by hypotension or a rise in the blood urea nitrogen, is unusual with this regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An exception to this general rule can occur in infants with congenital obstructive uropathy in whom the associated ADH resistance is sufficiently severe that the maximum urine osmolality is well below that of the plasma. In these infants, relief of the obstruction can lead to a marked water diuresis with subsequent hypernatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Following relief of obstruction, fluid status should be carefully monitored, and fluid therapy adjusted as necessary.",
"   </p>",
"   <p>",
"    It is possible that some of these patients have congenital nephrogenic DI, with polyuria not obstruction being responsible for urinary tract and bladder dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24312/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=see_link\">",
"     \"Treatment of nephrogenic diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/55/43889?source=see_link\">",
"       \"Patient information: Diabetes insipidus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyuria has generally been defined as a urine output exceeding 3",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    in adults and 2",
"    <span class=\"nowrap\">",
"     L/m2",
"    </span>",
"    in children. There are three major causes of polyuria associated with the excretion of large volumes of dilute urine (urine osmolality usually below 250",
"    <span class=\"nowrap\">",
"     mosmol/kg),",
"    </span>",
"    each of which has several underlying etiologies. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary polydipsia (also called psychogenic polydipsia), characterized by a primary increase in water intake. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H14#H14\">",
"       \"Causes of hyponatremia\", section on 'Primary polydipsia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central DI, due to deficient secretion of ADH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link\">",
"       \"Clinical manifestations and causes of central diabetes insipidus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nephrogenic DI, characterized by normal ADH secretion but varying degrees of renal resistance to its water-retaining effect. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link\">",
"       \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions that may result in the complaint of polyuria include nocturia due to prostatic hypertrophy, and a solute (osmotic) diuresis due, for example, to hyperglycemia or relief of urinary tract obstruction. As a general rule, salt wasting nephropathies do",
"    <strong>",
"     not",
"    </strong>",
"    cause sufficient sodium wasting to induce true polyuria. A solute diuresis can be differentiated from diabetes insipidus based upon the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The urine osmolality in a solute diuresis is usually above 300",
"      <span class=\"nowrap\">",
"       mosmol/kg,",
"      </span>",
"      in contrast to the dilute urine in a water diuresis.",
"     </li>",
"     <li>",
"      Total solute excretion is normal with a water diuresis (600 to 900",
"      <span class=\"nowrap\">",
"       mosmol/day)",
"      </span>",
"      but markedly increased with an osmotic diuresis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of polyuria (water diuresis) is often suggested from the history (eg, age of onset, rate of onset, eliciting the possible presence of the different causes of DI, family history), and by the plasma sodium concentration. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Onset of polyuria'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Family history'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Even if the history",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plasma sodium concentration and urine osmolality appear to be helpful, we recommend confirming the diagnosis in most patients by examining the response (urine volume and osmolality) to water restriction and, if appropriate, administration of exogenous ADH once the plasma osmolality reaches 295 to 300",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    or the plasma sodium is 145",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or higher. We prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    to aqueous vasopressin. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Plasma sodium and urine osmolality'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Water restriction test'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We recommend obtaining blood at baseline and after water restriction, to be sent for plasma ADH levels if the response to the water restriction test is equivocal. Urine ADH testing may be performed if high sensitivity plasma ADH assays are not available. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Plasma and urine ADH measurement'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We recommend",
"    <strong>",
"     not",
"    </strong>",
"    performing a water restriction test in patients with a dilute urine who are strongly suspected of having nephrogenic DI (eg, newborns and very young infants and long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    use in adults). In these settings, testing for a lack of response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    can be performed without prior water restriction. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Infants and children'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The response to water restriction and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    helps establish the diagnosis (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Interpretation'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A submaximal increase in urine osmolality in response to water deprivation (but usually to &ge;300",
"      <span class=\"nowrap\">",
"       mosmol/kg),",
"      </span>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      resulting in a rise in urine osmolality of more than 100 percent in complete central DI and 15 to 50 percent in partial central DI.",
"     </li>",
"     <li>",
"      Submaximal rise in urine osmolality in response to water restriction (but to well below 300",
"      <span class=\"nowrap\">",
"       mosmol/kg),",
"      </span>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      producing little or no elevation in urine osmolality in complete nephrogenic DI, and a small (&lt;45 percent) elevation in urine osmolality with partial nephrogenic DI.",
"     </li>",
"     <li>",
"      Primary polydipsia will be associated with a rise in urine osmolality, usually to above 500",
"      <span class=\"nowrap\">",
"       mosmol/kg,",
"      </span>",
"      and no response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      since endogenous release is intact.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the history and water restriction test provide equivocal results, plasma samples collected at baseline and following water deprivation (prior to the administration of ADH) should be sent for measurement of ADH. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Plasma and urine ADH measurement'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nephrogenic DI is excluded if there is an appropriate relationship between the rise in urine osmolality and plasma ADH",
"     </li>",
"     <li>",
"      Central DI is excluded if there is an appropriate rise in plasma ADH with the rise in plasma sodium or osmolality.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.748, 767.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/2\">",
"      Christensen JH, Rittig S. Familial neurohypophyseal diabetes insipidus--an update. Semin Nephrol 2006; 26:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/3\">",
"      Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 2005; 16:2836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/4\">",
"      McIver B, Connacher A, Whittle I, et al. Adipsic hypothalamic diabetes insipidus after clipping of anterior communicating artery aneurysm. BMJ 1991; 303:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/5\">",
"      Crowley RK, Sherlock M, Agha A, et al. Clinical insights into adipsic diabetes insipidus: a large case series. Clin Endocrinol (Oxf) 2007; 66:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/6\">",
"      Arthus MF, Lonergan M, Crumley MJ, et al. Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 2000; 11:1044.",
"     </a>",
"    </li>",
"    <li>",
"     Robertson, GL. Diseases of the posterior pituitary, In: Endocrinology and Metabolism, Felig, D, Baxter, JD, Broadus, AE, Frohman, LA (Eds), McGraw-Hill, New Yorkm 1981, pp. 251-277.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/8\">",
"      Miller M, Dalakos T, Moses AM, et al. Recognition of partial defects in antidiuretic hormone secretion. Ann Intern Med 1970; 73:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/9\">",
"      Zerbe RL, Robertson GL. A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. N Engl J Med 1981; 305:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/10\">",
"      Moses AM, Clayton B. Impairment of osmotically stimulated AVP release in patients with primary polydipsia. Am J Physiol 1993; 265:R1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/11\">",
"      Brewster UC, Hayslett JP. Diabetes insipidus in the third trimester of pregnancy. Obstet Gynecol 2005; 105:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/12\">",
"      Diederich S, Eckmanns T, Exner P, et al. Differential diagnosis of polyuric/polydipsic syndromes with the aid of urinary vasopressin measurement in adults. Clin Endocrinol (Oxf) 2001; 54:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/13\">",
"      Szinnai G, Morgenthaler NG, Berneis K, et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 2007; 92:3973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/14\">",
"      Gault MH, Dixon ME, Doyle M, Cohen WM. Hypernatremia, azotemia, and dehydration ue to high-protein tube feeding. Ann Intern Med 1968; 68:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/15\">",
"      Howards SS. Post-obstructive diuresis: a misunderstood phenomenon. J Urol 1973; 110:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/16\">",
"      Bishop MC. Diuresis and renal functional recovery in chronic retention. Br J Urol 1985; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/17\">",
"      Gibbons MD, Koontz WW Jr. Obstructive uropathy and nephrogenic diabetes insipidus in infants. J Urol 1979; 122:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/18\">",
"      Smoyer WE. Medical management of postobstructive polyuria. Am J Dis Child 1991; 145:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/19\">",
"      Boyd SD, Raz S, Ehrlich RM. Diabetes insipidus and nonobstructive dilation of urinary tract. Urology 1980; 16:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/20\">",
"      Ulinski T, Grapin C, Forin V, et al. Severe bladder dysfunction in a family with ADH receptor gene mutation responsible for X-linked nephrogenic diabetes insipidus. Nephrol Dial Transplant 2004; 19:2928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24312/abstract/21\">",
"      Shalev H, Romanovsky I, Knoers NV, et al. Bladder function impairment in aquaporin-2 defective nephrogenic diabetes insipidus. Nephrol Dial Transplant 2004; 19:608.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2381 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-2ED33AB258-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_47_24312=[""].join("\n");
var outline_f23_47_24312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Primary polydipsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Central DI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nephrogenic DI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Onset of polyuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Plasma sodium and urine osmolality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1100220\">",
"      Measurement of urine output",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Water restriction test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Infants and children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Interpretation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Sources of error",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Plasma and urine ADH measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SOLUTE DIURESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Salt-wasting nephropathy: not a cause of polyuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2381\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2381|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/61/15325\" title=\"figure 1\">",
"      Osmoregulation of ADH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10985?source=related_link\">",
"      Chapter 2D: Regulation of GFR and renal plasma flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=related_link\">",
"      Clinical manifestations and causes of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=related_link\">",
"      Etiology and evaluation of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/55/43889?source=related_link\">",
"      Patient information: Diabetes insipidus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=related_link\">",
"      Treatment of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=related_link\">",
"      Treatment of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12050?source=related_link\">",
"      Urine output in urinary tract obstruction and postobstructive diuresis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_47_24313="Radical prostatectomy for localized prostate cancer";
var content_f23_47_24313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radical prostatectomy for localized prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/47/24313/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24313/contributors\">",
"     Eric A Klein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/47/24313/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24313/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24313/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24313/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/47/24313/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24313/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/47/24313/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24077712\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard management options for men with clinically localized prostate cancer include radical prostatectomy, radiation therapy (RT), including external beam RT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    brachytherapy, and, for appropriately selected patients, active surveillance. Patients treated with RT who were classified as high risk based upon pretreatment assessment and those managed with radical prostatectomy who have significant adverse pathologic findings (positive margins, seminal vesical invasion, persistent elevation of serum PSA) may require a combined modality approach.",
"   </p>",
"   <p>",
"    The role of radical prostatectomy in the treatment of clinically localized prostate cancer will be reviewed here. Overall treatment options for men with newly diagnosed prostate cancer and the factors influencing the choice of therapy are discussed separately based upon the risk of recurrence and the extent of disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"       \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"       \"Initial approach to low-risk clinically localized prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link\">",
"       \"Initial management of regionally localized intermediate and high risk prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link\">",
"       \"Overview of the treatment of disseminated prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H167060109\">",
"    <span class=\"h1\">",
"     SURVIVAL IMPACT OF RADICAL PROSTATECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three randomized clinical trials have looked at whether radical prostatectomy improved survival compared with observation (watchful waiting) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The trials did not include definitive therapy at the first evidence of disease progression and need to be distinguished from active surveillance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13288?source=see_link\">",
"     \"Active surveillance for men with early prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two larger, contemporary trials provide important insights into the effectiveness of radical prostatectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Scandinavian Prostate Cancer Group 4 trial, 695 men with clinical stage T1 or T2 prostate cancer were randomly assigned to radical prostatectomy or watchful waiting, with active therapy deferred until advanced disease was present [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/1\">",
"       1",
"      </a>",
"      ]. In the most recent follow-up report from this trial, the 15-year cumulative incidence of death due to prostate cancer was lower in the radical prostatectomy group compared with those managed with watchful waiting (14.6 versus 20.7 percent, relative risk of death 0.62, 95% CI 0.44-0.87).",
"     </li>",
"     <li>",
"      In the PIVOT trial, 731 men with T1-T2NxM0 prostate cancer were randomly assigned to radical prostatectomy or observation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/3\">",
"       3",
"      </a>",
"      ]. Men assigned to observation were offered palliative therapy for symptomatic or metastatic progression. At a median follow-up of 10 years, there was no statistically significant improvement in overall survival with radical prostatectomy, the primary endpoint of the trial (hazard ratio for death 0.88, 95% CI 0.71-1.08). By the end of the study there was a 2.9 percent lower overall mortality in the radical prostatectomy group compared with those managed with observation (47.0 versus 49.9 percent). There was a statistically nonsignificant decrease in mortality due to prostate cancer or treatment (HR 0.63, 95% CI 0.36-1.09). However, there was a statistically significant decrease in the incidence of bone metastases (4.7 versus 10.6 percent, HR 0.40, 95% CI 0.22-0.70). Whether additional differences will become evident with longer follow-up is uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1302078\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical prostatectomy is a treatment option for patients with localized prostate cancer, along with external beam radiation therapy, brachytherapy, and in some cases active surveillance. Radical prostatectomy is not indicated for patients with clinical evidence of regional lymph node involvement or distant metastases or when there is tumor fixation to adjacent structures.",
"   </p>",
"   <p>",
"    The factors influencing the choice of prostatectomy rather than external beam radiation therapy, brachytherapy, or active surveillance are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24077719\">",
"    <span class=\"h1\">",
"     RETROPUBIC PROSTATECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical retropubic prostatectomy is the standard surgical approach for most men choosing surgery for definitive therapy of localized prostate cancer. Prostatectomy may be combined with a pelvic lymph node dissection depending upon the risk of lymph node involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1302094\">",
"    <span class=\"h2\">",
"     Open versus minimally invasive techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical prostatectomy can be performed using either an open approach or via a minimally invasive (robotic or laparoscopic) technique. Compared with an open technique, minimally invasive approaches use a smaller incision and provide magnification of the surgical field for the operator. Analyses of large databases indicate that the usage of robotic surgery has increased rapidly and now constitutes a majority of radical prostatectomies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized trials that compare open versus minimally invasive radical prostatectomy. Comparative studies of efficacy and side effects have yielded conflicting results, which appear to reflect differences in case selection and tumor characteristics and lack of long term follow-up.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two large single institution series suggest the incidence of positive margins is lower with a minimally invasive approach [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. However, a Medicare database study found that those treated with a minimally invasive radical prostatectomy were significantly more likely to require salvage RT or ADT within six months after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two large observational database studies suggested that a minimally invasive approach might offer advantages in terms of short length of stay and a decreased frequency of complications [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. However, single institution series from academic centers suggest that both approaches result in similar lengths of stay without differences in post discharge recovery [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An analysis using patient-reported data did not observe statistically significant differences in problems with urinary incontinence or sexual function [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21779374\">",
"    <span class=\"h2\">",
"     Experience of the surgeon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The experience of the surgeon is a critical factor associated with a successful outcome following radical prostatectomy regardless of whether an open or minimally invasive technique is utilized:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Open prostatectomy &ndash; In a series of 7765 men who underwent open radical prostatectomy by one of 72 surgeons at four US academic medical centers between 1987 and 2003, the learning curve did not plateau until a surgeon had performed at least 250 retropubic radical prostatectomies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/9\">",
"       9",
"      </a>",
"      ]. The probability of biochemical recurrence at five years was significantly lower when the surgeon had performed 250 prior operations (10.7 versus 17.9 percent when the surgeon had performed 10 prior operations).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minimally invasive prostatectomy &ndash; In a series of 4702 men who were managed with laparoscopic prostatectomy by one of 29 surgeons at seven centers, the five-year risk of recurrence progressively decreased with increasing experience (17, 16, and 9 percent with 10, 250, and 750 prior laparoscopic procedures) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/10\">",
"       10",
"      </a>",
"      ]. A similar learning curve was seen in a second multicenter study [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24078947\">",
"    <span class=\"h2\">",
"     Preoperative preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative counseling that includes the spouse or partner is essential to address the practical and emotional issues surrounding radical prostatectomy. Presurgical psychosocial interventions including a focus on stress management may be useful in improving quality of life following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the most important goals prior to treatment is to set reasonable expectations for the short-term and long-term effects of surgery on activity level, continence, and potency. Emphasis is placed on the type of anesthesia to be used, whether or not lymphadenectomy will be performed, and whether or not a nerve-sparing procedure is contemplated, as well as the anticipated length of hospital stay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H683372924\">",
"    <span class=\"h2\">",
"     Nerve-sparing approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erectile function following radical prostatectomy depends upon preservation of the autonomic cavernous nerves, located within the neurovascular bundles [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/13\">",
"     13",
"    </a>",
"    ]. Every effort should be made to preserve the bilateral neurovascular bundles as long as cancer control is not compromised. (See",
"    <a class=\"local\" href=\"#H24077796\">",
"     'Impotence'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Nerve-sparing radical prostatectomy can be performed safely in men with pathologic extraprostatic extension as long as the neurovascular bundles are not involved. The decision to perform a nerve-sparing approach is made during surgery based upon visual inspection and palpation of the gland and its relationship to the nerve bundle. If there is a clinical suspicion of extraprostatic extension involving the neurovascular bundles, intraoperative frozen section analysis may be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24077780\">",
"    <span class=\"h2\">",
"     Pelvic lymph node dissection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1302101\">",
"    <span class=\"h3\">",
"     Indications and extent of dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the widespread introduction of prostate specific antigen (PSA) testing, most patients are diagnosed with localized disease and there has been a concomitant decrease in the percentage of patients with regional lymph node involvement at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Key factors that are associated with an increased risk of occult lymph node metastases include a higher clinical tumor stage, Gleason score of 7 or more, and a higher serum PSA.",
"   </p>",
"   <p>",
"    The need for pelvic lymph node dissection in conjunction with radical prostatectomy is determined by the risk of regional lymph node involvement, which is based upon the extent of the local tumor (T stage), serum PSA, or Gleason score. Pelvic lymph node dissection can be omitted in patients with low risk disease and is usually performed in all others [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The extent of a pelvic lymph node dissection has a major impact on the frequency with which positive lymph nodes are detected as well as on the incidence of complications. The optimal extent of pelvic lymph node dissection is uncertain, but the available evidence suggests that an extended dissection is preferable, especially in patients with very high risk [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historically, pelvic lymph node dissection was limited to the obturator fossa and nodes associated with the external iliac vein. However, the primary lymphatic drainage of the prostate often bypasses these nodes and goes directly to the common iliac, hypogastric, paraaortic, presacral, or perirectal lymph nodes. A more extensive dissection not only yields greater numbers of positive nodes but also can identify lymph node involvement when the nodes within a more limited template are negative [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An improvement in survival from a pelvic lymph node dissection has not been demonstrated in randomized trials. However, the prolonged survival of men with microscopic lymph node involvement at pathologic staging suggests that pelvic lymph node dissection may be curative in some men. &nbsp;(See",
"    <a class=\"local\" href=\"#H24079785\">",
"     'Impact of pathologic staging on prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1302123\">",
"    <span class=\"h3\">",
"     Microscopic lymph node involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients in whom the pelvic lymph node dissection identifies microscopic evidence of lymph node involvement, the serum PSA provides important information on whether or not all disease has been resected and whether additional therapy is indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients in whom the serum PSA falls to undetectable levels following definitive surgery, careful monitoring is indicated including digital rectal examination and serum PSA every three to six months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=see_link\">",
"       \"Follow-up surveillance during and after treatment for prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the PSA remains detectable or subsequently rises, patients are presumed to have residual disease. Such patients should be evaluated for evidence of metastatic disease, and subsequent therapy is dictated by the results of that evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link\">",
"       \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38918?source=see_link\">",
"       \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30470?source=see_link\">",
"       \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1302131\">",
"    <span class=\"h2\">",
"     Pathologic staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are managed with radical prostatectomy are restaged after surgery based upon the extent of disease in the surgical resection specimen. Such patients may be reclassified, based upon the extent of the primary tumor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of microscopic involvement of regional lymph nodes. The information from pathologic staging can provide important information regarding prognosis.",
"   </p>",
"   <p>",
"    The management of patients with pathologic T3 or margin positive prostate cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33943?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathologic stage T3 and margin positive prostate cancer\", section on 'Pathologic versus clinical staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24077788\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AND QUALITY OF LIFE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24077796\">",
"    <span class=\"h2\">",
"     Impotence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of impotence depends upon multiple factors, including age, pretreatment sexual functioning, and type of surgery (nerve-sparing versus non-nerve-sparing). A validated model that may be useful in counseling patients has been developed to help predict the probability of erectile function two years after radical prostatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24077818\">",
"    <span class=\"h3\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potency can be preserved in many men with normal preoperative erectile function who undergo bilateral nerve-sparing radical prostatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/22-27\">",
"     22-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of erectile dysfunction depends upon the definition of erectile dysfunction and source of information. Potency rates as high as 76 to 86 percent have been reported by individual surgeons and centers performing nerve-sparing surgery on carefully selected men who then use phosphodiesterase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In contrast, sexuality problems (eg, poor erections, difficulty with orgasm) were a moderate or big problem in 59 percent of men two months after in a series of 603 patients who had undergone radical prostatectomy [50]. Although there was some gradual improvement with time, 43 percent still reported such problems two years after prostatectomy.",
"   </p>",
"   <p>",
"    The likelihood of regaining potency following radical prostatectomy decreases with increasing age. In one series, the potency rate after surgery was 86 percent in men in their 40s, and 80, 60, and 42 percent for men in their 50s, 60s, and 70s, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24077825\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penile sensation and the ability to have an orgasm are preserved even if the erectile nerves are removed during radical prostatectomy, leaving several options for treatment of erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/28\">",
"     28",
"    </a>",
"    ]. These include the use of oral phosphodiesterase-5 inhibitors, vacuum-assisted erection devices, penile self-injection (prostaglandin E1,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=see_link\">",
"     papaverine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    ), and intraurethral alprostadil. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16664?source=see_link\">",
"     \"Surgical treatment of erectile dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Men prefer noninvasive treatments although invasive treatments (intracavernosal injection therapy, penile implants, prostheses) are more effective [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/29\">",
"     29",
"    </a>",
"    ]. Sexual counseling should be recommended for men and their partners, as it may increase the use of and satisfaction with medical therapies.",
"   </p>",
"   <p>",
"    Phosphodiesterase inhibitors are most helpful in men who have undergone a nerve-sparing procedure. As an example, in one study of 91 men presenting with erectile dysfunction following radical prostatectomy, the response rates to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    in men who had undergone bilateral nerve-sparing, unilateral nerve-sparing, and a non-nerve sparing approach were 72, 50, and 15 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    increases with time following radical prostatectomy. In a study in which 95 percent of men had undergone nerve-sparing procedures, 60 percent reported benefit from sildenafil at 18 to 24 months after surgery, significantly higher than the 29 percent who reported benefit in the first six months after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H705967483\">",
"    <span class=\"h3\">",
"     Penile rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penile rehabilitation beginning shortly after surgery with oral phosphodiesterase inhibitors, vacuum assisted devices, or other interventions has been advocated to minimize the long-term incidence of erectile dysfunction, although the effectiveness of this approach is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/31-36\">",
"     31-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On-demand treatment with a 5-phosphodiesterase inhibitor may be as effective as penile rehabilitation using these agents. In a randomized, double-blind trial, 628 men were randomly assigned to nightly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    , on-demand vardenafil, or placebo for nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/37\">",
"     37",
"    </a>",
"    ]. After a two-month washout period, there were no differences in sexual performance between the two vardenafil regimens, and on-demand vardenafil was better than placebo throughout the trial. A second, much smaller trial, suggested that this approach might be beneficial, but the interpretation of that trial is problematic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal model data suggest that peri-operative use of oral phosphodiesterase inhibitors helps recovery, although there are no human studies to confirm. The author&rsquo;s routine is to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    (2.5 mg for three days preoperatively and 30 days postoperatively), followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    100mg two to three times per week as soon as the patient recovers continence. Injection treatment is added at eight weeks if erections have not returned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24077840\">",
"    <span class=\"h2\">",
"     Urinary incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Damage to the urinary sphincter can lead to urinary incontinence following radical prostatectomy. However, complete urinary incontinence is uncommon following retropubic radical prostatectomy. Nevertheless, the majority of men experience some degree of urinary incontinence after radical prostatectomy, particularly stress incontinence.",
"   </p>",
"   <p>",
"    The incidence of incontinence depends upon its definition, the time elapsed since surgery, and whether or not a nerve-sparing approach was used. Although physician-reported data from single institution studies indicate that 90 percent or more of patients are continent at 6 to 24 months after surgery [51,52], patient-reported data suggest that the frequency of at least some incontinence may be higher.",
"   </p>",
"   <p>",
"    In a multi-institution analysis that included 603 patients who had undergone radical prostatectomy, 52 percent of patients reported some urine leakage more than once a day two months after surgery [50]. By 12 and 24 months, this had decreased to approximately 15 percent. Approximately 7 percent continued to consider urinary symptoms to be a moderate or big problem at two years.",
"   </p>",
"   <p>",
"    Urinary incontinence typically improves with time following retropubic radical prostatectomy. Less than 1 percent of patients ultimately require surgical placement of an artificial sphincter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41737?source=see_link&amp;anchor=H637407126#H637407126\">",
"     \"Urinary incontinence in men\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24079816\">",
"    <span class=\"h2\">",
"     Urethral strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethral strictures following radical prostatectomy may be due to bladder neck contracture or narrowing of the urethra at more distal sites. Urethral stricture may be manifested by symptoms of decreased urinary stream or overflow incontinence.",
"   </p>",
"   <p>",
"    In a series of 3310 men from the CaPSURE database managed with radical prostatectomy, urethral stricture was diagnosed in 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/38\">",
"     38",
"    </a>",
"    ]. In another series of 1289 men who underwent radical prostatectomy between 1998 and 2004, 138 (11 percent) developed a bladder neck contracture [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/39\">",
"     39",
"    </a>",
"    ]. The incidence was significantly higher among men who had an episode of urinary retention within seven days after catheter removal.",
"   </p>",
"   <p>",
"    Most contractures can be easily managed with simple dilation. Dense strictures may require endoscopic incision [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36617?source=see_link\">",
"     \"Treatment of urethral stricture disease in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24077861\">",
"    <span class=\"h2\">",
"     Inguinal hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of inguinal hernias appears to be increased following retropubic radical prostatectomy, due both to the detection of preexisting hernias that were not diagnosed preoperatively as well as alterations of inguinal anatomy during surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/9,41,42\">",
"     9,41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational database study from Quebec, the frequency of inguinal hernia repair was significantly increased in 6422 men treated with radical prostatectomy compared with 4685 men managed with external beam radiation therapy (10-year rate 13.8 versus 7.8 percent, hazard ratio 2.3, 95% CI 1.9-2.7) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The increased risk may be limited to retropubic radical prostatectomy rather than perineal prostatectomy. In a series of 596 cases, the incidence of inguinal hernia at a median follow-up of three years was lower following perineal radical prostatectomy (5 of 285 [1.8 percent] versus 32 of 311 [10.3 percent] following retropubic radical prostatectomy) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24077868\">",
"    <span class=\"h2\">",
"     Perioperative complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative morbidity rates are generally under 10 percent. Serious complications include myocardial infarction, and thromboembolic, infectious, and neurologic events, but most complications are minor and resolve without sequelae. Operative mortality rates in most series are less than 1 percent, even in older men [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/43-47\">",
"     43-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perioperative complications are more common in men with significant comorbidity and in older men [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/24\">",
"     24",
"    </a>",
"    ]. In a report of 11,010 men who underwent radical prostatectomy in Ontario, Canada between 1990 and 1999, comorbidity was a strong predictor of almost all categories of early complications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/47\">",
"     47",
"    </a>",
"    ]. When adjusted for comorbidity and year of surgery, age was also associated with a significantly increased risk of 30-day mortality (odds ratio 2.04 per decade of age). Nevertheless, the absolute 30-day mortality risk was low, even in men aged 70 to 79 (0.66 percent versus 0.58 and 0.19 percent in men 60 to 69 and &lt;60 years of age, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H945981270\">",
"    <span class=\"h2\">",
"     BPH symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who undergo radical prostatectomy for localized prostate cancer frequently have pretreatment lower urinary tract symptoms that are due to benign prostatic hyperplasia (BPH) rather than tumor. Radical prostatectomy may partially reverse or prevent the progression of such symptoms.",
"   </p>",
"   <p>",
"    The impact on lower urinary tract symptoms was assessed in a study of 453 men who underwent an radical prostatectomy for localized prostate cancer and who completed the American Urological Association symptom score (AUASS) at baseline, and 12 and 48 months after surgery (",
"    <a class=\"graphic graphic_table graphicRef81331 \" href=\"UTD.htm?4/5/4189\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/48\">",
"     48",
"    </a>",
"    ]. Overall, 36 percent of patients had moderate or severe symptoms at baseline (AUASS &ge;8), while 64 percent had no or mild symptoms (AUASS &le;7).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among men with moderate to severe symptoms at baseline, there was a clinically and statistically significant decrease in symptoms at 12 months, which was maintained at 48 months (AUASS -5.0 versus baseline and -6.3 versus baseline at 12 and 48 months, respectively). The improvement in symptoms occurred despite the discontinuation of medical therapy for symptomatic BPH in all patients after radical prostatectomy.",
"     </li>",
"     <li>",
"      In men with mild symptoms, there was an initial slight worsening of symptoms in the first 12 months without further subsequent deterioration (AUASS +2.0 versus baseline and +1.7 versus baseline at 12 and 48 months, respectively). Although these increases from baseline were statistically significant, they were not clinically relevant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results were derived from a nonrandomized series. Although the natural history of BPH can be variable, the symptoms of BPH in some men appear to improve following surgery. A prospective study found that the benefit of radical prostatectomy in men with obstructive or irritative urinary symptoms was greatest in those with large prostate size [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/25\">",
"     25",
"    </a>",
"    ]. The potential impact of radical prostatectomy on such symptoms may be a factor when choosing definitive treatment of localized prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24078940\">",
"    <span class=\"h1\">",
"     PERINEAL RADICAL PROSTATECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In men with localized (T1-2) prostate cancer and a relatively small prostate gland, perineal radical prostatectomy is associated with less blood loss than open retropubic radical prostatectomy and is associated with a similar frequency of positive margins and biochemical relapse. However, recovery of potency is delayed and less frequent with the perineal approach, even with a nerve-sparing procedure. In addition, there also is a small but increased risk of rectal injury and fecal incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perineal radical prostatectomy is a reasonable option for men with low-risk primary tumors and relatively small prostates (eg, Gleason score &lt;6, serum PSA &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and a prostate gland &lt;80 g), and in whom a pelvic lymph node dissection is not indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Perineal radical prostatectomy may be particularly useful in men who have had prior pelvic surgery and in those for whom minimizing short-term toxicity is a priority. Perineal prostatectomy should be limited to centers with adequate expertise in this approach.",
"   </p>",
"   <p>",
"    In a randomized Italian trial, 200 men with clinical stage T1 or T2 prostate cancer and a prostate gland weighing less than 80 g were managed with either a perineal prostatectomy or a retropubic prostatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/53\">",
"     53",
"    </a>",
"    ]. Surgery for all patients was performed by a single surgeon who was trained in both techniques.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At a mean follow-up of 60 months, there was no difference in the biochemical relapse-free survival rate or incidence of positive margins (12 versus 11 percent and 14 versus 15 percent, respectively, for perineal and retropubic prostatectomies).",
"     </li>",
"     <li>",
"      The incidence and timing of return of urinary continence was the same with both surgical approaches (74 versus 76 and 96 versus 95 percent, at 6 and 24 months, respectively).",
"     </li>",
"     <li>",
"      Perineal prostatectomy was associated with significantly less blood loss, a shorter hospital stay, and a shorter duration of catheterization compared to retropubic prostatectomy (100 versus 400 mL, 8 versus 13 days, and 7 versus 12 days, respectively).",
"     </li>",
"     <li>",
"      Recovery of potency was significantly less common with perineal radical prostatectomy (potency 30 versus 45 percent at 6 months and 42 versus 60 percent, at 24 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24079785\">",
"    <span class=\"h1\">",
"     IMPACT OF PATHOLOGIC STAGING ON PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathologic examination of the resection specimen permits pathologic staging, which may differ significantly from the pretreatment clinical stage (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 3",
"    </a>",
"    ). The more accurate assessment of the extent of disease provides a better correlation with prognosis in determining whether further therapy is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33943?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathologic stage T3 and margin positive prostate cancer\", section on 'Pathologic versus clinical staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between pathologic staging and prognosis is illustrated by a multicenter series of 23,910 men who were managed with radical prostatectomy at four centers between 1987 and 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24313/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prostate cancer specific mortality at 15 years was a function of pathologic stage of disease (0.8 to 1.5 percent, 2.9 to 10.0 percent, 15 to 27 percent, and 22 to 30 percent, for pT2, pT3a, pT3b, and pN1 disease, respectively).",
"     </li>",
"     <li>",
"      The 15 year prostate cancer specific mortality rates also correlated with higher Gleason score (0.2 to 1.2 percent, 4.2 to 6.5 percent, 6.6 to 11 percent, and 26 to 37 percent at 15 years, for Gleason score &le;6 or less, 3+4, 4+3, and 8 to 10, respectively).",
"     </li>",
"     <li>",
"      The identification of higher pathologic stage (pT3 or pT4), microscopic lymph node involvement (pN1), or Gleason score 8 to 10 in the resection specimen did not preclude prolonged survival in a majority of cases. The approximate overall survival rates at 15 years for men with Gleason score 8 to 10 disease, seminal vesicle invasion, or microscopic lymph node involvement were 50 to 60, 50 to 70, and 60 to 65 percent, respectively, depending upon age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these results cannot be generalized to men who present with clinical T3 or T4 disease or clinical evidence of lymph node involvement. The occurrence of an isolated PSA recurrence following radical prostatectomy is not necessarily associated with the rapid development of more extensive disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H10#H10\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Natural history'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H683372761\">",
"    <span class=\"h1\">",
"     RADICAL PROSTATECTOMY VERSUS RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oncologic outcomes following radical prostatectomy compared with other treatment approaches are based upon risk stratification and are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"       \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link&amp;anchor=H1191026#H1191026\">",
"       \"Initial approach to low-risk clinically localized prostate cancer\", section on 'Radical prostatectomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link&amp;anchor=H1191266#H1191266\">",
"       \"Initial management of regionally localized intermediate and high risk prostate cancer\", section on 'Radical prostatectomy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4112758\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AFTER TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance strategies after treatment for localized prostate cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=see_link&amp;anchor=H11088148#H11088148\">",
"     \"Follow-up surveillance during and after treatment for prostate cancer\", section on 'Metastatic prostate cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/15/3315?source=see_link\">",
"       \"Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=see_link\">",
"       \"Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24077897\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with clinically localized prostate cancer, the preferred approaches for definitive therapy include radical prostatectomy and radiation therapy (RT); the choice is largely a matter of patient preference. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"       \"Initial approach to low-risk clinically localized prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retropubic radical prostatectomy is the standard approach for most patients who choose surgery for the definitive management. Retropubic prostatectomy can be performed using either an open or minimally invasive approach. (See",
"      <a class=\"local\" href=\"#H24077719\">",
"       'Retropubic prostatectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There are no randomized trials comparing an open versus a minimally invasive approach. In experienced hands, both the oncologic results and the frequency of complications are similar with both techniques. The choice of a minimally invasive approach or an open approach should be based upon the experience of the surgeon since the results with both open and minimally invasive approaches are associated with a significant learning curve. (See",
"      <a class=\"local\" href=\"#H1302094\">",
"       'Open versus minimally invasive techniques'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21779374\">",
"       'Experience of the surgeon'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      For patients with no evidence of tumor involving the neurovascular bundle, we recommend that a nerve-sparing approach be incorporated into the radical prostatectomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This approach is associated with faster return of urinary continence and a lower frequency of impotence in men who were potent prior to surgery. (See",
"      <a class=\"local\" href=\"#H683372924\">",
"       'Nerve-sparing approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perineal prostatectomy is an alternative to retropubic prostatectomy for men with clinical stage T1-2 disease, a relatively small prostate gland, and no indication for a lymph node dissection. This approach may be particularly useful in men who have had prior pelvic surgery and in those for whom minimizing short term toxicity is a high priority. Perineal prostatectomy should be limited to centers with expertise in this technique. (See",
"      <a class=\"local\" href=\"#H24078940\">",
"       'Perineal radical prostatectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients choosing radical prostatectomy as their primary definitive therapy, preoperative risk stratification is used to guide the decision of whether or not to perform a pelvic lymph node dissection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"       \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H24077780\">",
"       'Pelvic lymph node dissection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with high risk or very high risk disease, we recommend that pelvic lymph node dissection be incorporated into the surgical procedure (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with intermediate risk disease, we suggest that pelvic lymph node dissection be performed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with low risk disease we suggest that pelvic lymph node dissection be omitted (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with adverse laboratory or pathology features following prostatectomy (positive margins, seminal vesicle invasion, extracapsular extension, or detectable PSA), we suggest postoperative adjuvant RT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33943?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathologic stage T3 and margin positive prostate cancer\", section on 'Adjuvant RT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients in whom the pelvic lymph node dissection identifies microscopic evidence of lymph node involvement, the serum PSA provides important information on whether or not all disease has been resected and whether additional therapy is indicated. (See",
"      <a class=\"local\" href=\"#H1302123\">",
"       'Microscopic lymph node involvement'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The most important frequent complications associated with radical retropubic prostatectomy include urinary incontinence and erectile dysfunction. (See",
"      <a class=\"local\" href=\"#H24077840\">",
"       'Urinary incontinence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24077796\">",
"       'Impotence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/1\">",
"      Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/2\">",
"      Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl 1995; 172:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/3\">",
"      Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/4\">",
"      Trinh QD, Sammon J, Sun M, et al. Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. Eur Urol 2012; 61:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/5\">",
"      Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009; 302:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/6\">",
"      Hu JC, Wang Q, Pashos CL, et al. Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol 2008; 26:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/7\">",
"      Wood DP, Schulte R, Dunn RL, et al. Short-term health outcome differences between robotic and conventional radical prostatectomy. Urology 2007; 70:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/8\">",
"      Barry MJ, Gallagher PM, Skinner JS, Fowler FJ Jr. Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of medicare-age men. J Clin Oncol 2012; 30:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/9\">",
"      Matsubara A, Yoneda T, Nakamoto T, et al. Inguinal hernia after radical perineal prostatectomy: comparison with the retropubic approach. Urology 2007; 70:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/10\">",
"      Vickers AJ, Savage CJ, Hruza M, et al. The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study. Lancet Oncol 2009; 10:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/11\">",
"      Secin FP, Savage C, Abbou C, et al. The learning curve for laparoscopic radical prostatectomy: an international multicenter study. J Urol 2010; 184:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/12\">",
"      Parker PA, Pettaway CA, Babaian RJ, et al. The effects of a presurgical stress management intervention for men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2009; 27:3169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/13\">",
"      Lowentritt BH, Scardino PT, Miles BJ, et al. Sildenafil citrate after radical retropubic prostatectomy. J Urol 1999; 162:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/14\">",
"      Berglund RK, Sadetsky N, DuChane J, et al. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE. J Urol 2007; 177:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/15\">",
"      Allaf ME, Palapattu GS, Trock BJ, et al. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004; 172:1840.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on April 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/17\">",
"      Klein EA, Kattan M, Stephenson A, Vickers A. How many lymphadenectomies does it take to cure one patient? Eur Urol 2008; 53:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/18\">",
"      Zwergel U, Lehmann J, Wullich B, et al. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. J Urol 2004; 171:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/19\">",
"      Wawroschek F, Wagner T, Hamm M, et al. The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 2003; 43:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/20\">",
"      Mattei A, Fuechsel FG, Bhatta Dhar N, et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 2008; 53:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/21\">",
"      Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/22\">",
"      Ohori M, Wheeler TM, Kattan MW, et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995; 154:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/23\">",
"      Ng CS, Klein EA. Acute complications after radical retropubic prostatectomy. Prostate J 2000; 2:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/24\">",
"      Klein EA, Grass JA, Calabrese DA, et al. Maintaining quality of care and patient satisfaction with radical prostatectomy in the era of cost containment. Urology 1996; 48:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/25\">",
"      Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/26\">",
"      Kundu SD, Roehl KA, Eggener SE, et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004; 172:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/27\">",
"      Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000; 55:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/28\">",
"      Raina R, Agarwal A, Zippe CD. Management of erectile dysfunction after radical prostatectomy. Urology 2005; 66:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/29\">",
"      Schover LR, Fouladi RT, Warneke CL, et al. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer 2002; 95:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/30\">",
"      Hong EK, Lepor H, McCullough AR. Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP). Int J Impot Res 1999; 11 Suppl 1:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/31\">",
"      Padma-Nathan H, McCullough AR, Levine LA, et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008; 20:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/32\">",
"      Mulhall JP, Parker M, Waters BW, Flanigan R. The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. BJU Int 2010; 105:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/33\">",
"      Raina R, Pahlajani G, Agarwal A, et al. Long-term potency after early use of a vacuum erection device following radical prostatectomy. BJU Int 2010; 106:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/34\">",
"      Mulhall JP, Bella AJ, Briganti A, et al. Erectile function rehabilitation in the radical prostatectomy patient. J Sex Med 2010; 7:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/35\">",
"      Garcia FJ, Brock G. Current state of penile rehabilitation after radical prostatectomy. Curr Opin Urol 2010; 20:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/36\">",
"      McCullough AR, Hellstrom WG, Wang R, et al. Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. J Urol 2010; 183:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/37\">",
"      Montorsi F, Brock G, Lee J, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008; 54:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/38\">",
"      Elliott SP, Meng MV, Elkin EP, et al. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol 2007; 178:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/39\">",
"      Montgomery JS, Gayed BA, Daignault S, et al. Early urinary retention after catheter removal following radical prostatectomy predicts for future symptomatic urethral stricture formation. Urology 2007; 70:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/40\">",
"      Yurkanin JP, Dalkin BL, Cui H. Evaluation of cold knife urethrotomy for the treatment of anastomotic stricture after radical retropubic prostatectomy. J Urol 2001; 165:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/41\">",
"      Lughezzani G, Sun M, Perrotte P, et al. Comparative study of inguinal hernia repair rates after radical prostatectomy or external beam radiotherapy. Int J Radiat Oncol Biol Phys 2010; 78:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/42\">",
"      Stranne J, Lodding P. Inguinal hernia after radical retropubic prostatectomy: risk factors and prevention. Nat Rev Urol 2011; 8:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/43\">",
"      Ruckle HC, Zincke H. Potency-sparing radical retropubic prostatectomy: a simplified anatomical approach. J Urol 1995; 153:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/44\">",
"      Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999; 162:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/45\">",
"      Zincke H, Bergstralh EJ, Blute ML, et al. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol 1994; 12:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/46\">",
"      Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996; 276:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/47\">",
"      Alibhai SM, Leach M, Tomlinson G, et al. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst 2005; 97:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/48\">",
"      Slova D, Lepor H. The short-term and long-term effects of radical prostatectomy on lower urinary tract symptoms. J Urol 2007; 178:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/49\">",
"      Iselin CE, Robertson JE, Paulson DF. Radical perineal prostatectomy: oncological outcome during a 20-year period. J Urol 1999; 161:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/50\">",
"      Lance RS, Freidrichs PA, Kane C, et al. A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group. BJU Int 2001; 87:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/51\">",
"      Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/52\">",
"      Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/53\">",
"      Martis G, Diana M, Ombres M, et al. Retropubic versus perineal radical prostatectomy in early prostate cancer: eight-year experience. J Surg Oncol 2007; 95:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24313/abstract/54\">",
"      Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185:869.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6944 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_47_24313=[""].join("\n");
var outline_f23_47_24313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24077897\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24077712\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H167060109\">",
"      SURVIVAL IMPACT OF RADICAL PROSTATECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1302078\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24077719\">",
"      RETROPUBIC PROSTATECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1302094\">",
"      Open versus minimally invasive techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21779374\">",
"      Experience of the surgeon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24078947\">",
"      Preoperative preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H683372924\">",
"      Nerve-sparing approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24077780\">",
"      Pelvic lymph node dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1302101\">",
"      - Indications and extent of dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1302123\">",
"      - Microscopic lymph node involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1302131\">",
"      Pathologic staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24077788\">",
"      COMPLICATIONS AND QUALITY OF LIFE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24077796\">",
"      Impotence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24077818\">",
"      - Incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24077825\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H705967483\">",
"      - Penile rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24077840\">",
"      Urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24079816\">",
"      Urethral strictures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24077861\">",
"      Inguinal hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24077868\">",
"      Perioperative complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H945981270\">",
"      BPH symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24078940\">",
"      PERINEAL RADICAL PROSTATECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24079785\">",
"      IMPACT OF PATHOLOGIC STAGING ON PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H683372761\">",
"      RADICAL PROSTATECTOMY VERSUS RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4112758\">",
"      SURVEILLANCE AFTER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24077897\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6944\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6944|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/5/4189\" title=\"table 1\">",
"      AUA Urinary Symptom Score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/19/41277\" title=\"table 2\">",
"      TNM staging prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/43/10941\" title=\"table 3\">",
"      TNM group prostate CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13288?source=related_link\">",
"      Active surveillance for men with early prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=related_link\">",
"      Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=related_link\">",
"      Follow-up surveillance during and after treatment for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=related_link\">",
"      Initial approach to low-risk clinically localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=related_link\">",
"      Initial management of regionally localized intermediate and high risk prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33943?source=related_link\">",
"      Pathologic stage T3 and margin positive prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/15/3315?source=related_link\">",
"      Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=related_link\">",
"      Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=related_link\">",
"      Prostate cancer: Risk stratification, other prognostic factors, and predictive tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30470?source=related_link\">",
"      Rising serum PSA after treatment for localized prostate cancer: Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=related_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=related_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38918?source=related_link\">",
"      Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16664?source=related_link\">",
"      Surgical treatment of erectile dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36617?source=related_link\">",
"      Treatment of urethral stricture disease in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41737?source=related_link\">",
"      Urinary incontinence in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_47_24314="Treatment regimens for chronic hepatitis C virus genotype 1";
var content_f23_47_24314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment regimens for chronic hepatitis C virus genotype 1",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/47/24314/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24314/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/47/24314/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24314/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/47/24314/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/47/24314/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/47/24314/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H148833304\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C virus (HCV) can cause both acute and chronic hepatitis. The acute process is self-limited, rarely causes hepatic failure, and usually leads to chronic infection. Chronic HCV infection often follows a progressive course over many years and can ultimately result in cirrhosis, hepatocellular carcinoma, and the need for liver transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal of treatment is to eradicate hepatitis C virus RNA, which is predicted by the achievement of a sustained virologic response (SVR), defined by the absence of HCV RNA by polymerase chain reaction six months after stopping treatment. An SVR is associated with a 99 percent chance of being HCV RNA negative during long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/1\">",
"     1",
"    </a>",
"    ]. Achievement of an SVR has also been associated with improved clinical outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35768?source=see_link&amp;anchor=H9#H9\">",
"     \"Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection\", section on 'Long-term efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link&amp;anchor=H9643992#H9643992\">",
"     \"Overview of the management of chronic hepatitis C virus infection\", section on 'Goal of antiviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the treatment of patients with chronic HCV genotype 1. Treatment of patients with other genotypes, data regarding the efficacy of various treatment regimens, experimental agents for the treatment of HCV, the treatment of acute HCV, the selection of patients for treatment, the management of treatment-induced side effects, and factors that predict a response to treatment are discussed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"       \"Overview of the management of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=see_link\">",
"       \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link\">",
"       \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link\">",
"       \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=see_link\">",
"       \"Investigational therapies for hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link\">",
"       \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link\">",
"       \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148833475\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment guidelines for chronic hepatitis C virus (HCV) genotype 1 infection were published in 2011 by the American Association for the Study of Liver Diseases (AASLD) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/2\">",
"     2",
"    </a>",
"    ] and can be accessed at",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     www.aasld.org/practiceguidelines/Pages/default.aspx",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In addition, UK consensus guidelines were published in 2012 regarding the treatment of patients with genotype 1 with protease inhibitor-based combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/3\">",
"     3",
"    </a>",
"    ]. The recommendations that follow are consistent with both the AASLD and UK consensus guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148833538\">",
"    <span class=\"h1\">",
"     FACTORS ASSOCIATED WITH A RESPONSE TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several host and viral characteristics have been associated with a response to antiviral therapy. One important determinant of a response to treatment is the patient's IL28B genotype. The 2011 AASLD guidelines suggest that IL28B testing be considered when the patient or provider wishes additional information on the probability of a treatment response or to make decisions regarding treatment duration. The importance of the IL28B genotype, as well as other factors associated with a response to treatment, is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148833677\">",
"    <span class=\"h1\">",
"     SELECTION OF PATIENTS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;How to determine which patients are candidates for treatment is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=see_link\">",
"     \"Patient selection for antiviral therapy for chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148833684\">",
"    <span class=\"h1\">",
"     MONITORING VIRAL LOAD DURING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once therapy has been started, the likelihood that a patient will fail to achieve a sustained virologic response (SVR) can be predicted by the virologic response at 12 weeks of therapy and probably even earlier. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link&amp;anchor=H32984769#H32984769\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'Changes in viral load during treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rapid virologic response is the strongest on-treatment predictor of achieving an SVR. Some but not all data suggest that shorter courses of therapy (eg, 24 weeks) may not adversely affect patients who achieve a rapid virologic response (negative HCV RNA after four weeks of treatment). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27990?source=see_link&amp;anchor=H15546553#H15546553\">",
"     \"Response-guided therapy for chronic hepatitis C virus infection\", section on 'Shortening therapy for patients who achieve an RVR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An early virologic response (EVR) is defined as at least a 2 log",
"    <sub>",
"     10",
"    </sub>",
"    reduction in HCV RNA or HCV RNA negativity by week 12. A patient with a \"complete EVR\" has attained complete viral suppression by week 12; a patient with a \"partial EVR\" has achieved greater than a 2 log",
"    <sub>",
"     10",
"    </sub>",
"    decline in viremia but continues to have detectable HCV RNA. An SVR is unlikely in patients who lack an EVR, and it is generally recommended that treatment be stopped in patients who fail to achieve an EVR. Patients who are \"partial responders\" have lower overall SVR rates compared with complete responders (ie, no detectable viremia at 12 weeks). Studies are ongoing to determine if there are patients (such as patients who have a slow decline in HCV RNA) who would benefit from extended courses of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27990?source=see_link&amp;anchor=H15546859#H15546859\">",
"     \"Response-guided therapy for chronic hepatitis C virus infection\", section on 'Lengthening therapy for those who fail to achieve a complete EVR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest that patients have their viral loads checked at baseline and at weeks 4, 12, and 24 of therapy to assess for a treatment response and to make decisions about continuing treatment or possibly altering the duration of treatment. In addition, patients who are receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    should have a viral load checked at week 8 since this influences the recommended duration of therapy. Patients with an end-of-treatment response (negative HCV RNA at the completion of treatment) also have a viral load checked 24 weeks after therapy is completed to assess for an SVR. An SVR is associated with a 99 percent chance of being HCV RNA negative during long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148833691\">",
"    <span class=\"h1\">",
"     CHOICE OF PEGINTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peginterferon alfa-2a (Pegasys, Roche Pharmaceuticals) and peginterferon alfa-2b (Peg-Intron, Schering-Plough Corporation) differ in their pharmacokinetics. Studies comparing the two peginterferons in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    have had variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]. While the largest randomized trial (IDEAL) showed that peginterferon alfa-2a and peginterferon alfa-2b appeared to have comparable efficacies in the treatment of chronic hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/5\">",
"     5",
"    </a>",
"    ], results from meta-analyses and a systematic review suggest a slight advantage for peginterferon alfa-2a [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One meta-analysis compared sustained virologic response (SVR) rates and adverse event rates between patients treated with peginterferon alfa-2a and alfa-2b [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/11\">",
"     11",
"    </a>",
"    ]. The analysis included only randomized controlled trials. Eight trials with 4335 patients were included in the analysis of SVR rates. The analysis found that peginterferon alfa-2a was superior to peginterferon alfa-2b (SVR rates of 47 versus 41 percent; relative risk [RR] 1.11, 95% confidence interval [CI] 1.04-1.19).",
"   </p>",
"   <p>",
"    When patients with genotypes 1 and 4 were examined, the results continued to favor peginterferon alfa-2a (RR 1.21, 95% CI 1.03-1.24). Similar results were noted for patients with genotypes 2 and 3 (RR 1.11, 95% CI 1.02-1.22). There was no difference between the treatments with regard to adverse events, though the number of patients included in the meta-analysis was too small to draw definitive conclusions. For patients with chronic HCV genotype 1 being treated with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    alone, we suggest treatment with peginterferon alfa-2a rather than treatment with peginterferon alfa-2b.",
"   </p>",
"   <p>",
"    However, in patients receiving a protease inhibitor there are no data to suggest that one form of peginterferon is superior. In a randomized trial with 161 patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    with either peginterferon alfa-2a or peginterferon alfa-2b, there was no significant difference in SVR rates between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/14\">",
"     14",
"    </a>",
"    ]. Based on the available data, either peginterferon alfa-2a or alfa-2b is a reasonable choice in patients receiving a regimen that includes a protease inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148833698\">",
"    <span class=\"h1\">",
"     DOSES OF PEGINTERFERON AND RIBAVIRIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two peginterferon preparations used in the treatment of HCV (peginterferon alfa-2a and peginterferon alfa-2b). The doses of peginterferon differ for the two preparations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For peginterferon alfa-2a, the dose is 180 micrograms subcutaneously per week.",
"     </li>",
"     <li>",
"      For peginterferon alfa-2b, the dose is 1.5",
"      <span class=\"nowrap\">",
"       microgram/kg",
"      </span>",
"      subcutaneously per week.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with genotype 1,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    dosing is weight-based. Ribavirin is given in divided daily doses (typically twice per day):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving peginterferon alfa-2a, the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      dose is 1000 mg for patients who weigh &le;75 kg or 1200 mg for those who weigh &gt;75 kg.",
"     </li>",
"     <li>",
"      For patients receiving peginterferon alfa-2b, the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      dose is 800 mg for patients weighing &lt;65 kg, 1000 mg for 65 to 85 kg, 1200 mg for &gt;85 to 105 kg, and 1400 mg for &gt;105 kg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148834010\">",
"    <span class=\"h1\">",
"     TREATMENT REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with genotype 1 should receive therapy with peginterferon, weight-based",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , and a protease inhibitor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    ). The addition of a protease inhibitor to regimens containing peginterferon and weight-based ribavirin significantly increases sustained virologic response rates compared with treatment with peginterferon and weight-based ribavirin alone (70 to 80 percent versus 40 to 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/12\">",
"     12",
"    </a>",
"    ]. Protease inhibitors should",
"    <strong>",
"     never",
"    </strong>",
"    be used as monotherapy due to the development of resistance. Changes in viral load during treatment are used to determine the duration of treatment (response-guided therapy). (See",
"    <a class=\"local\" href=\"#H148839646\">",
"     'Efficacy of protease inhibitor containing regimens'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Terms used when describing treatment regimens for patients with genotype 1 include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dual therapy",
"      </strong>",
"      : Treatment with peginterferon and weight-based",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"     </li>",
"     <li>",
"      <strong>",
"       Triple therapy",
"      </strong>",
"      : Treatment with peginterferon, weight-based",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      , and a protease inhibitor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment regimens vary depending upon the patient&rsquo;s prior treatment status:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Treatment-na&iuml;ve",
"      </strong>",
"      : Patients who have never received any treatment for HCV",
"     </li>",
"     <li>",
"      <strong>",
"       Prior relapsers",
"      </strong>",
"      : Patients who had an undetectable viral load at the end of a prior attempt at treatment (end of treatment response) but who did not achieve a sustained virologic response (negative HCV RNA 24 weeks after completing treatment)",
"     </li>",
"     <li>",
"      <strong>",
"       Partial responders",
"      </strong>",
"      : Patients who achieved a 2 log",
"      <sub>",
"       10",
"      </sub>",
"      drop in HCV RNA by week 12 of treatment but who did not achieve an end of treatment response",
"     </li>",
"     <li>",
"      <strong>",
"       Null responders",
"      </strong>",
"      : Patients who did not achieve a 2 log",
"      <sub>",
"       10",
"      </sub>",
"      drop in HCV RNA by week 12 of treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment can be used in patients with compensated cirrhosis, though patients with compensated cirrhosis may be at increased risk of hepatic decompensation if treated with protease inhibitors when used in combination with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , so the drugs should be used cautiously. Protease inhibitors have not been studied in patients with decompensated cirrhosis. In addition, peginterferon is contraindicated in patients with decompensated cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=see_link&amp;anchor=H9641794#H9641794\">",
"     \"Patient selection for antiviral therapy for chronic hepatitis C virus infection\", section on 'Advanced hepatic fibrosis and compensated cirrhosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized trials suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    have similar efficacies when compared with placebo, and the UK consensus guidelines do not recommend one agent over the other [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/3\">",
"     3",
"    </a>",
"    ]. However, we prefer telaprevir to boceprevir as it has a simpler treatment regimen and has been studied in prior null responders. Telaprevir has been shown to be effective in treatment-na&iuml;ve patients, relapsers, partial responders, and null responders. Boceprevir has been shown to be effective in treatment-na&iuml;ve patients, relapsers, and partial responders, but it has not been studied in prior null responders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=see_link&amp;anchor=H7#H7\">",
"     \"Investigational therapies for hepatitis C virus infection\", section on 'NS3/4A protease inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Protease inhibitors are associated with multiple drug-drug interactions, which can lead to potentially serious side-effects or decreased efficacy of the treatment for HCV. When possible, these other medications should be stopped prior to treatment for HCV to allow for treatment with a protease inhibitor. (See",
"    <a class=\"local\" href=\"#H148834094\">",
"     'Drug interactions with protease inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148834017\">",
"    <span class=\"h2\">",
"     Telaprevir-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     Telaprevir",
"    </a>",
"    has been shown to be effective in patients with HCV genotype 1. Preliminary data suggest it may have activity against genotype 2 but limited activity against genotypes 3 and 4 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/15\">",
"     15",
"    </a>",
"    ]. Currently it is only used for the treatment of patients with genotype 1. Telaprevir is given as 750 mg (two 375 mg tablets) three times per day with food (",
"    <strong>",
"     not",
"    </strong>",
"    low-fat). Telaprevir is given from the outset of therapy without a lead-in period of treatment with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . The efficacy of treatment is influenced by a patient's prior treatment status (treatment-na&iuml;ve, relapser, partial responder, or null responder) and by changes in viral load during therapy, which in turn influences the recommended duration of treatment (",
"    <a class=\"graphic graphic_figure graphicRef62836 \" href=\"UTD.htm?34/61/35805\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148834024\">",
"    <span class=\"h3\">",
"     Treatment-naive patients or prior relapsers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are treatment-na&iuml;ve or are prior relapsers should start with triple therapy (peginterferon,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    ). Patients should have their HCV viral loads checked at 4 and 12 weeks. If the HCV RNA is undetectable at both time points, then triple therapy is given for 12 weeks, followed by another 12 weeks of dual therapy (peginterferon and ribavirin). Thus, patients are treated for a total of 24 weeks.",
"   </p>",
"   <p>",
"    However, patients with cirrhosis who are treatment-na&iuml;ve and have undetectable HCV RNA at 4 and 12 weeks may benefit from 36 weeks of dual therapy instead of 12 weeks, for a total of 48 weeks of therapy. In such patients, we suggest the 48-week course of treatment. This is based upon subgroup analyses, which suggest higher SVR rates with longer courses of treatment in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/16\">",
"     16",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Patients who have detectable HCV RNA (1000",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    or less) at 4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    12 weeks should receive triple therapy for 12 weeks, followed by another 36 weeks of dual therapy, for a total treatment duration of 48 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148834031\">",
"    <span class=\"h3\">",
"     Prior partial or null responders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are prior partial or null responders should be treated with peginterferon,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    for 12 weeks, followed by 36 weeks of peginterferon and ribavirin, for a total treatment duration of 48 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148834038\">",
"    <span class=\"h3\">",
"     Discontinuing treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient with an HCV RNA level greater than 1000",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    at week 4 or 12 is unlikely to achieve an SVR, and it is recommended that treatment be stopped in such patients. In addition, treatment should be stopped in patients with detectable HCV RNA (regardless of level) at 24 weeks of treatment. Finally, 2011 guidelines from the American Association for the Study of Liver Diseases (AASLD) and 2012 UK consensus guidelines suggest that patients who have virologic breakthrough during treatment (&gt;1 log",
"    <sub>",
"     10",
"    </sub>",
"    increase in HCV RNA above the nadir) should have their",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    discontinued while continuing the peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The AASLD recommends against switching from one protease to another in patients who experience virologic breakthrough or who relapse on one protease inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148834045\">",
"    <span class=\"h2\">",
"     Boceprevir-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     Boceprevir",
"    </a>",
"    is a competitive inhibitor of the NS3 protease complex of HCV genotype 1. As such, it does not have significant activity against other HCV genotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Boceprevir is given as 800 mg (four 200 mg capsules) three times per day starting at week four of treatment, following a four-week lead-in period of treatment with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . The efficacy of treatment is influenced by a patient's prior treatment status (treatment-na&iuml;ve, relapser, partial responder, or null responder) and by changes in viral load during therapy, which in turn influences the recommended duration of treatment (",
"    <a class=\"graphic graphic_figure graphicRef74596 \" href=\"UTD.htm?15/33/15902\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link&amp;anchor=H148838137#H148838137\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\", section on 'Boceprevir'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    should be given with food.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148834052\">",
"    <span class=\"h3\">",
"     Treatment-naive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the first four weeks of treatment, patients are treated with dual therapy (peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    ). After four weeks of treatment, patients are switched to triple therapy (peginterferon, ribavirin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    ). The treatment duration is then determined by changes in viral load:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Undetectable viral load at weeks 8 and 24: Triple therapy is continued through week 28 of treatment (ie, the patient receives 4 weeks of dual therapy followed by 24 weeks of triple therapy). However, if the patient had detectable HCV RNA at 4 weeks, extending treatment may increase sustained virologic response rates. If patients with a detectable viral load at 4 weeks are tolerating treatment, we suggest continuing therapy through 48 weeks (4 weeks of dual therapy followed by 44 weeks of triple therapy).",
"     </li>",
"     <li>",
"      Detectable viral load at week 8, undetectable viral load at week 24: Triple therapy is continued through week 36 of treatment (4 weeks of dual therapy followed by 32 weeks of triple therapy). After week 36, the patient returns to dual therapy, which is given for an additional 12 weeks, for a total treatment duration of 48 weeks. Dual therapy instead of triple therapy is used during the last 12 weeks since it is not clear that an additional 12 weeks of triple therapy is of benefit to such patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148834059\">",
"    <span class=\"h3\">",
"     Previous partial responders or relapsers",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the first four weeks, patients are treated with dual therapy (peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    ). After four weeks of treatment, patients are switched to triple therapy (peginterferon, ribavirin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    ). The treatment duration is then determined by changes in viral load:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Undetectable viral load at weeks 8 and 24: Triple therapy is continued through 36 weeks of treatment (ie, the patient receives 4 weeks of dual therapy followed by 32 weeks of triple therapy).",
"     </li>",
"     <li>",
"      Detectable viral load at week 8, undetectable viral load at week 24: Triple therapy is continued through week 36 of treatment (4 weeks of dual therapy followed by 32 weeks of triple therapy). After week 36, the patient returns to dual therapy, which is given for an additional 12 weeks, for a total treatment duration of 48 weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148834066\">",
"    <span class=\"h3\">",
"     Previous null responders",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     Boceprevir",
"    </a>",
"    has not been studied for the treatment of patients who failed to achieve a 2 log",
"    <sub>",
"     10",
"    </sub>",
"    drop in HCV RNA with prior attempts at therapy. If boceprevir is used in such patients, it is suggested that patients first be treated with 4 weeks of peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , followed by 44 weeks of peginterferon, ribavirin, and boceprevir, for a total treatment duration of 48 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148834073\">",
"    <span class=\"h3\">",
"     Patients with compensated cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the first four weeks, patients are treated with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . After four weeks of treatment,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    is added, and all three drugs are continued for 44 weeks, for a total treatment duration of 48 weeks. This is based upon subgroup analyses, which suggest higher efficacy with longer treatment durations in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148834080\">",
"    <span class=\"h3\">",
"     Discontinuing treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be discontinued if the HCV RNA is 100",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    or greater at week 12 or if HCV RNA is detectable at week 24. In addition, 2011 guidelines from the American Association for the Study of Liver Diseases (AASLD) and 2012 UK consensus guidelines suggest that patients who have virologic breakthrough during treatment (&gt;1 log",
"    <sub>",
"     10",
"    </sub>",
"    increase in HCV RNA above the nadir) should have their",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    discontinued while continuing the peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The AASLD recommends against switching from one protease to another in patients who experience virologic breakthrough or who relapse on one protease inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148834087\">",
"    <span class=\"h2\">",
"     Patients not receiving a protease inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are unable to receive a protease inhibitor should be treated with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for a total of 48 weeks. For patients in whom HCV RNA does not become undetectable until after week 12 (late responders), treatment for a total of 72 weeks can be considered in an attempt to increase the sustained virologic response rate. We offer a prolonged course of treatment to those patients with significant liver disease who have been tolerating therapy well. For all patients, treatment should be discontinued if HCV RNA is detectable after 24 weeks of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27990?source=see_link&amp;anchor=H15546859#H15546859\">",
"     \"Response-guided therapy for chronic hepatitis C virus infection\", section on 'Lengthening therapy for those who fail to achieve a complete EVR'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148834094\">",
"    <span class=\"h2\">",
"     Drug interactions with protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     Telaprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    are cleared by",
"    <span class=\"nowrap\">",
"     CYP3A4/5",
"    </span>",
"    and numerous drug interactions have been noted (",
"    <a class=\"graphic graphic_table graphicRef78070 \" href=\"UTD.htm?11/30/11744\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66181 \" href=\"UTD.htm?7/31/7664\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/20\">",
"     20",
"    </a>",
"    ]. The drugs should not be given in conjunction with medications that are",
"    <span class=\"nowrap\">",
"     CYP3A4/5",
"    </span>",
"    inducers or with drugs that are highly dependent on",
"    <span class=\"nowrap\">",
"     CYP3A4/5",
"    </span>",
"    for clearance and that are associated with serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening events when plasma concentrations are high. When possible, such drugs should be discontinued prior to starting treatment with a protease inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=see_link&amp;anchor=H4#H4\">",
"     \"Drugs and the liver: Metabolism and mechanisms of injury\", section on 'Phase I reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     Telaprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    are known to affect the pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    . In a study performed in healthy volunteers, coadministration of telaprevir with cyclosporin resulted in an increase in the terminal elimination half-life of cyclosporin from a mean of 12 hours to 42 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/21\">",
"     21",
"    </a>",
"    ]. For tacrolimus, it increased from 41 hours to 196 hours. In addition, exposure to cyclosporin was increased 4.6-fold, and exposure to tacrolimus was increased 70-fold. In a similar study in healthy volunteers, coadministration of boceprevir with cyclosporin increased the half-life of cyclosporin from 11 hours to 16 hours, and for tacrolimus from 37 to 61 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/22\">",
"     22",
"    </a>",
"    ]. Exposure to cyclosporin was increased 2.7-fold, and exposure to tacrolimus was increased 16-fold. In a study of 10 patients receiving sirolimus following liver transplantation, administration of telaprevir led to a decrease in drug clearance from a mean of 139 to 0.5",
"    <span class=\"nowrap\">",
"     L/hour",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/23\">",
"     23",
"    </a>",
"    ]. This resulted in a 1.5-fold increase in the terminal elimination half-life and a 26-fold increase in exposure to the drug.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    is used in combination with certain ritonavir-boosted HIV protease inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , lopinavir,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    ), the effectiveness of both medications may be decreased. The US Food and Drug Administration recommends that patients taking boceprevir along with one of the listed ritonavir-boosted protease inhibitors should be closely monitored for potential HCV and HIV virologic rebound [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/24\">",
"     24",
"    </a>",
"    ]. The treatment of HCV in patients coinfected with HIV, including recommended drug combinations, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=see_link&amp;anchor=H819606#H819606\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\", section on 'Potential drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148839646\">",
"    <span class=\"h1\">",
"     EFFICACY OF PROTEASE INHIBITOR CONTAINING REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the introduction of the",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    protease inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    , only 40 to 50 percent of patients with chronic HCV genotype 1 would achieve an SVR. With the addition of these protease inhibitors, the rate has increased to 70 to 80 percent.",
"   </p>",
"   <p>",
"    Response rates to protease inhibitor-containing regimens vary depending upon the patient's prior treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment-na&iuml;ve patients: response rates between 67 and 75 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/16,19,25-29\">",
"       16,19,25-29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prior relapsers: response rates between 69 and 88 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/27,30-33\">",
"       27,30-33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prior partial responders: response rates between 40 and 59 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/30-33\">",
"       30-33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prior null responders: response rates between 23 and 38 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/27,31,32\">",
"       27,31,32",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, response rates to protease-containing regimens among African Americans are lower (approximately 40 to 50 percent), but are higher than those seen with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    alone (approximately 10 to 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/19,29,31\">",
"     19,29,31",
"    </a>",
"    ]. Data are limited regarding the effect of IL28B genotype on response rates among patients receiving protease inhibitor-containing regimens, but there may be a higher response rate in some patients with favorable genotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/27\">",
"     27",
"    </a>",
"    ]. However, response rates may be as low as 14 percent in patients with cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link&amp;anchor=H16094290#H16094290\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'Race'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No trials have directly compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    -based regimens. In a meta-analysis of six trials of treatment-na&iuml;ve and four trials of treatment-experienced patients with chronic HCV, there was no significant difference in outcome between the two regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/34\">",
"     34",
"    </a>",
"    ]. A prespecified subgroup analysis of 841 patients with prior treatment relapse did suggest greater relative efficacy with telaprevir compared with boceprevir (OR 2.6, 95% CI 1.2-5.5). Nevertheless, there remains insufficient direct evidence to recommend one protease inhibitor over another based on efficacy alone (apart from prior null responders, in whom boceprevir has not been studied). &nbsp;",
"   </p>",
"   <p>",
"    Details of the studies looking at the efficacy of various treatment regimens are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link&amp;anchor=H8#H8\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\", section on 'Combination therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148835671\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY IN NONRESPONDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies had suggested that interferon-based treatments may be associated with clinical improvement, even in patients who do not achieve an SVR. However, final results of the HALT-C trial (evaluating low-dose peginterferon alfa-2a) were negative; long-term maintenance therapy did not halt liver disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/35\">",
"     35",
"    </a>",
"    ]. Currently, maintenance therapy is not recommended for nonresponders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link&amp;anchor=H6411393#H6411393\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\", section on 'Maintenance therapy in nonresponders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148835814\">",
"    <span class=\"h1\">",
"     TREATMENT IN SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261126198\">",
"    <span class=\"h2\">",
"     Compensated cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment can be used in patients with compensated cirrhosis, but peginterferon is contraindicated in patients with decompensated cirrhosis. Patients with compensated cirrhosis treated with protease inhibitors may have higher rates of severe adverse events compared with patients who do not have cirrhosis. Preliminary results of a study that included 455 patients with HCV genotype 1 and Child A cirrhosis found that 49 percent of those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    and 38 percent of those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    experienced serious adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/36\">",
"     36",
"    </a>",
"    ]. The serious adverse events lead to treatment discontinuation in 15 and 7 percent, respectively.",
"   </p>",
"   <p>",
"    In addition, protease inhibitors have not been studied in patients with decompensated cirrhosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148835822\">",
"    <span class=\"h2\">",
"     Recurrence after liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence of HCV occurs in more than 95 percent of patients after liver transplantation. However, the therapeutic options are limited in this population, and rigorous clinical trials are difficult to conduct. Note that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    should not be used in this population until further data are available because of drug-drug interactions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H148834094\">",
"     'Drug interactions with protease inhibitors'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=see_link&amp;anchor=H15#H15\">",
"     \"Liver transplantation for hepatitis C virus infection\", section on 'Treatment of recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148835829\">",
"    <span class=\"h2\">",
"     Coinfection with HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;All human immunodeficiency virus (HIV) infected patients should undergo screening for HCV. Treatment should be considered in these patients because coinfection is associated with an accelerated course of HCV. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    in this population is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=see_link\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81998977\">",
"    <span class=\"h2\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early menopause has been associated with lower SVR rates in women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/37\">",
"     37",
"    </a>",
"    ]. This observation led to a randomized trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    for the treatment of HCV in 123 postmenopausal women with HCV genotype 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/38\">",
"     38",
"    </a>",
"    ]. The women were assigned to receive either raloxifene combined with pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    or pegylated interferon and ribavirin alone. Women who received raloxifene were more likely to achieve an SVR that women who did not (61 versus 34 percent). If these findings are confirmed in other trials, there may be a role for raloxifene in the treatment of postmenopausal women with HCV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148835836\">",
"    <span class=\"h2\">",
"     Thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCV infection in patients with thalassemia is common, with reported prevalences of anti-HCV antibodies in such patients of 4 to 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/39\">",
"     39",
"    </a>",
"    ]. Treatment in these patients may be complicated by the hemolysis associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , leading to worsening iron overload. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\", section on 'Anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines from the American Society of Hematology (which were released prior to the introduction of protease inhibitors) recommend the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combination therapy with peginterferon plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      should be suggested to patients with HCV chronic hepatitis or compensated cirrhosis.",
"     </li>",
"     <li>",
"      Therapy should be administered for 48 weeks to patients infected by genotype 1.",
"     </li>",
"     <li>",
"      Antiviral therapy should be withdrawn after 12 weeks if serum HCV RNA levels have not decreased by at least 2 log",
"      <sub>",
"       10",
"      </sub>",
"      compared with baseline.",
"     </li>",
"     <li>",
"      An increase in the number of blood transfusions during antiviral therapy may be required to maintain a hemoglobin level of more than 9",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      The guidelines do not recommend the use of growth factors such as erythropoietin (which is already elevated in these patients).",
"     </li>",
"     <li>",
"      Intensification of chelation treatment before starting antiviral treatment should be considered in patients with severe iron burden. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of beta thalassemia\", section on 'Iron chelation therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=see_link\">",
"       \"Chelation therapy for iron overload states\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinical monitoring of liver disease is necessary in thalassemia patients with HCV chronic hepatitis or cirrhosis who have contraindications to antiviral therapy or have failed previous antiviral therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no guidelines about whether patients with a drop in hemoglobin during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    should have their ribavirin dose reduced. In one study of patients with thalassemia undergoing treatment for HCV, the dose of ribavirin was reduced if the patient's blood transfusion requirement doubled [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/40\">",
"     40",
"    </a>",
"    ]. Until additional data become available, we believe that it is reasonable to decrease the dose of ribavirin by 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in patients whose transfusion requirements double.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148836436\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effects of interferon (standard or pegylated) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , as well as their management, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Side effects are common with both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    . Currently there are no data to support switching between the protease inhibitors if significant side effects develop. However, in the case of anal pruritus associated with telaprevir, switching to boceprevir may lead to resolution of the pruritus. In most cases, provided the side effects are not severe (such as Steven's-Johnson syndrome), the approach is to try to provide supportive care while maintaining the patient on the protease inhibitor if possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148836537\">",
"    <span class=\"h2\">",
"     Telaprevir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    are rash, pruritus, anemia, nausea, hemorrhoids, diarrhea, anorectal discomfort, dysgeusia, fatigue, vomiting, and anal pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/41\">",
"     41",
"    </a>",
"    ]. Fatalities have been seen in patients who developed severe rashes while receiving telaprevir, peginterferon, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . Patients with rashes with systemic symptoms or with severe rashes that are progressive should have all three drugs discontinued immediately.",
"   </p>",
"   <p>",
"    Rashes and pruritus occur in approximately half of patients but are usually mild to moderate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. By comparison, rashes are seen in approximately one-third of patients treated with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . In randomized trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    , 56 percent of patients receiving telaprevir developed a rash, but only 6 percent stopped telaprevir because of the rash, and only 1 percent stopped all three medications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/43\">",
"     43",
"    </a>",
"    ]. In most cases, the rash was characterized as a pruritic eczematous dermatitis.",
"   </p>",
"   <p>",
"    Severe rashes (without Steven's-Johnson syndrome) have been seen in about 4 percent of treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/43\">",
"     43",
"    </a>",
"    ]. Drug rash with eosinophilia and systemic symptoms (DRESS), Steven's-Johnson syndrome, and toxic epidermal necrolysis appear to be very rare, and serious skin reactions are reported in less than 1 percent of patients.&nbsp;However, fatal skin reactions have been reported in patients with progressive rash and systemic symptoms who continued to receive combination therapy including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    . Because of this, in December 2012, the US Food and Drug Administration (FDA) issued a black box warning instructing providers to discontinue telaprevir, peginterferon, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    immediately in patients who have a rash with systemic symptoms or who have a progressive severe rash. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=see_link&amp;anchor=H31#H31\">",
"     \"Drug allergy: Classification and clinical features\", section on 'Drug-induced hypersensitivity syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Different approaches to patients with mild to moderate rashes or severe rashes that are not associated with systemic symptoms include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The FDA recommends that patients with mild to moderate rashes that progress should have their",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      discontinued. However, if there is no improvement, peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      should also be discontinued [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/41\">",
"       41",
"      </a>",
"      ] (",
"      <a class=\"external\" href=\"file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf\">",
"       file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The author's approach is to attempt to treat patients with mild to moderate rashes with topical corticosteroids. If the rash does not improve with steroids or if the rash is serious (more than 50 percent of the patient's skin is involved, or vesicles), we discontinue the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      . If the rash has not improved after seven days, the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      and peginterferon are also stopped. Patients who develop mucositis in the setting of a serious rash may be showing initial signs of Steven's-Johnson syndrome and should have all three drugs stopped.",
"     </li>",
"     <li>",
"      An alternative approach used by some for patients with persistent or moderate to severe rashes without systemic symptoms is to first decrease the dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      to 600 mg per day (with consideration given to holding the ribavirin for a few days prior to resuming it at a lower dose for more severe rashes) instead of stopping the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      . However, as above, in patients with serious skin reactions without systemic symptoms or in patients whose rashes progress despite decreasing the dose of ribavirin (but do not progress to the point of being severe), telaprevir is discontinued, but peginterferon and ribavirin are continued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to topical corticosteroids, oral antihistamines may provide symptomatic relief, but the effectiveness of this approach has not been established. The use of systemic corticosteroids to treat the rash is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be decreased (ie, if it is to be continued, it needs to be given at full strength).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     Telaprevir",
"    </a>",
"    has also been associated with anemia beyond that seen with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    therapy alone (36 versus 17 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/41\">",
"     41",
"    </a>",
"    ]. The FDA recommends that patients have their complete blood count monitored prior to starting treatment and at weeks 2, 4, 8, and 12. For patients with significant anemia, discontinuation or dose reductions of ribavirin or the use of erythropoietic growth factors may be required. However, the dose of telaprevir should",
"    <strong>",
"     not",
"    </strong>",
"    be decreased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\", section on 'Anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     Telaprevir",
"    </a>",
"    has also been associated with anal pruritus. In such patients, switching to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    may lead to symptom relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148836544\">",
"    <span class=\"h2\">",
"     Boceprevir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    include fatigue, anemia, nausea, headache, and dysgeusia. Other side effects include dry mouth, vomiting, and diarrhea.",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    to regimens using peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    has been associated with decreases in hemoglobin concentration beyond those with peginterferon and ribavirin alone. As an example, in a randomized trial (SPRINT-2) with 1097 patients who were treatment-na&iuml;ve, patients were assigned to treatment with boceprevir, peginterferon, and ribavirin or peginterferon and ribavirin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/44\">",
"     44",
"    </a>",
"    ]. Patients who received a boceprevir-containing regimen were more likely to develop anemia than those who did not (50 versus 38 percent). The FDA recommends that a complete blood count be obtained prior to treatment and at weeks 4, 8, and 12. For patients with significant anemia, discontinuation or dose reductions of ribavirin or the use of erythropoietic growth factors may be required. However, the dose of boceprevir should",
"    <strong>",
"     not",
"    </strong>",
"    be decreased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\", section on 'Anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SVR rates appear to be similar with the different anemia management strategies among patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    -containing regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In SPRINT-2, 726 patients received a boceprevir-containing regimen and 363 (50 percent) developed anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/44\">",
"     44",
"    </a>",
"    ]. Patients with anemia were managed with: erythropoietin and a reduction in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    dose (40 percent), erythropoietin alone (38 percent), ribavirin dose reduction alone (8 percent), or neither erythropoietin nor a dose reduction in ribavirin. The SVR rates among the patients with anemia were similar, regardless of management strategy, ranging from 70 to 74 percent. In addition, among patients who received boceprevir, those who developed anemia had higher SVR rates than those who did not (72 versus 58 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     Boceprevir",
"    </a>",
"    has also been associated with neutropenia and thrombocytopenia beyond that seen with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    alone. Patients who develop neutropenia may require a dose reduction or discontinuation of peginterferon and ribavirin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\", section on 'Neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148836724\">",
"    <span class=\"h1\">",
"     FOLLOW-UP AFTER TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who achieve a sustained virologic response (SVR) who do not have cirrhosis do not require any specific follow-up for their HCV, though some will check an HCV viral load one year after the completion of treatment to confirm that the patient has achieved an SVR. Patients who fail to achieve an SVR should be followed for signs of progression of their liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the management of chronic hepatitis C virus infection\", section on 'General management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with cirrhosis, regardless of whether they attain an SVR, require ongoing monitoring because they continue to be at risk of hepatocellular carcinoma&nbsp;and require ongoing surveillance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154377924\">",
"    <span class=\"h1\">",
"     COST-EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two studies have examined the cost effectiveness of treatment with protease inhibitors for patients with HCV and suggest that triple therapy with peginterferon,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , and a protease inhibitor is cost-effective for patients with advanced fibrosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One 2012 study found that compared with standard therapy, universal treatment with triple therapy for patients with advanced fibrosis was associated with an incremental cost effectiveness ratio (ICER) of $36,300 per quality-adjusted life-year (QALY), whereas treatment of patients with mild fibrosis was associated with an ICER of $70,100 per QALY [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/46\">",
"       46",
"      </a>",
"      ]. Gains from IL28B genotype-guided triple therapy were smaller.",
"     </li>",
"     <li>",
"      A second 2012 study found that response-guided therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      for previously untreated patients with F2 fibrosis had an ICER of &euro;7,520 per QALY compared with dual therapy, and response-guided therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      had an ICER of &euro;10,755 per QALY [",
"      <a class=\"abstract\" href=\"UTD.htm?23/47/24314/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link&amp;anchor=H16092947#H16092947\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'IL28B polymorphisms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/22/4451?source=see_link\">",
"       \"Patient information: Latest medicines for hepatitis C (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/35/30258?source=see_link\">",
"       \"Patient information: Treatment for hepatitis C (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148836809\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to treat a patient with chronic hepatitis C virus (HCV) infection is based upon several factors, including the natural history of the disease, the stage of fibrosis, and the efficacy and adverse effects related to therapy. In general, patients being considered for treatment should have histologic and virologic evidence of chronic HCV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=see_link\">",
"     \"Patient selection for antiviral therapy for chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with chronic HCV genotype 1 who are candidates for therapy, we recommend triple therapy with peginterferon, weight-based",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      , and a protease inhibitor (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      ) rather than dual therapy with peginterferon and weight-based ribavirin (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Treatment with peginterferon and weight-based ribavirin alone results in sustained virologic response rates of 40 to 50 percent in patients with chronic HCV genotype 1. With the addition of a protease inhibitors (telaprevir or boceprevir), the rate increases to 70 to 80 percent. (See",
"      <a class=\"local\" href=\"#H148834010\">",
"       'Treatment regimens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H148839646\">",
"       'Efficacy of protease inhibitor containing regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       Telaprevir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      are given three times daily. Both drugs should be given with food.",
"     </li>",
"     <li>",
"      We suggest that patients who are prior null responders (patients who failed to respond to treatment with peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      ) be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). While randomized trials suggest that telaprevir and boceprevir have similar efficacies when compared with placebo, only telaprevir has been studied in prior null responders. Either drug is a reasonable choice in patients who are treatment-na&iuml;ve or are prior partial responders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link\">",
"       \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The duration of therapy depends upon the patient's treatment history, the choice of protease inhibitor, and the virologic response during treatment (",
"      <a class=\"graphic graphic_figure graphicRef62836 \" href=\"UTD.htm?34/61/35805\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef74596 \" href=\"UTD.htm?15/33/15902\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H148834010\">",
"       'Treatment regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       Telaprevir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      are only used for the treatment of patients with HCV genotype 1 and not for patients with genotype 2, 3, or 4. Telaprevir has been shown to be effective in patients with genotype 1. Preliminary data suggest it may also have activity against genotype 2 but limited activity against genotypes 3 and 4. Boceprevir is a competitive inhibitor of the NS3 protease complex of HCV genotype 1. As such, it does not have significant activity against other HCV genotypes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link\">",
"       \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      are associated with the development of anemia. In addition, rashes are common in patients receiving telaprevir. (See",
"      <a class=\"local\" href=\"#H148836436\">",
"       'Side effects of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Numerous drug interactions have been noted with both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef78070 \" href=\"UTD.htm?11/30/11744\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66181 \" href=\"UTD.htm?7/31/7664\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H148834094\">",
"       'Drug interactions with protease inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients being treated with peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      (without the addition of a protease inhibitor), we suggest treatment with peginterferon alfa-2a rather than peginterferon alfa-2b (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Peginterferon alfa-2a is associated with a slight increase in sustained virologic response rate compared with peginterferon alfa-2b in patients receiving therapy with peginterferon and ribavirin. However, whether there is a difference in efficacy among patients with genotype I who are also receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      is unknown, and in such patients, the use of either form of peginterferon is reasonable. (See",
"      <a class=\"local\" href=\"#H148833691\">",
"       'Choice of peginterferon'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should have their viral loads checked at baseline and at weeks 4, 12, and 24 of therapy to assess for a treatment response and to make decisions about continuing treatment or possibly altering the duration of treatment. In addition, patients who are receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      should have a viral load checked at week 8 since this influences the recommended duration of therapy. Patients should also have a viral load checked 24 weeks after therapy is completed to assess for a sustained virologic response. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=see_link&amp;anchor=H488641848#H488641848\">",
"       \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\", section on 'Monitoring viral load during therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/1\">",
"      Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/2\">",
"      Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/3\">",
"      Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012; 35:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/4\">",
"      Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006; 45:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/5\">",
"      McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/6\">",
"      Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 2007; 14:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/7\">",
"      Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009; 49:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/8\">",
"      Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/9\">",
"      Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/10\">",
"      Awad T, Thorlund K, Hauser G, et al; Cochrane Hepato-Biliary Group. Peginterferon alpha-2a may achieve higher sustained virological response than peginteferon alpha-2b in chronic hepatitis C: a Cochrane systematic review of randomized clinical trials. Hepatology 2009; 50(Suppl):707A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/11\">",
"      Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010; 51:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/12\">",
"      Chou R, Hartung D, Rahman B, et al. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 2013; 158:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/13\">",
"      Flori N, Funakoshi N, Duny Y, et al. Pegylated Interferon-&alpha;2a and Ribavirin versus Pegylated Interferon-&alpha;2b and Ribavirin in Chronic Hepatitis C : A Meta-Analysis. Drugs 2013; 73:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/14\">",
"      Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/15\">",
"      Smith LS, Nelson M, Naik S, Woten J. Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother 2011; 45:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/16\">",
"      Sherman KE, Flamm SL, Afdhal NH, et, al. Telaprevir in combination wtih peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: Final results of phase 3 ILLUMINATE study. Hepatology 2010; 52:401A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/17\">",
"      Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006; 50:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/18\">",
"      Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/19\">",
"      Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/20\">",
"      Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/21\">",
"      Garg V, van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/22\">",
"      Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/23\">",
"      O'Leary JG, McKenna GJ, Klintmalm GB, Davis GL. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. Liver Transpl 2013; 19:463.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm291119.htm (Accessed on February 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/25\">",
"      Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/26\">",
"      H&eacute;zode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/27\">",
"      Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/28\">",
"      Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/29\">",
"      McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/30\">",
"      Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/31\">",
"      McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/32\">",
"      Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/33\">",
"      Flamm SL, Lawitz E, Jacobson I, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol 2013; 11:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/34\">",
"      Kieran J, Schmitz S, O'Leary A, et al. The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clin Infect Dis 2013; 56:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/35\">",
"      Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/36\">",
"      Hezode C. CUPIC: French Early Access Program - Compassionate use of protease inhbitors in viral C cirrhosis. J Hepatol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/37\">",
"      Villa E, Karampatou A, Camm&agrave; C, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011; 140:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/38\">",
"      Furusyo N, Ogawa E, Sudoh M, et al. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J Hepatol 2012; 57:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/39\">",
"      Di Marco V, Capra M, Angelucci E, et al. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood 2010; 116:2875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/40\">",
"      Sood A, Sobti P, Midha V, et al. Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C. Indian J Gastroenterol 2010; 29:62.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf (Accessed on May 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/42\">",
"      Jacobson IM, McHutchison JG, Dusheiko GM. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: Final results of phase 3 ADVANCE study. Hepatology 2010; 52:427A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/43\">",
"      Roujeau JC, Mockenhaupt M, Tahan SR, et al. Telaprevir-Related Dermatitis. Arch Dermatol 2012; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/44\">",
"      Sulkowski MS, Poordad F, Manns MP, et al. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology 2013; 57:974.",
"     </a>",
"    </li>",
"    <li>",
"     Poordad F, Lawitz EJ, Reddy R, et al. A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin. EASL abstract, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/46\">",
"      Liu S, Cipriano LE, Holodniy M, et al. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012; 156:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/47/24314/abstract/47\">",
"      Camm&agrave; C, Petta S, Enea M, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012; 56:850.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16592 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-197.136.42.3-3C9D172F08-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_47_24314=[""].join("\n");
var outline_f23_47_24314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H148836809\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148833304\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148833475\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148833538\">",
"      FACTORS ASSOCIATED WITH A RESPONSE TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148833677\">",
"      SELECTION OF PATIENTS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148833684\">",
"      MONITORING VIRAL LOAD DURING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148833691\">",
"      CHOICE OF PEGINTERFERON",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148833698\">",
"      DOSES OF PEGINTERFERON AND RIBAVIRIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148834010\">",
"      TREATMENT REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148834017\">",
"      Telaprevir-based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148834024\">",
"      - Treatment-naive patients or prior relapsers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148834031\">",
"      - Prior partial or null responders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148834038\">",
"      - Discontinuing treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148834045\">",
"      Boceprevir-based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148834052\">",
"      - Treatment-naive patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148834059\">",
"      - Previous partial responders or relapsers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148834066\">",
"      - Previous null responders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148834073\">",
"      - Patients with compensated cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148834080\">",
"      - Discontinuing treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148834087\">",
"      Patients not receiving a protease inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148834094\">",
"      Drug interactions with protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148839646\">",
"      EFFICACY OF PROTEASE INHIBITOR CONTAINING REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148835671\">",
"      MAINTENANCE THERAPY IN NONRESPONDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148835814\">",
"      TREATMENT IN SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H261126198\">",
"      Compensated cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148835822\">",
"      Recurrence after liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148835829\">",
"      Coinfection with HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H81998977\">",
"      Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148835836\">",
"      Thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148836436\">",
"      SIDE EFFECTS OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148836537\">",
"      Telaprevir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148836544\">",
"      Boceprevir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148836724\">",
"      FOLLOW-UP AFTER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154377924\">",
"      COST-EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148836809\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/16592\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/16592|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/61/35805\" title=\"figure 1\">",
"      Treatment of HCV genotype I telaprevir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/33/15902\" title=\"figure 2\">",
"      Treatment of HCV genotype I boceprevir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/16592|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/30/11744\" title=\"table 1\">",
"      Telaprevir drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/31/7664\" title=\"table 2\">",
"      Boceprevir drug interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=related_link\">",
"      A short primer on cost-effectiveness analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=related_link\">",
"      Chelation therapy for iron overload states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=related_link\">",
"      Drug allergy: Classification and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=related_link\">",
"      Drugs and the liver: Metabolism and mechanisms of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=related_link\">",
"      Investigational therapies for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=related_link\">",
"      Liver transplantation for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35768?source=related_link\">",
"      Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/22/4451?source=related_link\">",
"      Patient information: Latest medicines for hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/35/30258?source=related_link\">",
"      Patient information: Treatment for hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=related_link\">",
"      Patient selection for antiviral therapy for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=related_link\">",
"      Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27990?source=related_link\">",
"      Response-guided therapy for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=related_link\">",
"      Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=related_link\">",
"      Treatment of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=related_link\">",
"      Treatment of hepatitis C virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_47_24315="Treatment of Candida CNS infections";
var content_f23_47_24315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of Candida infections of the central nervous system in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Primary",
"       </td>",
"       <td class=\"subtitle2\">",
"        Alternative",
"       </td>",
"       <td class=\"subtitle2\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A lipid formulation of amphotericin B 3 to 5 mg/kg IV daily with or without flucytosine 25 mg/kg orally four times daily for several weeks, followed by fluconazole 400 to 800 mg (6 to 12 mg/kg) orally* daily",
"       </td>",
"       <td>",
"        Fluconazole 400 to 800 mg (6 to 12 mg/kg) orally* daily for patients unable to tolerate a lipid formulation of amphotericin B",
"       </td>",
"       <td>",
"        Treat until all signs and symptoms, cerebrospinal fluid abnormalities, and radiographic abnormalities have resolved. Removal of intraventricular devices is recommended.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Since fluconazole is highly bioavailable, oral therapy is appropriate for most patients. IV therapy (at the same dose) should be given to patients who are unable to take oral medications, who are not expected to have good gastrointestinal absorption, or who are severely ill.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infections Diseases Society of America. Clin Infect Dis 2009; 48:503. Copyright &copy; 2009 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_47_24315=[""].join("\n");
var outline_f23_47_24315=null;
var title_f23_47_24316="Lupus arthritis versus RA";
var content_f23_47_24316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of features of musculoskeletal disease in systemic lupus erythematosus or rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lupus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthralgia",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthritis",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Deforming",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symmetry",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Joints involved",
"       </td>",
"       <td>",
"        PIP&gt;MCP&gt;wrist&gt;knee",
"       </td>",
"       <td>",
"        MCP&gt;wrist&gt;knee",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synovial hypertrophy",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synovial membrane abnormality",
"       </td>",
"       <td>",
"        Minimal",
"       </td>",
"       <td>",
"        Proliferative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synovial fluid",
"       </td>",
"       <td>",
"        Transudate",
"       </td>",
"       <td>",
"        Exudate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subcutaneous nodules",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        35 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erosions",
"       </td>",
"       <td>",
"        Very rare",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morning stiffness",
"       </td>",
"       <td>",
"        Minutes",
"       </td>",
"       <td>",
"        Hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myalgia",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myositis",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteoporosis",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avascular necrosis",
"       </td>",
"       <td>",
"        5 to 50 percent",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deforming arthritis",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Swan neck",
"       </td>",
"       <td>",
"        10 percent, reducible",
"       </td>",
"       <td>",
"        Common, not reducible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulnar deviation",
"       </td>",
"       <td>",
"        5 percent, reducible",
"       </td>",
"       <td>",
"        Common, not reducible",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_47_24316=[""].join("\n");
var outline_f23_47_24316=null;
var title_f23_47_24317="Normal puberty in girls";
var content_f23_47_24317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F82350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F82350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sequence of events during normal puberty in girls",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 278px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    As this schematic shows, menarche is a relatively late event in puberty, occurring after both breast and pubic hair development are well-advanced. On average, menarche occurs at 12 and a half years in US Caucasian girls and at 12 years in African-American girls.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted&nbsp;from:&nbsp;Tanner JM.&nbsp; The development of the female reproductive system during adolescence. Clin Obstet &amp; Gynecol 1960; 3: 135.",
"     <br>",
"      <br>",
"       Additional references:",
"       <br>",
"        Wu T, Mendola P, Buck GM. Ethnic Differences in the Presence of Secondary Sex Characteristics and Menarche Among US Girls: The Third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics 2002; 110: 752.",
"        <br>",
"         <br>",
"          Herman-Giddens ME, Kaplowitz PB, Wasserman R. Navigating the Recent Articles on Girls' Puberty in Pediatrics: What Do We Know and Where Do We Go from Here? Pediatrics 2004;113; 911.",
"          <br/>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_47_24317=[""].join("\n");
var outline_f23_47_24317=null;
var title_f23_47_24318="Contents: Pediatric otolaryngology";
var content_f23_47_24318=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric otolaryngology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric otolaryngology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Congenital anomalies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/36/44615\">",
"           Ankyloglossia (tongue-tie) in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/49/12055\">",
"           Congenital anomalies of the ear",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/59/1977\">",
"           Congenital anomalies of the jaw, mouth, oral cavity, and pharynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/42/37543\">",
"           Congenital anomalies of the larynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/47/35575\">",
"           Congenital anomalies of the nose",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Epistaxis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/16/27912\">",
"           Epidemiology and etiology of epistaxis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/42/18086\">",
"           Evaluation of epistaxis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/58/26536\">",
"           Management of epistaxis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hearing loss",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/36/35397\">",
"           Ear barotrauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/38/19050\">",
"           Etiology of hearing impairment in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/19/44344\">",
"           Evaluation of hearing impairment in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/13/27865\">",
"           Screening the newborn for hearing loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/14/29927\">",
"           Treatment of hearing impairment in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hoarseness",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/29/44505\">",
"           Etiology and management of hoarseness in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/0/4102\">",
"           Evaluation of the child with hoarseness",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/16/5385\">",
"           Acute mastoiditis in children: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/5/16471\">",
"           Acute mastoiditis in children: Treatment and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/35/8760\">",
"           Acute otitis media in children: Diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/60/29642\">",
"           Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/0/21514\">",
"           Acute otitis media in children: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/28/41417\">",
"           Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/26/31144\">",
"           Approach to the management of croup",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/32/43529\">",
"           Clinical features, evaluation, and diagnosis of croup",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24857\">",
"           Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/45/4826\">",
"           Epiglottitis (supraglottitis): Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8632\">",
"           Etiology and clinical manifestations of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/62/32743\">",
"           External otitis: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22153\">",
"           Otitis media with effusion (serous otitis media) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/11/31928\">",
"           Pharmacologic and supportive interventions for croup",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/61/43992\">",
"           Retropharyngeal infections in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/26/8616\">",
"           Acquired torticollis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12823\">",
"           Cerumen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/51/42808\">",
"           Cholesteatoma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/22/35178\">",
"           Tonsillectomy and adenoidectomy in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6615\">",
"           Jaw fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/50/33575\">",
"           Nasal trauma and fractures in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tympanostomy tubes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/56/3978\">",
"           Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/38/36457\">",
"           Prevention and management of tympanostomy tube otorrhea in children",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-82F3A475F2-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f23_47_24318=[""].join("\n");
var outline_f23_47_24318=null;
var title_f23_47_24319="Lymphangioleiomyomatosis CT II";
var content_f23_47_24319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Advanced lymphangioleiomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 187px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAC7AUUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxXVtX8Q6h8QNT0611vUog15OECTO2ApY4AB9q6rTPAfxF1fadKv8AxFMh/wCWkoaFPzaQfypnwiJX9py3IxkXt91Gf+WM1fZjTT7hvmfPYAYoA+Z9I+BPxGugraj4wewUnkNcSSMPwDY/Wt//AIZ/10AbvilqOe4Fo5/9r17uq5GCcknIPpT1Vv4VUfjQB4CfgF4gKkp8TdTbHraOP/a9IPgF4hzg/E3UgfT7I/8A8fr6CKtgbiRk9qcEPPAoA+fB8APERwR8TNSx/wBer/8Ax+lf4AeIBEGX4naizE42/ZXH/tevoZIH4z8o6+9TxwonIGW9TQB86J+z54kfp8S9TA97R/8A4/Ug/Z58RY5+J+pZ9BaOf/a9fRQO4fKcDpmkcrEvHU+tAHzuf2efECrl/ijqK/8Abo//AMfqE/s/69nCfFDUiT0zZuM/+R6+g/vXALKZNyk7sfKuMcdevPp61NsBjDtjPXOOlAHzwP2ffEOBu+J+pAnoPsjn/wBr0f8ADPviADLfE7U8HuLNz/7Xr6DJHUg7cYHHNTpHxubj29KAPnr/AIZ38Qf9FQ1L/wAA3/8Aj9J/wzx4h3Y/4Wfqf1+xv/8AH6+is54X86UDAoA+df8AhnfxD/0VDUv/AADf/wCP0wfs9eITyPifqW31No4/9r19DufNwFzjPPOK8e+MfxJutI1H+wvD0yxXMShrq42hthPIUZ796AOZb9nnxGq5/wCFm6kfpaP/APH6cn7PPiBlDD4oalg/9Ob/APx+q/gT4vatpepRReI7l9Q0yZwHldR5kOf4gR1A9DX0dHMk0Ec9u6yQuodWU5DA8gigD56/4Z38Q9/ihqX/AIBv/wDH6P8AhnfxDj/kqGpf+Ab/APx+vofzV7/nTlZSBgjB6UAfOrfs8eIgPl+J2pH/ALdH/wDj9N/4Z58Rf9FN1P8A8BH/APj9fRpHPU0h3eq/lQB84v8As++IFk2f8LP1POM/8eb/APx+gfs++ICOPifqfJx/x5v/APH6+i/NPA2fN6ZpUYMfukMeuRQB88D9nfxD/wBFQ1L/AMA3/wDj9I37PPiFf+aoakT/ANeb/wDx+vosH0ppB7Yx70AfObfs9+IFHzfFDUgfQ2b/APx+nL+zz4iYZHxP1LH/AF6P/wDH6+ivLGcnk+9EZO3DLtP1zQB85n9nzxApw/xP1Nff7G5H/o+nj9njXyMj4o6l/wCAb/8Ax+vopl3Ag4xVUxsrHbnn3xmgDwD/AIZ38Q/9FQ1P/wAA3/8Aj9J/wzx4hA5+KGpf+Ab/APx+vf2ndSAwAUDGc96kj3lDufHcYFAHz4f2ePEH/RUNS/8AAN//AI/R/wAM8eIe3xQ1L/wDf/4/X0OMt1XGP1pArZGAAPrQB88/8M8eIf8AoqGpf+Ab/wDx+j/hnjxD/wBFP1L/AMA3/wDj9fQ5Q785HHaomSctkMMHsaAPnz/hnnxBz/xdDUuP+nN//j9L/wAM8eIeP+Ln6l/4Bv8A/H6+ghLKrbZo8r/eA4pRcx45YhexxQB8Y/AnXdWvI9aN3qd7MVMO3zJ2bH3+nNFZ37P3+q13/eg/9nooGSfCMZ/aahH/AE+33/omavs1F4AySvbB718bfBxQ/wC1Bbq3Q3t//wCiZq+2URVGVUDNAiqkTkcD1+90qZLYD75yB2qweB/KlAzjk0AN2jA9PajAQE5wKGZV6nB+tVZGadtqnA96AJ/MXn5j9aSVmKgRZO47cjt705YVA5JP1NEqAL8mA3b2oAkChQqrgKKbNHvHGM+44p0bFkBZdp9KXPNAFZA6tjyzk9T2qZVxFtfGO9KWOeSAKiUKWJY59STQBKu0D5B06Uu3P3jn27UZGODxQGDHCn8aAAFccdvSkILjkkA9qQKYwcEEflSh1wMkZoAgupRZWlzcOCyxRtIQOpABNfF+p3cupahd6jdOzTXM7yP3ySeP6V9puFuRJC6boWQqwPcHgivii7iMFzcxqV2JO6KR2AY4oAhDA8Arg8EN/hXuX7PnjJmB8Lai+SitJZSMeqj70f4dR+NeGsS24ng45z35qeyubmxurW8spDDdwSCSFhwVYUAfa7HYChxjtmo9vzYOOtc98PvFUPjDwtDqKqqXSHyriLP3JB1/A9R9a6MKxHJLdjjjNAE4GABnNLUe4htqjPFPA9aAGSFR8zAcdzSJIXOFwFHeq+pXNrYwtdX1wsMMYzl3Cj9epr541j4w+K0103NpZQwacr/JbtHu8xAe7epHpQB9J44PWmj5skE8dq4nwb8TPDvieFFS6WyvtoMltcHYVPoCeD+Fdq+B8wzk8DBoACxXO4DHqKcMHuM+1MCsQT9ePWmhXQYXOPzoAUOTkHnHcU9cYyD1quWIPOc/SlVsE7mKnrkUAWGUMORmjHHA496g82Q4I6H+8MZp4lP8aEH1FABG4yytkEH0qQexyKRWVh8pGPc0uDnjigBOOoyaXBNN57E5+tJucHGAxoAcPrSEDoVH40b8DLcCgY9j39aAPhv9n7/Va7/vQf8As9FH7P3+q13/AHoP/Z6KBln4M/8AJ0Vt/wBft/8A+iZq+2hj396+I/g6pb9p63UHBN7f85x/yxmr7SMLKu7OcDnFAi1uUYHU96iaYbwNgHozUy1QnB5CjnrU7qJVx/Dnt2oArSMC5zhjirFsoWMEDLHqaGVUjO1ef1NVlEgzt3gn8KALcsgXgMN3pVcHeQ7FSenPH5UsWAxMmSx/ShyGc7MqvegCeM5DdT9elPAx1FRLIBgDkn7uORUgIxjPPegB9VrjGeAvHBPQ15p4w+LWk6VfvZ6fMLuZDtd4+UjPfnua8tg+LXi3TtSaU3MV1ZySErBNGCCpPQN1FAH0/EAYtrHOPfmpERV5A5PWvNvCnxSsdSto18QxjRrmWXy4SxJjk4HRscde9egwX9pPFJJFdQSJEcOyyAhfqe1AFuoQSrkFhjrk1zut+PPDOj27y3Wr2zlc4jgcSMx9ABXkPiP426rc3I/4R21gs7VefMuR5juPcdBQB9BFkVSeSDXkPin4KaffXFxdaFqMlhLMxcW8o3xAnrj+IVydp8b/ABBCVF7p2nXQ/wBlihNep/D74haX4yjktolay1OMbntZGBJHcoe4oA8pT4KeJhLs+0WGz/npn+nWtK0+BeoklbnVbdF4IZFJP05r31AFUAU6gDg/hd4DfwQupCS/+1/a2QgBNoULn9ea7vd0peoNVndgeGCrjnNAEoIEr59BzVHxBrFpoGi3Wqak+y2t03NtGSfQAdySQKsxD5vmGR69q5f4saL/AG/4F1S1DOjxJ9oTaM7inzY/SgD5s8Y+Lbjxp4lF9f3DWdtnZBCSXSJfUj1PeqOqyXOlabb21vdSBkkZpY1zlCen4EVgZeSEqyqFPB4/Ouv0a60d9EXUvFcdxd/P9jEcL7TIuDhyfVf60AYWnzS6nOtjcYlBBfco+ZCOc5r0L4YfErUdDmmh1S7kv9Et0+64LSIe20n+VeYXNw0bSLZS+VAjlowfvY7bjWxrksUOlab9jUxy6hH5tyuMLkEjj8qAPrzwx4k0nxPpy3ui3kdzFgblBw8ZPZl6qfrWx2r4Z0bVLzR75L3SLqazuk43x9CPcd69S034teKrzTrW4S7sYzby+XcCWIYmX19jQB9KVGYkP8P1xXl+jfGnQ7iKCTVY3sYZcqJ87k3jqD3Fej6Vqtjq9kl3plzFdW7/AHXjbI/+tQBZ2KOM4pcEdOKUnk+lIcj7vI9KAI5doJJQ9MZqMTFSqsMg9CDVjPB7Y6ioZF2oSikr3XvQBKrAj5CCKU9yQM9M1UQbQCjMBjp6VItxkclSPX1oAnOSfX6U0hQ2cDdjGQOcVH56kZ2tj2NIZ0x0JoA+If2fv9Vrv+9B/wCz0Ufs/f6rXf8Aeg/9nooGWvgxn/hqK2x1+23/AP6Imr7XkdUXEmDn0718T/Brn9qG2/6/b/8A9EzV9tIqj7oHHegRXEZaTKoVTOat8dhScgev1o3c479xQAvbJxQP1pOcDP5YpQCTkkgDtQAjKTnge3rUDQFgMgn6mrVJ0yWIxQBEIsR4OAR/drwr9oHxrNBcQ+G9IuXiwokvJI2wx/upn8ya6/4o/ED+ylGjeHpI5tZuAQzq2Rbr6+7eg7V82axPLcahJNfMxuXOZDjqfzoApbgFxj8exNafh+8gi1CC3vUWWzkcKFcZ2P2YfjWWSoPyDnOOa0/DtgNT1MrI6iG2ia6cMcblTHyj3yRQBuTG+js76x1iIeak++3WVCePRPTjFb3inQrvXfDz+JdHZMWsMcd/Z20jBtgUfOV9Rg5+h965TQvEdzJrwluZGkiuW/dq+G8tuikfhXV6dHrvhvXTq0twmjNE8cbNOpEV5C5ywYc568Y6UAeaIU25QDkfK26ns4JUtwccgivS/irb+EbLVra407RZsXpd5DFP5a4B+8i4IwevbrWBP4RF/pLar4Nu/wC17WEbrm0ZdtzbfVM/MvuPyoA5AZ2ngHJx05q5ZXF1p19Be6fK0F3bsHjkU4wRVdJNzZDcZ5AGOfenKNoHyY5JGDwaAPrz4b+K4fGHhiDUFwlyv7u5iH8Eg6/georqa+Rfh14zuvBet/aURpdPnIW5t88Y/vD3FfVHh/XNP8QadHfaTdJcW791PKn0I7GgDSHI6YqPy0bnHenO2AcdcVzfjrxHD4X8OTXpljF267LWOTpJKRwMCgDoUBE0mQfY9qzfE+qwaL4fvtQumjjSKFiokIAZsfKv4nAr5xsviT48uNRF4ty0sUTbntliARh3GOtVviT4rvPFulRXeqs9o0Mw8rT1BCbf7xzyWoA8/bedzOCruzOdo681pav/AKP4e0BMBC6SSle/JAyay4I57tvKs1dpCT8q9B9W7V0+q6JPqN/YxTarpoghtlVpfM4hAySCO5oA5adkKoZAkZPU4xmtC7E2opYEuFWNCAzEDj0q/wCFdU03Qtblni2XbeW0SyXUW6Pn+MDP5Vja/bPa6iVaUOko81HB+Ug+mKAJ4tNSSZEl1WBd6EnaGJ47dOtLJqwWzFrY2ccenggSBj80x7kntWfaSm3864h+RwPKGcEknqargr1Iz7UAacuqoLZ7aysbeCF234bMnPtnoa1fBPjXXPCM1yNDlijN0BuinXcmR6D1/wAa5YsDja3buvSltdguYfNAZdwyTxj6UAfSOhfHO3dLeLX9Lkt52H7x4GDJn6GvW9H1Cz1ayju9OnWWBxkEHp7GviG6kkaRjBaSjc22Njk7h3rV8GeMNf8ADGpQXGnzzfZ4XAmtmyUZSeQRQB9rdSOP1o4JIGR3zWV4e1iz8QWEV7p88ckZUFwp5QkZKn3rWUg8AcetAFO6jUnEiAgnOO2ajA3gEMHXGdwP6ir7AH5WxjtmqUsPlEADanQYoAgKgn698d6dJnYSNuB/e61LKArAkfe7jmkSMMrYYctxu70AfFH7P3+q13/eg/8AZ6KP2fv9Vrv+9B/7PRQMs/Bo4/ahtj/0+3//AKJmr7ay3px718S/Bpgv7UNsScAXt/z/ANsZq+11kDdBxQIkxkn19KcFA6cE0i+3IpSAeKAEJ44NNDSK3IBT265pSRk55rzn4n/ElfCksdhpkEd3qkgywLfLAPVvegDT+I3jtPCcEUNram71KZSyRE/Kg/vNjtXh+tfEbV/EkUttNqckDYIEdv8Auo8+hI5P41x8/ibVrnXJNXnu2nupGBffypH932HtVq48QWN1cs954ftREww627lGz3IoAksLfU4rKa/jG+4T90jAgkA9TnvTNTktbbRYYr7TGN9M5droydR3AFTz6jpgsXm0u2vLXTtwQRmTcxb0zWVeyWd/pstwkt0L23Kxx27jcoj7tn8qAM1nUKSI2A7Z5wK0tIZStytoZBcCL5nkIChc8jj1rIXLuFT55D0VecmteHWDp+jzaOkdrNHO/mXMjR/vM4+6G7YoAiibS7K6aWF7i4dCGhZQFVD3B9a62W6ufGFrF/alzcTw7QkAY8Iy/wAOa8/mjOP3O4oRhT3Gema73Vru51Wy0DQbaaz046fGGdF+VWZud7N60AReKJEvfC1nLdRNaajp8otxbuCC8R4yK5rQ9UvtC1WDUtJn+z3sJyrKeHX+6w7g9wa7M3aXcd1Lcs2qWNlbeXcwOf3hcdGVuormtNTRL26lDyTWMjjMAmAdGbsGbjA96APTfEvg628feG4PGPg61EF9Kp+2WGMCRx97b/tA/mPevHsOA6FHDKx3KTtKkdjXq/wTu9e0Lxz/AGXqCzx6bcRs0inmJWwSrg9s8D8aufHjwFJbXj+JNHti9tNzfJHzsb+/j0PegDxouQxZV4C9u9bPhPxLqHhPWYtQ0mRggH763JOyVe4I9fQ1jnawJDcnBGR+lIzBclyNxHJFAH2j4f1e213RrLVLMn7Pdx7xk8qe4P0OR+FfOnxT1TVda8a3hu7YCz08tBbANlQB/EPVjW/p3iCbwx+z/ApJS91GSWG0U8HaW5YfTn86810u4vJ9Of7O4ItseY0rZAP8Lc0ASzNbTaLp9xHeNp900jC4XeQ8hHRsdhUF54i1G2a40++jt5YJEERFzGHcKejBhisbUxcTKJ7uKZpW+VpWT5Tz0FV4VeRjKQzbful/XsBmgDeu7e+k0yO10+1jiaNiJlhYAzeh5OazFCaERHJbh9QniIkVgD5eT0x61o+DfDZ8Q6hcG7uTZW8cbMs7vtzIOijPc1oXWn3UYuBLpolnVSY5JD84I68/rQBzF5Faw2BJLxX24IEXldp6596vXVnpYEUE12+IowzSgcgnsB6Cs5I5obVL+e3jdJXKKWc5LDrkVGZxMxmuFQRhgpiz970waAJNbs/sE0IiJmsdu6KYrgOe+T2rOHHIwSeQK29K1G6+1eXFBDLaJJ5z6fI2UlA/hyeR+FM8S2cUJiubXTp7KC8JlERO/wAnn7gPp9aAMRmU52kk54461d0yCCQXV3dzbYoIzsLDIkkPAWqQBbaI0lbJxhVPJ9KnvyYoobIOFWL5n9N5/mRQBf0rUbtrWZvtiq9nB+5R+epGcetZkup3szB/OIzxwAP0qs+FQufmx+FPurRoYLadZon89CwCnDJ9aAPf/wBmDxA7Nf6LctCP+WoycOx9ffjP5V9ARp5WQuSD0z29q+BdFun0zV7S8t5Gt5Ymysi9QcV9RfAj4h3PiTTptN8QTo2qwOVjduGnXrk+9AHrUmOPXNIQHQg5I9TRuyecjHandB0zQBRYtHG8bY3Zyox2qIhTsYhuDyas3aHcjqOlVz8rn5juHGaAPiv9n7/Va7/vQf8As9FH7P3+q13/AHoP/Z6KBk/wdYL+0/bk4wL2/wCv/XGavtiDEnzEYxXxN8Hwp/adg3dPtt//AOiZq+2rcL5WUUgE9KBExIzSE4PQnnANA+YHkYpr7h14Hr2oA5v4jeJD4S8H32rIgkuEASFSOC54Gf1r5PudRkvbfVNTvZGk1C9kEecYBJ5Yj6V6v+0peX0t3p8Vu0hsLcESoBwZT0J9eMV4/e27IbSJ1aK3lAZSThVfvmgDOJHA2lscZB60rALgMCrLwAec+1OMbGZ4ECu2duQcA475pNywgrEfnPG4jigC9bqH0q7EsnlEMrxRsep7nFN0UTyXbtaRO5CElQM59jU+iW8S3sMuqSva2rSL82zeW5zgD0NWfE2vi9vJodMgjsLBJSY1hGx392I/lQA6S8sora7ttPtljvAoxJ1IP8QFc8WAAyVUjO7PWp0nDOrOuJlORIp5+h9a29Ps9LuLK41DWkFqsZKqkecTt7CgDMisZ/7H8w21yPOlCxbBw4+lbiwRQ6NPpbWDTXjOjNLMMGBe/wBaw77VWuZkxLcbFXZGm7btX0Fa1v411610mLS7eW2SyRshTApcn3fGTQBtaCbHTfE8QTV006xnhNvOSBKWUjBXB4yawrPQ4NR1GaDTrrzIEkP7u4/duyg8cH1FGtWS3enya5bS2zFZBFeQQ8GJ+zqO6n1qW6t7aDRbHVb2Gc6jdA+UYpBs4PDP3B9qAOl8Q6tJbtHBpWoTPZRQrHMkTkruHYE9cV7l8KdVuPEPgaBtUt5MjdATMMiZRxnnqO1ee/BHQ4/EVzeazf29s2mKvkpaFQQsoxlvcYzXuVtFFBbpFbxiKJBtVFXaAPpQB5lqfwR8N3d481rNe2SuSTFE4KjPpkcVr6F8KPCekqM6f9tk/v3beZ+nT9K7yigDhfid4Ei8V+GYbKw8q1urI77TjCDjlcDoDivnS80HVvDE7WOv6ZLBa3jiKWTaSpAPVT0NfYtVdQsbXUbc299Ak8J52uMjNAHx/wCJnk0eEabFcy+WW8xVR8gD3HrWNe391H5EcD4VIw4BAySe9epfHXwLDpWq2WoaQrrFfMY5EY7lD9Rj0zXGXmjNd2Gl6PbWm3WII3aWdfm830TA6EUAcpf3Ul1JzITGwBZAxC7vpWlYa7qflRWsU80tzGw8iIDO8f3fes67067t55Ip7XDx8MoPSrvhu9utA1xdUt4h9otI/NjMqZC54Bx+NAFjxHoNxDex4tXhluVEhQHKxueoPpU8d9omk+Exp82iW2oazLMzfbWmYCMccYB7YrNtNZvp9WmlubmSaa+k3SMxxlz6enWsiZHiupY5AdyOylQMnrQBrx3mmzRFZNPitrsDCvbsSo9yM9am8NXemIkket6xqUDI2LcQrvT/AIFntmsK2ZUvInXJ+bDD1FNuFAnmTaqqHIBPbmgDTu9a1C3lltbeWOOPzgzbFALkfxZ7VmXaCTUZgzxqGbqchQT71JcEXVjBMFAljbypHP8AGOxpNRtzFJG9w6ySFOYwf50AVXgkEgjKGSY8Db8276VJfW1xDa28lxbSIijy2YrwDnuaatxcQyq9u5jlVfk2HoO9XdB1GSG7aC68y5tLoFGhdgQz/wAJ596AKGn2Muo3fk2ynyx87OTwijqc1vf20+kXMGp6dM8cm4BTGMblHGfY1Pp8M7J9nmWNWKOrQIRlRnqR+FQaTv2T2E8MMlpaI0rFhzx0x3oA+uvAni3TfE+l232W8WS/WBHniPDrkdxXUnAHWviX4c+Jr7SvF+mzwtia4mSIkcnaTjGO4r7ZHzEgHgcH3oAbMqyQlcZ46VTSMOqZLEdm9KvAYUrx9aqR5VHDfwnIzQB8Tfs/f6rXf96D/wBnoo/Z+/1Wu/70H/s9FAyX4Q/8nOQcZ/02+/8ARM1fbcJIiG4AGviX4Qf8nO2//X7ff+iZq+24xlRkc470CHoNyMB6mkiJMjjOVHHTvQh2ZJ6Hr7UplVVJHIALZHtQB4X+0DIzzWcNlLDmE+ZdAfeHPGa8nmuJL+OKFJB5CuW2swIAPU1oeLdSm1fxFrVwkhWWeZok5+8AegrmTH9njayf5ZxlpG3fdb+7QBoJDDrGpiyUwuQNkLxDaW9h6mse+SK1vJLdYJY5ImKnzuGz/Sodixt95opY/mBOQQfb0ram1/UNViEur+Vex28HlbmQBsfwkkdT70AQ6RFNdLPdttmt7NfOcSNjd7DPWqMuyeRpLVD82S0R52fStbw14f1TxbJe/YQPJsIGnnkdtkcagZxn14rChkCyLKjsjg/eAoAVY2nlWJCmW4G7qPetLUrxby2tbCFUEFihEbg4aRieSf6fStDTJdO/sPUVLXMmubWCbUHlNGcZPqCPpWBZK0ksaZLfKR06cUAQA7gGyGDZyO4p67c9SzY47fmaZkFQTlscZx0qReFJCbkHBJoAtWU0lvdo0eACQHU8hh6Ed6dI7/a5pFkK4ctjHyj04qO2jea5gihQyTO6oi46ntVrWLWaz1S8tblUW4STa4XlQ3tQB9QfAezitfhtp0scQjkuS80mP4mLEZ/Su/j5XOCCfWsPwLp66R4P0ewU5EVsoJ9yMn+dby5wM9aAFooooAKQcjmlooA5j4i6HH4g8JX1q52yRDz4m7q6cj/D8a+RrrV719SN9BObaYP8ojbG3HtX25MqvG6sMqw2t9DXxb4v0WXQPFGp6VOpLwSlkbGNyE5B57UAYt5uupJbhtzSO2ZFJ5z61NDdTy6XeWxbcwUMpY/MEB+79Oc4qo4AJIyGByTmtrQGEVre3d1ZW8u5CLeeQ4+f0Ud6AIfBrWcOpfatZUHTth/eFclH/hI9TVK9s1u7ie6092uo3dncIhDoM9SvpQ7XV5pqz3E2baGbaIgdu09TgVV+0tBeG4td0JB+Xa+CPr60AQwsjzxRoWALgY6Y96nmW3/tCZXkyokOG67uelb3h/xM9vq9s+tabY6na58uSNk2syn0Yd/es+/uYbnXL9NN02HT4Z2ZILdTuaHHTnvQBf8ADFjapqlzZ6tBFPb3MW+ORXA8phyCK5i5ZjeTlsFyx+9wCKWMtbTrIzEMrbThuRV64s5PtLWU+xL2PmNy3+sU9B9aAMpuB93dgcDH6mprOIB/tUpEcUJDDcOXbsAKi2FmdnA2ocOSeeO1MmcyynCKsa/dUHgUAWo7q3GrRXazSwLu3Pnk57/hW9qF/bQLJ5kf+jXKFY3jGS49ce1ckQQQQqgH8TWpZPDeaSlpNKIZYZC0UhPHPY0AdV8FdJs9R+JuiRS3AMMJM6rIuPMZeQBX2W28FFTGO5NfMH7Mvhyafx5farcKPL0y3MSuOQzyZzg/QV9OoGMpDZAUk/WgB5zvOOpqlIvztgHGc/WrvBZj1HTpUWNwOfXpmgD4g/Z+/wBVrv8AvQf+z0Ufs/f6rXf96D/2eigZY+DhA/agtif+f2+/9EzV9tgdexNfEPwiz/w05Bjr9tvv/RM1fbq9ABnmgQZyAAfrUVztS0nYDGI2/lUqHkjJz2pl0pe0mXaCTGwA9TigD47vZTaahcRgKQJ2ZJCM7Tmo/FTQvMtzbwGN50HnNnqwGCce+KkdWTUL8XgMbea+QPXPpUF1fWoSKCVPtMQPJLYz9KAM/T4o3aO8vY/Ns7Y5mRm5f2HrWzaW8uuPbw6NpwkjunKtbRIdyKT1z6Cm3F1bW9ss7W6vbwHEMBGPnP8Af9cVkWOsapDfPPZXckd3OhiAhOw7SOgA6UAdD41ubrw5Yw+C7e4WO0tyZbyW3OPtUrdmPcD0rjY1achIA8kgH3Y1yR/9att3t9PjWO7Q3l2w3PBLyEJ7ls5zTV8SXltotxpdlFbW1tcOHeSKL95kdt3JAoAa8sdrAvk3Cm+dMTDPC+w+tWxptvp6299NeobWQbCsfO1mHT8K55iP4sEDqwGK1rGSHSoLiHVIftMF3HuFsGwVP8L57d6AMko0Mrxj+Ekkg8sOxFODEFsZAI710ms61pXiCDTUm0ptPvLaEQG5t2BWQDpuXHX8axYbaGUFVvoUbIGJQR+vNAEcbPHIpR2VlIKlT0Prmu38K6DF4q8dWtgqSApKHuJG/jQck/WucnsItMMLSuJZW6leY1PbHrXqPwS08t4yjna8+0PDbF2Crt2k9jQB78iLDshhULGgCgeg9Ks1WDlplI9cGrNABRRRQAUUUUABGfpXlvxk+Hf/AAl1sl/ppSLWbVCuW4E8f90kdx2r1AuAwABJJxx2psTlydybcdOc5FAHxTpK6dBdLHf2j3jLKMjdtjXB53DrUciXer+IfMbItYpQSY1/dwx/0rs/jH4XudP+Il6LWIPDqC/aYkiYJjswx9a5rTrC50xbldVXyLW6XyzGLkDcffHpQBg67E0WpSptxDuLRBT95P73FUMZJ2bUTrnrXY+JdCd7HTriwjVIdhhQPINzkHt+dUR4SuX0iW98+3F1E+Hst251X+8SOAKAOZbhd2WDDDZJGK3YY7XT4bTUtSgM93Nl0tixXGOjH61Dp9vbWVzHd6m9vPFG2/7KG5kNReJYr6DVXl1KN1e4AkjJwRsPIxjpQBeS+0HVzImq6SLC5lbK3lo5IU+jKfX1zSatpltqXiMW+h3X2eR9qxxXh24Yej+lY9lp9xfrvQbbVW+eeT5UX1+proEv9Ln0uK1h86bVo3ZvPkQeWw/hC9wR9aAMnxMLi6vhcy2iwMV8qUQp8vmrwePX3rBOwE4Dbh6/54rur8W+oWemzWd09nrjIwKSH93Njt7NXLz3dwZ5Fvba3kmQ7WVl2nP4UAZLYUtkADswbJz9K1YdKD2Lec4ilVRKFcYJFdF4H8PXXiabVbfQtKt7nULe2EyCSTCqM4I56k9q6H4YeHp/G/iW3hXTRa2envi8uGJbdg8pzxnINAHsvwE8PN4e8EJdTKVuL9/N2Mc/J0X8eteoCQlAShBxUVvDHBHFFCmEjUKq/wB0CpCQxC9jQAoB24BOfeq6NuZwOhPWpyew71XtV3MW9zQB8Sfs/f6rXf8Aeg/9noo/Z+/1Wu/70H/s9FAyf4PLu/aegH/T5f8A/omavtVWdrX9ywWQqQhcbl3Y4yMjj8q+Kvg8wX9p63J6fbb7/wBEzV9p2pwXC8Z54PWgRMm7zU3spJXBIGATUjDk7OWByQajYEkY57r9adI7eUHTGe59KAPmH4v6BPovji6unRhZ3zedHJ2BP3lI6VwsFlF9oBnjklhbJAQ7R7DNfY3iLRbHxHpctpexpIpGFYjO0+oNfL3j3w9ceG9audDku2eORRNGwGAy+/vQBz4DJE8eosIoDgsFJIz259aWwtokdX010lkXlnc8gegpQvnaUmmLl5JCZVkzwGH9KrW7G2s/ImiKTvIGSRT9wDrmgDOuH8y7mkmXbKzkspBpowB8v47c8Vr6usF7dyT29xEJAQm0LgMR3FUbmyuLVIZLiIqk2djn+KgCAKWZQHX5iBhR71Ne7/tcu4ZwQvYngCkW3l8syjKxqcbzwB+FPfyZ5WeEuxOCxPG31NAFUAg4w2fQipwG4OAVPPQdKRmCyug/ej+8etPTLYJOcDo1AG1ospvLY2M25RGN6hVGSK9e/Z40dluda1kS+ZHIwgjXB5PUnP6Vwnwz8Dar4r1OC7CNFoqSFZrlm2lgOqp3Jr6Y8N6Lp/h3SodM0mHy7aLpzuJPck9zQBoxx4X5yCfYYoBIcoCeBnntTzjv2pFHzMx70ALkAgHqaCwBAJHPFBPp0ozQAc0Kc54xS03+IH60AMZAsglJYnG3HbBNLGgRQiAhV6HNO+8WUjimEkKdpOQehoA4b4o+A4fG+lqY3FrrVnk20/Yg9UbHO0+3Q8+oPylrOn3OmancWGq25tr2FtkiPljn1HqDwc19xPO2cLgnrxWVc+H9Lv8AVY9R1HTrS4vIhhJZIwWA/GgD45to457MW97P5cif8eTOP4u4PpWw17N4c+zwaQITcyoFuhnc0271z29KZ418N6vaeLNRivLGZfPuXeN9nylScjHbGKV0sbnU2d7aczxRBPnGzcQMZH5UAUtN0MXOq3JmsD5CKzbfOAweucn+VGm3E512GLQEaYS8/v18wHHXAbOBVDUVuY7SFGMnlrkORkck9D61a8LzSWH2nURcmPEEkKRRD55cjnHoPegCpruoza9q0rTtDbqpwsSHbFkd8dMn1pllpTvAl55iM8UhDW2/EoUAncPbisoKAgVuDjpjtW7plmsmhS3M9wqFJQkEDjDSKfvHPpQBPqNhqcVraXb24FtORJErnD8Hk81Q1uznv7+S+t9k8FwRyDyGA5GK0ZLi5uriF7mcCCM+SluV3ZXuc9PStXwh4avfFetRWGmrLFsfLSj5ViTPJ96AO7/Zc0jUoLjV9UEKNYXCrbMCdrblOcj8zx7175pOl2Wk2n2TTLaK2t9xcqgxkk5JPqeai8PaNZ6BpFvptgqpDEOSOC7d2Pua0gRk980AIBt6cDpQPU854+lNIDMSTwKc7bFyeAPSgCKeXZHtB+ZuBRbJth5OWJ59Khw08nA4xjNW1UBQoPGO1AHw5+z9/qtd/wB6D/2eij9n7/Va7/vQf+z0UDLHwcXd+1Bbr63t/wD+iZq+zYwUcnHK9hXxr8F/+TpLX/r9v/8A0RNX2xLAr5IyD7UCGqN45HP8qRf3b/dJDcn/ABphDQkZzs9qmV0bkdOpxQA+ONI1xGoVeuBXO+KvDmmeKrO4tL6FcsuxLhR+8jPsa3d5UEqQw64z0pu1H3MBhjyaAPlTxr4L1DwRerJdRJNpm7bHPtyHz6+hrmrieC8tnMRCsr7m3cHnsCa+w9Y0mz1nSZ9O1W3S5s5l2sh/mPQ+9eFeMfgve6daySeGZ2voHbLQS4DoPQetAHlN7AtppyqXErvL825eQAOKqo8kNsZV/drIdoXqMd+tb0+lapphEV3Ytu6SeahwRUN7ppGmxSWsbNJblvMULuwp/i+lAGCWLZDMeef/AK1Lt3ZOB7A1YhjeWYLbpvduAq/NXqvgb4NX+qwpea9I1lbMflgXiRl9T6UAeSohdhFEjySN0XGSfYV7H8OPg3d6i8N/4sBtdP4dLJDiSX/fP8I9hzXsHhbwVoPhmJY9L0+ETDrcSqGkY/WupAwAMk+9AFa3s4bKzitbFI7W1iXaqRqAEHt2p4Y8LChCD+L/AAqR1DsM5+U5p9ADNpLBiSMdvWl5OQeB296WgDHFACYwoHcUoPHX60p6ZppGcEd+1ABn2oK8j1FDYxzmhRglm6/yFADqglRxIzJn5hjjsanPSigCuFKJu6H0x0qFg8mGG5jTomMskkgyADhfcUokOflAB7g0ANdVmUxuqMCMMG5rzT436bZw+EYltLBfNMuFlRcFPXOOa9TBz2Kn9DVOT99dS2txZB7ZUWRZnKsjMSwKbc5BAAOSMfMMHg0AfGepNcadcq5nEiORtU56Y5p2lSz3ouI7aOO3kj/ebo/4h6Zr6K8Z/CXRtfhZtPb+zrveZQ6jK5PUEV5xqvwp1jwzEptY/wC1BJnzJIuNvoMdaAPJPO2mUSFBubcfk5J/3q0IBJeyW99c7RZ2gCFWblgPSvTIvgbqcpFwbqOO3cB3iZMuCewrp9L+DsF4sY1QSGKNdqL93I/2h3oA8XsLK9bUkhOnG7kvcPbxROeEJ6kjkV9UfDrwvYeHNDha1sntrmZQZRIdzbu/Na2m+H9O0xIGgt4Y5IYxGsm0ZVRWrGEzvX5if4qAHKpI+YAfSlcKFJboKFBGSx5/QU0necgjaKAGruxkkA444qCcsSqxkZ7gipWOcrHkt646U6GIry+C/rQBFBAsI4CmQ/efHNThdx7gDp70qxqigKvA6D0qKV3DgMPkPGB1P+FAHw/+z9/qtd/3oP8A2eij9n7/AFWu/wC9B/7PRQMsfBxin7UFuwxxe3/X/rjNX2ykrNglcCvib4N4/wCGoLbIBH22/PP/AFxmr7ZA+pHbHagQkFz5skq+W4WNtm9hgMfb296eYIySyjDHnIpqjHGPYGnEnHGQaAF8v6E/SowNj+lSxuW4Iwf50rKGGD+dAEWBmlC856nvTGUrkpk44Knoacjbu2COooAr3djb3UZS4hR1I5DKCSPrWDc+CdJlnFxbRNaygYJj6MPQ11HHuaO/IIHpmgDntP8ACOgafdC7g0u3jueu8L39a6HBPJWlHI4xQB05JoAQjggnI9BSRsRw3JA/Glbd0Tr6mkWMBtxJZvU0APQgoGHQ880O4TrnJ6AUjEKSdwFImGOSPmHegB6FiuWGDSlgASTgCkHI/wAKU8g0AL2yKAABgcVAAYQvde47/UVNuAAPUGgBaKQHP0o64oASR1RGZzhR1qu0jO4zwoPCdz9ac376XbnCr1HrTkhRDuA59c0AOO3Gen060xkVn3YDMOnNO25Oc5NJ5Y389+woAqjIlLK7E9CD0q1GobOWBAPaiaFXiKDii1jEUWwDnOSfU0ASEADhQaAw7H2xTs0UANBJI44xTAzupZeucAHipaSgCNIQOXO9j3NSABRwAKQk5wF/Wo3yerdPTpQASNuOOgB/E09V7vz7elNjQZ3EcinDBO/PGOKAH0122+5pN+eAMfWmkc570APVg319KbMFCMWwPc00qQVIXGCBxT5Aj4Vhu74oA+Gv2fv9Vrv+9B/7PRR+z9/qtd/3oP8A2eigY34X6hZaV+0lHe6pd21nZxXt6XnuZVijTMUoGWYgDJIH1NfXX/CxPBWTnxf4dI/7CcH/AMVXgmt/D/wxcazfzTaWrSSTuzN50nJLH/aql/wrnwp/0CV/7/Sf/FUAfRP/AAsPwTnP/CYeHc/9hOD/AOKpf+FieCv+hw8Of+DOH/4qvnX/AIVz4U/6BK/9/pP/AIqj/hXPhT/oEr/3+k/+KoCx9Ff8LE8FZz/wmHhzP/YTg/8AiqcPiN4KJCnxh4d+v9pwf/FV85/8K58Kf9Alf+/0n/xVH/CufCn/AECV/wC/0n/xVAWPoz/hYngo8/8ACYeHARx/yE4P/iqjf4g+Cs7l8YeHVYemqQHP/j1fO/8Awrnwp/0CV/7/AEn/AMVR/wAK58Kf9Alf+/0n/wAVQFj6IX4jeC24Pi/w8p9RqcOD/wCPUn/CwvBmSz+MPDjHPGNThGP/AB6vnj/hXPhT/oEr/wB/pP8A4qj/AIVz4U/6BK/9/pP/AIqgLH0V/wALD8Fc7vGPhw89tTg/+KpV+IngrHPjHw5n/sJw4/8AQq+dP+Fc+FP+gSv/AH+k/wDiqP8AhXPhT/oEr/3+k/8AiqAsfRSfEXwUwYN4w8Occf8AIThH/s1Ob4ieCtpx4w8OA+o1OD/4qvnP/hXPhT/oEr/3+k/+Ko/4Vz4U/wCgSv8A3+k/+KoCx9FL8QvBJHz+MfDZOc5/tOD/AOKp/wDwsPwTk/8AFYeG8H/qJwf/ABVfOX/CufCn/QJX/v8ASf8AxVH/AArnwp/0CV/7/Sf/ABVAWPo3/hYvgrp/wmPhz/wZwf8AxVL/AMLF8EjH/FYeHP8AwZwf/FV84/8ACufCn/QJX/v9J/8AFUf8K58Kf9Alf+/0n/xVAWPo4/ETwSf+Zw8N5/7CcH/xVQxfEXwVGwX/AIS7w7tP/UTgwD/33Xzv/wAK58Kf9Alf+/0n/wAVR/wrnwp/0CV/7/Sf/FUBY+jT8RfBXGPGHhvH/YTg/wDiqbN8RfBaxuY/GHhzeRx/xM4Ov/fVfOn/AArnwp/0CV/7/Sf/ABVH/CufCn/QJX/v9J/8VQFj6Kh+IXgpI0V/GXhxmAwW/tODn/x6n/8ACxPBX/Q4+G//AAZwf/FV85f8K58Kf9Alf+/0n/xVH/CufCn/AECV/wC/0n/xVAWPo3/hYngn/ocPDf8A4M4P/iqP+FieCc/8jj4b/wDBnB/8VXzl/wAK58Kf9Alf+/0n/wAVR/wrnwp/0CV/7/Sf/FUBY+jP+Fi+CR/zOPh0/wDcTg/+Kpf+FieCSMf8Jj4c/wDBnB/8VXzl/wAK58Kf9Alf+/0n/wAVR/wrnwp/0CV/7/Sf/FUBY+i5PiH4JJVh4w8OfKc/8hSD/wCKoHxH8EnJHi/w9n31OH/4qvnT/hXPhT/oEr/3+k/+Ko/4Vz4U/wCgSv8A3+k/+KoCx9Fj4i+CyOfGHhwf9xSDP/oVEnxE8FkfL4x8N599Th/+Kr50/wCFc+FP+gSv/f6T/wCKo/4Vz4U/6BK/9/pP/iqAsfQo+Ing88P4v8NgnsNUgwP/AB6pf+FheCQuP+Ex8OZx/wBBOH/4qvnX/hXPhT/oEr/3+k/+Ko/4Vz4U/wCgSv8A3+k/+KoCx9Gj4h+CCoH/AAmHhzHp/acH/wAVSN8RfBJP/I4eHMen9pw8/wDj1fOf/CufCn/QJX/v9J/8VR/wrnwp/wBAlf8Av9J/8VQFj6KPxE8FdB4v8Of+DSD/AOKo/wCFieCs8eMPDmP+wnD/APFV86/8K58Kf9Alf+/0n/xVH/CufCn/AECV/wC/0n/xVAWPolviJ4K4P/CX+HDyP+YnD/8AFVKfiJ4IP/M4eHP/AAZwf/FV84/8K58Kf9Alf+/0n/xVH/CufCn/AECV/wC/0n/xVAWOP/Z+/wBVrv8AvQf+z0V7H8OvB2g6aNQFjYCISeXuxK5zjdjq3vRQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Advanced lymphangioleiomyomatosis characterized by severe destruction of the lung parenchyma with replacement by cysts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_47_24319=[""].join("\n");
var outline_f23_47_24319=null;
